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Thesis Outline 
 
Chapter 1: Literature Review 
A literature review of lysosomal storage disorders (LSD’s) is detailed and the current research 
exploring the pathogenesis of the diseases, diagnosis and potential treatments, with a specific 
focus on metabolomics applications is presented. The dysfunction of the lysosome is 
detrimental to health, characteristically causing serious damage to the central nervous system 
(CNS), although other major organs can be affected, resulting in short life expectancy. For 
the purpose of this thesis the review focuses on three lysosomal storage disorders; Gaucher’s 
Disease (GD), Niemann Pick Disease (NPC), GM1 and GM2 Gangliosidosis, are described 
in-depth and the challenges currently faced with these diseases are described. The lack of 
metabolomic applications in this field is addressed, which could contribute to further 
understanding of the disease pathology, clinical prognosis and potential treatments.   
Chapter 2: Methods 
An in-depth comprehensive methodological review of the mechanisms and history of 
metabolomics in conjunction with utilising the core techniques nuclear magnetic resonance 
(NMR) and mass spectrometry (MS). The techniques’ compatibility with biofluid analysis is 
explored, alongside the advantages, disadvantages, operation and theory of both techniques. 
The evolution of metabolomics is reviewed; expressing the exponential growth in the field 
in the last few decades, inclusive of applications to blood, urine and cerebrospinal fluid (CSF). 
Multivariate statistical methods, used to investigate these large datasets acquired by the 
techniques described above, and the significance of these approaches’ methodologies are 
outlined. The viability of these methods to seek biomarkers and understand disease severity 
are also addressed and the potential challenges faced in undertaking this study e.g. xenobiotic 
interactions.  
Chapter 3: Gaucher’s Disease 
Metabolomic data derived from aged-matched plasma samples from human GD patients 
and corresponding controls aged 35-70 years were acquired using 700 MHz 1H NMR 
(Oxford University) and analysed via multivariate statistics. Principal component analysis 
(PCA) showed a significant difference between the controls and GD patients and a sub-
clustering within the GD cohort. Lipid disturbances are evident in plasma profiles with a 
reduction in high density lipoprotein (HDL), low density lipoprotein (LDL) and very-low 
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density lipoprotein (vLDL). Urine poses more of a challenge comparatively due to 
significantly more drug metabolites present, in addition to naturally occurring metabolites. 
Drug metabolites were removed and no significant differences were observed in the urine 
samples, which may be a result of all the GD patients receiving treatment.  
Chapter 4: Niemann Pick Disease 
1H NMR is used to study feline urine to achieve further understanding into the potential use 
of hydroxypropyl-β-cyclodextrin (HPβCD) as a treatment to the disorder. Utilising 400MHz 
1H NMR (De Montfort University), HPβCD was not detected in feline urine, nor the 
antibiotics taken by the felines. Three HPβCD treatment approaches were used, two 
intrathecal methods were administered using a 120 mg dose, one initiated at 3 weeks, pre-
symptomatically (n = 36) and another initiated at 6 weeks, post-symptomatically (n = 36). 
The third approach involved subcutaneous injection of 1,000 mg/kg and 120 mg 
intrathecally and this was initiated at 3 weeks of age (n = 23). Significant differences were 
not present upon comparison of the treated and untreated NPC felines using the intrathecal 
120 mg dose presymptomatically or post symptomatically. However, the felines treated by 
subcutaneous injection of 1000 mg/kg and intrathecal injection of 120 mg of HPβCD 
initiated at 3 weeks of age significant differences were observed. Partial least Square-
Discriminant Analysis (PLS-DA) provided a Q2 = 0.53 and p = 0.028, utilising permutation 
and validation methodologies. Significant metabolites included felinine, creatine/creatinine, 
hippurate, phenylacetylglycine, trimethylamine oxide, betaine and taurine, amongst others 
which pathways are explored in depth. 
Chapter 5: GM1 Type II 
1H NMR was used to seek and identify new biomarkers of disease activity, severity and 
progression in plasma, cerebrospinal fluid and urine from human patients with GM1 Type 
II gangliosidosis. Urine and plasma were collected from control participants. Statistically 
significant metabolites include urinary upregulated citrate, N-acetyls, creatinine, creatine and 
lactate amongst other metabolites. Additionally, in plasma downregulated LDL and 
upregulated creatinine and lactate amongst other metabolic disturbances were observed. 
However, these results were interpreted with caution, due to the different ages and fasting 
status in the two respective cohorts. The impact of xenobiotics was also considered, such as 
drugs and supplements, that the GM1 Type II cohort were taking as part of this investigation. 
This study reveals the complexity of analysing lysosomal storage disorders using a human 
model using a global untargeted approach. 
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PC3 representing 16.8%, 14.1% and 12.6% of dataset variance 
respectively. 10-fold cross validation was performed whereby PC3 
gave a Q2 = -0.07. Permutation testing was also performed which 
provided a p-value of p = 0.02 with 2000 permutations. 
86 
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Figure 4.1 Average stack plots of the 1H NMR profiles of NPC and control 
felines in red and blue, respectively, from 0 - 9.50 ppm. U1-U9 
represent unknown metabolites, with the broad U6-U9 
resonances presumably representing those of protein aromatic 
amino acids. Abbreviations: 1-MH, 1-methylhisitidine; 1-MN, 1-
methylnicotinamide; 3-HB, 3-hydroxybutyrate; DMA, 
dimethylamine; DMG, dimethylglycine; I-3-I, indole-3-lactate; IS, 
Indoxyl sulphate; LAC, L-acetylcarnitine; NAC, N-acetyl groups; 
PAG, phenyl-acetyl-glycine; p-creatine, phosphocreatine; TMA 
and TMAO, trimethylamine- and trimethylamine-N-oxide-
N(CH3)3 respectively. 
117 
Figure 4.2 Average 1H NMR profiles of NPC felines versus those treated with 
1000 mg HPβCD. Metabolite differences are assigned only. 
Abbreviations: 3-HB, 3-D-hydroxybutyrate; DMG, 
dimethylglycine; IS, indoxyl sulphate; I-3-I, indole-3-lactate; NAC, 
N-acetyl groups; PAG, phenylacetylglycine. 
118 
Figure 4.3 8 significant bucket regions found by ANOVA involving 
comparisons of gender and disease status. Shown are mean±SEM 
plots for hippurate, taurine/betaine and felinine/lactate, which 
were found to be statistically significant (p < 0.05). with This 
includes all datasets from 8–24 weeks for both control and NPC 
feline urine samples. Bottom right inset: Time series two factor 
analysis PCA scores plot of control vs. untreated NPC Felines at 
8, 10, 16. 20 and 24 weeks. PC1, PC2 and PC3 represent 22.6%, 
13.8% and 12.6% of the total data variation respectively. 
119 
Figure 4.4 PCA scores plot of control felines (n = 35) vs. untreated NPC 
felines (n = 22) showing PC1 and PC2 representing 22.0 and 
13.8% of the total dataset variance respectively from 8 - 24 age 
weeks, showing differences only between males and females. 95% 
confidence ellipses are shown for each group.  
121 
Figure 4.5 (a) PLS-DA plot of control felines (n = 35) vs untreated NPC 
felines (n = 22) showing PC1, PC2 and PC3 representing 12.7%, 
14.2% and 11.2% of the dataset variance respectively. Q2 = 0.49 
when applying 10-fold cross validation methodology on PC6 and 
p = 0.084 using prediction accuracy during training as the 
permutation test using 2000 permutations (b) PLS-DA plot of 
control felines (n = 21) vs untreated NPC felines (n = 22) 
showing PC1, PC2 and PC3 representing 12.6%, 13.2% and 
14.6% of the dataset variance respectively. Q2 = 0.62 on 
component 6 applying 10-fold cross validation methodology and 
p = 0.0125 using prediction accuracy during /training as the 
permutation test using 2000 permutations. 
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Figure 4.6 ANOVA analysis of control versus NPC felines grouped by 
gender, showing data from 16 – 24 weeks only. Above are 7 of 
the metabolites which showed statistical significance. Mean±SEM 
plots show those for pyruvate, taurine/betaine/TMAO, 
DMA/Glutamine and Felinine 
125 
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Figure 4.7 (a) PCA scores plot of control females, control males, untreated 
females and untreated males in red, green, blue and light blue 
respectively. PC1 and PC2 represent 25.4 and 15.5% of the total 
dataset variance respectively. 95% confidence ellipses are mapped, 
and there are no evident outliers in this dataset. (b) PLS-DA plot 
of control females, control males, untreated females and untreated 
males in red, green, blue and light blue respectively. PC1, PC2 and 
PC3 represent 18.9, 17.6 and 15.5% of the total dataset variance 
respectively. 
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Figure 4.8 PLS-DA scores plot of untreated NPC felines (n = 22) vs. 
cyclodextrin-treated felines (a combination of SQ (1,000 mg/kg) 
and IT 120 mg early was administered) (n = 23), showing that 
PC1, PC2 and PC3 representing 17.1, 7.9 and 6.8% of the total 
dataset variation respectively.  Q2 = 0.53 when applying 10-fold 
cross validation methodology on a 4 component model, and p = 
0.028 using prediction accuracy during training as the permutation 
testing regimen, which used 2,000 permutations. 
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Figure 4.9 Top: Student’s t-tests using equivalent group variances with an 
adjusted p value cut off value of 0.005. Bucket regions are labelled 
with corresponding assignments and include hippurate, felinine, 
lactate, phenylacetylglycine, creatine/creatinine and a felinine 
derivative. Bottom: Volcano Plot showing significance (y-axis) 
versus fold-change (x-axis) in which the fold threshold is 2, and the 
equivalent group variance p value threshold is 0.1. Bucket regions 
in red are significant, and those in blue are insignificant. Bucket 
regions values were then displayed as box and whisker plots, in 
which red and green show the 1,000 mg/kg SQ and 120 mg IT 
HPβCD and untreated NPC groups, respectively. 
129 
Figure 4.10 Mean±SD TSP-normalised integral values of felinine and 
hippurate bucket regions with corresponding feline age and 
treatment type. For the control group, males and females have 
been divided in order to evaluate between-gender differences. 
Data was not collected for treated 1,000 mg/kg SQ and 120 mg 
IT HPβCD felines at 10 weeks of age.  
130 
Figure 5.0(a) Partial Profiles of CPMG 1H NMR spectra of GM1 Type II CSF 
in the 0.10 ppm-2.70 ppm range. 
146 
Figure 5.0(b) Partial CPMG 1H NMR spectra of GM1 Type II CSF in the 2.70 
ppm – 5.20 ppm range. 
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Figure 5.0(c) Partial CPMG 1H NMR spectrum of GM1 Type II CSF (sample 
code GSL011) in the 5.65 – 8.55 ppm range. 
148 
Figure 5.1(a) Partial CPMG 1H NMR spectrum of typical blood plasma sample 
collected from GM1 Type II patients (0.80 -4.70 ppm range). 
149 
Figure 5.1(b) Partial 1H NMR spectra of blood plasma samples collected from 
GM1 Type II patients. Typical spectra are shown (5.00-9.50 ppm 
and 14.10-14.50 ppm regions) 
150 
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Figure 5.2(a) Partial NOESY single-pulse 1H NMR spectrum of GM1 Type II 
patient urine (0.85-4.70 ppm range). 
151 
Figure 5.2(b) Partial NOESY single-pulse 1H NMR spectrum of GM1 Type II 
patient urine (4.70-9.30 ppm range). Typical spectra are shown. 
153 
Figure 5.3 (a) Examples of resonances in the 1H NMR profiles of human 
urine collected from GM1 type II patients of valproate metabolite 
1-O-valproyl-β-glucuronide, including methyl protons [1] (t); [2] 
and anomeric proton (d); [3] References showing previous 
assignments of these resonances [193], [194]. (b) Example of 
resonances in the 1H NMR profiles of human urine from GM1 
Type II patients attributable to miglustat, including methyl 
protons [1]; β-CH2 [2]; γ-CH2 [3] and miglustat piperidine ring-
C3/C1A-CH [4]. (c) [1]-[4] are resonances that arise from from 
drug administrations. Patient was receiving lamotrigine but these 
resonances do not correspond to this drug or its metabolites.   
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Figure 5.4   (a) Left: PCA scores plot showing controls (red) and GM1 Type 
II (green) study participants, together with 95% confidence 
ellipsoids. PC1 and PC2 represent 62.7 and 10.2% of the total 
dataset variance respectively. (a) Right: PLS-DA scores plot 
showing controls (red) and GM1 Type II (green), along with 95% 
confidence ellipsoids. PC1 and PC2 represent 60.3 and 12.9% of 
the total dataset variance respectively. Removal of all glucose 
bucket regions, which were clearly elevated in GM1 Type II 
participants in view of non-fasting of participants, was performed 
prior to performing this analysis. (b): VIP scores plot attributable 
to the PLS-DA analysis showing significantly elevated bucket 
regions, and corresponding metabolite assignments. Red and 
green represent metabolites elevated or depleted in GM1 Type II 
and controls respectively. The higher the VIP score, the more 
important the bucket region is considered in this PLS-DA model 
(all VIP values ≥ 1 were considered significant). Abbreviations: 
LDL, Low density lipoprotein; TAG, triacylglycerol; vLDL, very 
low-density lipoprotein. 
157 
Figure 5.5 (a) PCA scores plot of plasma profiles from controls grouped by 
age 25 years or under, 30 years or under and 60 years or under, 
shown in red, green and blue, respectively. PC1 and PC2 are 
shown representing 69.2 and 12.7% of the dataset variance 
respectively. 95% confidence ellipses are shown. PLS-DA analysis 
was also performed on this dataset (data not shown), and the 
highest Q2 value obtained was only 0.22 on a 3 component model 
using LOOCV and upon permutation testing using separation by 
distance p = 0.43 was determined with 2,000 permutations (b) 
PCA plot of plasma profiles from controls grouped by male (M) 
and female (F) represented in green and red respectively. PC1 and 
PC2 are shown representing 67.8 and 12.9% of the dataset 
variance respectively. 95% confidence ellipses are shown. PLS-
DA analysis was also performed on this dataset (data not shown), 
and the highest Q2 value obtained was only -0.35 on a 6 
component model using LOOCV and upon permutation testing 
158 
Page 19 of 216 
 
 
using separation by distance, a p value of 0.388 was determined 
with 2,000 permutations. (c) PCA scores plot of plasma profiles 
from GM1 Type II patients grouped by age 10 years or under and 
20 years or under shown in red and green, respectively. PC1 and 
PC2 are shown representing 38.3 and 28.9% of the dataset 
variance respectively. 95% confidence ellipses are shown. PLS-
DA analysis was also performed on this dataset (data not shown) 
and the highest Q2 value obtained was only 0.24 on a 5 
component model using LOOCV, and upon permutation testing 
using separation by distance p = 1 was determined using 2,000 
permutations. (d) PCA scores plot of plasma profiles from GM1 
Type II patients grouped by male (M) or female (F) or under 
shown in green and red, respectively. PC1 and PC2 are shown 
representing 38.3 and 28.9% of the dataset variance respectively. 
95% confidence ellipses are shown. PLS-DA analysis was also 
performed on this dataset (data not shown) and the highest Q2 
value obtained was only 0.02 on a 1 component model using 
LOOCV and upon permutation testing using separation by 
distance p = 0.582 was determined using 2,000 permutations. 
Figure 5.6 (a) 2D PCA scores plot from the 1H NMR urinary profiles of 
controls (red) and GM1 Type II (green) participants. PC1 and 
PC2 are shown to represent 56.6 and 13.3% of the total dataset 
variance respectively. 95% confidence ellipses are shown. Outliers 
are circled in blue. (b) Corresponding 3D PLS-DA plot with 
control (red) and GM1 Type II (green) participants denoted. PC1, 
PC2 and PC3 are shown to represent 48.7, 18.7 and 6.1% of the 
total dataset variance respectively. Accuracy = 0.965; Q2 = 0.56; 
and R2 = 0.73 using LOOCV on a model with 4 components. 
Permutation testing obtained: p < 0.0005, using 2,000 
permutations. 
160 
Figure 5.7 Top Left: (a) PCA scores plot of urinary profiles from controls and 
GM1 Type II grouped by age 10 years or under, 20 years or under, 
30 years or under and 70 years or under, represented in red, green, 
blue and turquoise, respectively. PC1 and PC2 are shown 
representing 29.8% and 19.1% of the dataset variance respectively. 
95% confidence ellipses are shown. (b) PCA plot of urinary profiles 
from controls and GM1 Type II grouped by male and female, 
represented in green and red, respectively. PC1 and PC2 are shown 
representing 29.8% and 19.1% of the dataset variance respectively. 
95% confidence ellipses are shown. (c) PCA scores plot of GM1 
Type II samples only grouped by age 10 years or under and 20 years 
or under in red and green respectively. PC1 and PC2 represent 41.7 
and 23.4% of the dataset variance respectively. 95% confidence 
ellipses are shown. PLS-DA plot of GM1 Type II samples only 
grouped by age 10 years or under and 20 years and under in red 
and green respectively was subjected to overfitting (Figure not 
shown here). PC1 and PC2 represented 41.1 and 17.1% of the 
dataset variance respectively and the highest Q2 value obtained was 
0.63 using a 1 component model using leave one out cross 
validation. Permutation testing using 2000 permutations 
162 
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determined a p value of p = 0.2445 showing overfitting as a result 
of small sample numbers. (d) PCA scores plot of control samples 
only grouped by age 20 years or under, 30 years or under and 70 
years or younger in red, green and blue respectively. PC1 and PC2 
represent 33.8 and 13.4% of the dataset variance respectively. 95% 
confidence ellipses are shown.       
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Abstract 
 
Lysosomal storage disorders (LSDs) are predominantly rare, autosomal recessive, orphan 
diseases that impact the storage of specific molecules within the lysosome. This work 
explores current metabolomics research on LSDs with a specific focus on Niemann Pick 
Disease Type C, Gaucher’s Disease and Gangliosidoses. Moreover, metabolomic 
techniques are explored with a history and theory outlined for nuclear magnetic resonance 
(NMR) and liquid chromatography-mass spectrometric analytical strategies. Statistical 
analyses, particularly multivariate approaches, and machine learning applied to the analysis 
of these metabolomic datasets are also discussed. Human urinary and plasma metabolomics 
investigations were then performed using the 1H NMR technique on samples provided 
from Gaucher’s Disease and GM1 Type II patients with corresponding controls. 
Furthermore, using a feline model, a 1H NMR urinary investigation was performed to 
investigate the impact of Niemann Pick Disease Type C on the metabolome, and also to 
evaluate metabolic changes in felines treated with 2-hydroxypropyl-β-cyclodextrin. 
Statistical evaluations were performed for all three conditions, and the significance of these 
are highlighted, with some key potential biomarkers identified. The advantages of using a 
1H NMR approach are summarised, in addition to the challenges of performing complex 
metabolomics analysis of LSDs, with particular considerations of the limited sample sizes 
of these available for such studies.   
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Chapter 1: Literature Review 
 
1.0 Introduction 
 
In the functional lysosome, lipids and other macromolecules, such as carbohydrates, 
peptides, nucleic acids etc., are degraded via catabolism through the action of acid hydrolases. 
However, inherited defects in genes that encode lysosomal enzymes and non-enzymatic 
proteins can cause the build-up of macromolecules within the late endocytic system [2]. The 
‘umbrella’ term for these diseases is lysosomal storage disorders (LSDs), and these can be 
further sub-categorised into lipid storage disorders (LLSDs or lipidoses), 
mucopolysaccharidoses, glycoprotein storage disorders and mucolipidoses. LLSDs are the 
focus of this review, and are listed in Table 1.0, together with their corresponding defective 
genes encoding the specific enzyme/protein which is depleted or malfunctional, and any 
diagnostic tests available. Niemann-Pick type C (NPC) disease is caused by mutations in two 
genes NPC1 (95% of clinical cases) and NPC2 and exhibits a different pathological 
expression to those of other LLSDs, in that the transportation of lipids and cholesterol is 
predominantly affected. Indeed, a complex storage pattern of multiple lipids within late 
endosomes/lysosomes represents a characteristic feature of this condition. It appears that 
the lysosomal storage of sphingosine gives rise to a loss of lysosomal calcium ions, leading 
to the secondary accumulation of unesterified cholesterol and glycosphingolipids. NPC1 
encodes a large membrane glycoprotein that resides in the limiting membrane of the 
lysosome and is termed NPC1. NPC2 encodes a small soluble lysosomal protein that binds 
cholesterol within the lysosomal lumen, and which is believed to transfer cholesterol to the 
NPC1 protein. 
Lipid Storage Disorder Defected 
Gene 
Diagnosis Approved 
Therapies 
GM1 Gangliosidosis GLB1 - Patient history 
- Clinical features 
- Symptomatic 
approach 
- Confirmation of 
increased storage or 
genetic tests 
- Typical approaches 
to confirm storage 
are enzyme-based 
S/S 
Sandhoff Disease (GM2) HEXB S/S 
Tay-Sachs Disease (GM2) HEXA S/S 
Niemann-Pick type A & B 
(NPA & NPB) 
SMPD1 S/S 
Niemann-Pick type C1 
(NPC1) 
NPC1 
(95%) 
SRT 
Niemann-Pick type C2 
(NPC2) 
NPC2 
(5%) 
SRT 
Gaucher’s Disease (GD) types 
I-III 
GBA ERT and 
SRT 
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Fabry Disease (FD) GLA - Some tests are 
invasive and require 
a skin biopsy 
 
ERT and 
CT 
Krabbe Disease (KD) GLB HSCT and 
S/S 
Table 1.0 Lipidoses (LLSDs) with corresponding defective genes (adapted from [3]). 
Abbreviations: CT, Chaperone Therapy; ERT, Enzyme Replacement Therapy; HSCT, 
Haematopoietic Stem Cell Therapy; S/S, Symptomatic and Supportive Therapy; SRT, 
Substrate Reduction Therapy.   
For these debilitating disorders, mortality incidence is often high at a young age, i.e. within a 
few months or years of birth. However, selected disease-specific variations may allow 
sufferers of some of these conditions to live into adulthood. For example, NPA is the most 
severe of the three types of Niemann-Pick (NP) conditions, whereas in NPC disease, patients 
may display no signs and symptoms until adulthood. LLSDs display a wide range of 
symptoms, and this renders diagnosis a challenging process. Furthermore, LLSDs range in 
severity and onset, but overall life expectancy for them is low. No single symptom can 
robustly diagnose LLSDs; instead, a combination of patient history, observed and monitored 
symptoms, and more specific testing is required in order to obtain a reliable diagnosis [4], [5] 
as noted in Table 1.0. Often, untargeted metabolomics analysis strategies are able to provide 
an insight into early markers for diseases, and hence valuable contributions provided by the 
applications of such techniques to LLSDs may be vital, since some diagnoses can be onerous 
and take a considerable period of time.    
At present, the applications of multivariate (MV) metabolomics strategies have been 
comprehensively reviewed for many diseases and their biomarkers [6], for example specific 
reviews focused on cancer [7], [8] and Parkinson’s Disease [9]. The core linkages between 
LSDs and other neurological disorders have also been described [2], [3]. Interestingly, the 
chemopathological aetiologies and developments associated with GD and gangliosidoses 
may give rise to an improved understanding of Parkinson’s disease, inclusive of 
neuropathological, genetic and clinical features within disease groups [2], [3]. An increase in 
blood serum gangliosides has also been related to cancer, and GD3 synthase has been 
suggested as a novel drug target for cancer [10]. Hence, an improved understanding of LSD 
processes has the potential to enhance our knowledge of both related and unrelated disorders 
too.  
This literature review will consider how metabolomics strategies have been applied to 
LLSDs, and the relative merits of these applications, including how such approaches have 
developed our current understanding of these disorders, and their role as a technique in the 
development of new and innovative therapeutic strategies. Our focus will include high-
resolution nuclear magnetic resonance (NMR) spectroscopic, mass-spectrometric (MS), and 
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respective hyphenated techniques i.e. liquid chromatographic-mass spectrometric (LC-MS) 
and LC-MS/MS analyses. Applications of metabolomics techniques to LSD biomarker 
research has increased since the late 2000s, and full details of all contributions made are 
documented in Chapter 2. These methodologies for candidate biomarkers are not only 
assisting in or confirming disease diagnosis, but also their severities and scope. Often, 
elevations or depletions of one or more biomarkers is symptomatic of disease severity [11], 
and therefore the monitoring and prognostic stratification of these diseases may be possible. 
Currently, a range of biofluids and biomarkers have been considered in both human and 
animal trials, and these will be discussed in depth for GD, NPC and gangliosidoses. 
 
1.1 Niemann Pick Diseases 
 
Most of the metabolomics research conducted on sphingolipid storage diseases has been 
focused on NPC1 disease [12]. High-resolution 1H NMR analysis has been successful in 
identifying potential urinary biomarkers for NPC1 disease diagnosis, and these include 
branched-chain amino acids (BCAAs), selected bile acids (BAs) and 3-aminoisobutyrate [13], 
the latter arising from either BCAA catabolism or thymine degradation. This analysis further 
indicated that the brain and liver were the prominent sites affected, which is consistent with 
the pathology described above. with area under the curve (AUROC) values ranging from 
0.81-0.91 for the most significant metabolites, and partial least squares-discriminatory 
analysis (PLS-DA) yielding significant values of Q2 (0.56) and an accuracy of 0.93 [13]. This 
approach has potential applications for disease progression monitoring, but these benefits 
have yet to be demonstrated in practice. At the sub-cellular level, the lysosome, ER and 
mitochondria were the main organelles affected in this investigation. Moreover, high-
performance liquid chromatographic (HPLC) analysis coupled with a UV detection system 
has also been utilised to target specific amino acid imbalances and DNA methylation in 
murine cerebellum collected from experimental mice with this condition, in which BCAAs 
significantly (p > 0.05) arose from elevated glutamine/glutamate oxidation, in a response to 
prolonged neuron survival [14]. The combination of DNA methylation, which corroborated 
amino acid imbalances, explores new mechanisms which are ascribable to neurodegeneration 
in NPC disease. Indeed, this combinatorial approach could influence new treatment 
strategies, in which these amino acid imbalances are addressed by specific treatments.  
LC-MS analysis has been used to understand upregulations or downregulations of potential 
biomarkers, as well as changes in biomarker expression in NPC1 disease as a response to 
treatment with miglustat and 2-hydroxypropyl-β-cyclodextrin (HPβCD) [11]. This study 
Page 27 of 216 
 
monitored the effectiveness of drug administration and uptake, and identified specific 
upregulated markers in mouse brain, liver and spleen. These included elevated levels of 
ceramide, GM1, GM3, sphingolipid species, and lactosylceramide in NPC1 tissues, which 
markedly reduced upon treatment with HPβCD, comparatively to miglustat [11]. Elevated 
markers in human plasma and CSF were identified as monohexosylceramides and ceramides 
[11]. It was demonstrated that upon administration of the substrate reduction therapy drug 
miglustat (whereby inhibition of GlcCer synthase occurs) these markers did not significantly 
reduce [9]. However, it was proposed these biomarkers may downregulate on administration 
of HPβCD, as this was observed in the tissues of the mouse model [11]. This research needs 
further confirmation of biomarkers prior to translation into clinical practice for disease 
diagnosis or clinical progression. Another research study, [15], also monitored the 
effectiveness of treatment with HPβCD in mice, using 2,4(S)-hydroxycholesterol (2,4(S)-HC) 
as a pharmacodynamic marker in a National Institute of Health (NIH) clinical trial, and 
employed the LC-MS/MS technique to assess metabolic activity in NPC1 disease. Brain 
2,4(S)-HC build-up was found to arise from high cholesterol levels. 2,4(S)-HC is produced 
exclusively at this location, and acts as a biological response to eliminate cholesterol; excess 
cholesterol is toxic, and 2,4(S)-HC can cross the blood-brain barrier (BBB), unlike cholesterol 
itself [15]. A different investigation, [16], also monitored 2,4(S)-HC levels in blood plasma in 
order to assess treatment outcomes with HPβCD in murine models, and from these studies 
proposed this agent as a biomarker for diagnostics and therapeutics development.  
Oxidation products of cholesterol are commonly monitored biomarkers in NPC disease, not 
only because of the increased levels of intercellular free cholesterol, but also in view of 
oxidative stress which is a feature of the condition. Similarly, selected BAs also serve as 
disease biomarkers; since these are also synthesised from cholesterol in the liver, they have 
been correlated to cholestasis in NPC1 patients [13], [17]. One study, [17], has reported 
increases in of cholestane-3β5α6β-triol levels in NPC1 patient plasma profiles, and in mouse 
plasma and liver, whole brain and cerebellum tissues. Cholestane-3β5α6β-triol, a further 
oxidation product of cholesterol, which functions as an endogenous neuroprotectant, has 
been reported to be upregulated in the blood plasma of NPC patients [18]–[21]. Other 
disorders, such as lysosomal acid lipase deficiency and cerebrotendinous xanthomatosis, have 
also been shown to correlate with enhanced cholestane-3β5α6β-triol concentrations in 
human plasma, and hence this biomarker suffers specificity issues for the diagnosis of NPC1 
disease [20]. Others indicated that cholestane-3β5α6β-triol could be used as a biomarker in 
conjunction with lyso-sphingomyelin-509, an approach which provided a model with 91% 
specificity and 100% sensitivity [21]. These findings were validated using HPβCD, with 
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cholestane-3β5α6β-triol significantly downregulated with treatment [17]. However, such 
critical effective drug-based validation processes were not performed in the studies of [18]–
[21]. 
Two investigations, [17], [18], also reported an elevation in 7-ketocholesterol, which is also 
an oxidation product of cholesterol, indicating that this may be non-specific as a biomarker 
for diagnosis, as suggested in other studies [20], [22]. Human plasma 7-ketocholesterol 
concentrations were also found to be elevated in NPB, sterol disorders, peroxisomal diseases, 
metachromatic leukodystrophy, mucolipidosis II/III, LAL-deficiencies [20] and 
cardiovascular diseases [23]. Notably, other correlations between NPC and NPB patients 
have been noted, since both exhibit elevated levels of lysosphingomyelin in blood plasma 
and dried blood spots as a diagnostic marker [24], [25]. Indeed, current literature 
predominately focuses on biomarkers known to be associated directly with the disorder, and 
the accumulation of intracellular metabolites, rather than what effect this has on the 
metabolome as a whole. A combination of statistically significant biomarkers, such as 
cholesterol oxidation products, BAs and 3-AIB, inclusive of those which are directly and 
indirectly associated with the disease, could offer a more sensitive and specific solution for 
the long-term monitoring of LSDs [26]. Other potential sphingomyelin precursors have been 
investigated including sphingosylphosphorylcholine, which has been demonstrated to be 
marginally increased in NPC plasma using an LC-MS/MS strategy in a pilot study [27]. 
However, it was recommended that this biomarker should be used in conjunction with for 
example plasma lysosphingomyelin-509, also known as N-palmitoyl-O-
phosphocholineserine [28] (with a median fold-change value of 65 in NPC plasma relative 
to healthy controls), in order to be applied in practice as a significant biomarker for diagnostic 
purposes [27].  
Further studies have been performed using LC-MS-based methodologies, analysing no more 
than 2 NPC samples which monitored urinary bile acid sulphate conjugates for diagnostics, 
i.e. 3β-sulfooxy-7β-hydroxy-5-cholen-24-oic acid and 3β-sulfooxy-7-oxo-5-cholen-24-oic 
acid, both of which were found to be very significantly upregulated in NPC disease [29]–
[31]. However, more recently, a larger study was performed by the same group and 
demonstrated upregulations in 3β-sulfoxy-7β-hydroxy-5-cholen-24-oic acid and its glycine 
and taurine conjugate, using urine samples from NPC patients (n = 23) and control (n = 28) 
participants [32]. A further investigation with control (n = 38) and NPC patients (n = 28) 
found similar findings with an AUROC value > 0.92 for 3β-sulfoxy-7β-hydroxy-5-cholen-
24-oic acid, 3β-sulfoxy-7-oxo-5-cholen-24-oic acid, non-amidated 3β-sulfooxy-7β-N-
acetylglucosaminyl-5-cholen-24-oic acid, glycine-amidated 3β-sulfoxy-7β-N-
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acetylglucosaminyl-5-cholen-24-oic acid, and taurine-amidated 3β-sulfoxy-7β-N-
acetylglucosaminyl-5-cholen-24-oic acid [33]. The most significant marker with an AUROC 
value of 1.0 was 3β-sulfooxy-7β-hydroxy-5-cholen-24-oic acid [33]. The sensitivity and 
specificity of these biomarkers, and how treatments can affect them, needs to be explored.  
BAs have been identified as potential biomarkers for early diagnosis in view of the observed 
upregulation of their precursors 7-oxocholesterol and cholestane-3β5α6β-triol in human 
urine and plasma. A novel MS assay was created in order to detect these bile acid biomarkers 
in dried blood spots, urine and plasma, and with a much larger sample size than those 
featured in the above studies [34]. Elevated BA concentrations indicate liver dysfunction; 
however, there not as yet definitive evidence for a decrease in these biomarkers following 
disease-modifying treatments, and hence they require further validation [34].  
A combination of these biomarkers in selected biofluids could provide more statistical 
power, since the majority of the analyses performed in these studies were targeted and 
univariate, whilst MV approaches could provide improved specificity for NP disease 
diagnostics. However, few investigations have evidenced these markers against disease 
progression and disease severity indices, which are clearly of much importance for clinical 
management in this disorder [35]. It is therefore necessary to ensure that potential biomarkers 
selected for NPC1 disease are specific to this condition in order to avoid misdiagnoses. At 
present, there is a lack of evidence in the literature to show the intrinsic value of these 
candidate biomarkers individually. Indeed, most of these diseases exhibit subtly different 
manifestations, translating into modified metabolic responses. Therefore, without thorough 
testing of the range of other LSDs, and assurance of the validity of such biomarkers, these 
cannot be entirely confirmatory, and hence misdiagnosis remains a possibility.  
Studies performed on Chinese hamster ovary cells, and those collected from an NPC patient 
versus an NPC carrier, and also COS-7 and fibroblast cells from an NPC patient, have also 
been analysed using an HPLC electrospray ionisation (ESI)/MS/MS strategy to determine 
sphingomyelin levels [36]. This study demonstrated an upregulation in total sphingomyelin, 
including specific species, such as d18:1/18:1, d18:1/18:0, d18:1/20:0, d18:1/22:0, 
d18:1/24:1, and d18:1/26:1 [36]. Moreover, this investigation showed that Rab9, a GTP-
binding protein that controls trafficking from the late endosome to the Golgi, is defective 
[36] and upon reducing sphingomyelin within the cell using sphingomyelinase, Rab9 was able 
to function more effectively, and cholesterol accumulation was concomitantly diminished 
significantly [36]. Consequently, sphingomyelin reduction is another potential therapeutic 
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target for NPC disease. This demonstrates the usefulness of metabolomics analysis of cell 
systems in lysosomal storage disorders to assess the mechanisms of cellular pathogenesis.  
Finally, high-resolution NMR analysis has been employed to observe the urinary excretion 
of miglustat, valproate, and valproate metabolites in NPC1 disease [37], which could 
contribute to more personalised medicine approaches in human patients. Similar studies have 
also been performed with high-performance liquid chromatography coupled with a light- 
scattering detection system (HPLC-LS), and these demonstrated the detection of HPβCD in 
human urine [38]. 
 
1.2 Gaucher’s Disease 
 
Similar to NPC disease, there are variants of Gaucher disease (GD) (types 1, 2 and 3): GD1 
(OMIM 230800) is non-neurological, whilst GD2 (OMIM 230900) and GD3 (OMIM 231000) 
are neurological conditions also involving the spleen and liver. Targeted metabolomics 
approaches have also been applied to GD, using LC and LC-MS technologies. The plasma 
biomarker glucosylceramide (GlcCer), and ceramide ratios, have been used in combination 
with ERT treatment for this condition, with levels significantly decreasing with 
corresponding treatments in GD1 patients [39]. Moreover, glucosylsphingosine has also been 
determined to be a biomarker in dried blood spots (DBS) from children with GD1 and 3 
diseases [48]. Glucosylsphingosine has also proven to have diagnostic potential in in other 
LSDs, further validating its potential as a generalised LSD-specific biomarker [40], [41]. 
However, as discussed by [24], glucosylsphingosine is also markedly elevated in the plasma 
of patients with NPC disease, but to a different extent - GD concentrations of 
glucosylsphingosine are relatively higher [24]. Another investigation showed an upregulation 
of glucosylsphingosine in Krabbe Disease (KD) and GD plasma samples, but the 
concentrations were distinguishable, since GD patients had significantly higher levels [42]. If 
this were the biomarker of choice, essential reference ranges would ensure that the correct 
diagnosis was given. Urine has received little attention as a potential biofluid sample type for 
GD metabolomics studies.  
Another investigation, [43], reported a potential marker for GD in serum, specifically GlcCer. 
Notwithstanding, there were validation issues in view of the lack of controls and 
heterozygous carrier samples integrated into the study for comparative purposes. Indeed, 
with a sample size of 2, the results presented by [43] also raises concerns regarding the 
reliability of results acquired. However, this represents one of the challenges presented by 
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the monitoring a rare LSD in human participants. Furthermore, samples were collected using 
invasive methodologies. Invasive sample collection is a common theme in the observation 
and monitoring of LSDs; more data could be generated by considering urinary metabolic 
profiles, together with those of other readily-accessible biofluids such as saliva, perhaps, 
which has successfully been utilised for the diagnosis of other diseases, including cancer and 
diabetes [44]. 
 
1.3 GM1, GM2 and GM3 Gangliosidoses   
 
Although much is known regarding the clinical aspects of the GM1 (OMIM 230500) (GM1), 
and GM2 gangliosidoses (OMIM 268800) (GM2), the cellular mechanisms leading to 
neurodegeneration are poorly understood, and the precise functions of gangliosides (i.e., 
their cellular and biochemical properties) remain incomplete. Moreover, very few 
metabolomics studies are yet to be performed on the GM1 and GM2 gangliosidoses. 
More recently, reversed-phase LC has been utilised to investigate potential biomarkers that 
can be analysed in biofluids by observing those detectable and validated in brain and liver 
tissues from mice, and hippocampus samples from humans with Sandhoff (SD, GM2) 
disease [45]. PCA analysis was able to successfully distinguish between SD and control 
hippocampus samples from humans, in addition to brain and liver samples from control and 
SD mice [45]. Disturbances were observed in pathways associated with protein catabolism 
and lipid metabolism. N-acetyl compounds were altered in the SD brain from humans and 
mice, including elevated N-acetylgalactosamine 4-sulphate which has been proposed to be 
correlated with a deficiency in the HexB enzyme [45]. N-Acetyl-L-aspartate and L-glutamate 
were downregulated in the brain [45]. The investigation focussed on brain samples and 
provided potential new targets for biomarkers which may be accessible in non-invasively 
collected biofluids.  
A study [46] distinguished between different gangliosides in a study which unfortunately did 
not account for the matrix effects exerted by biofluids, since the experiments were performed 
in vitro. Another investigation, [47], went further and developed a liquid chromatography-
electrospray ionisation-mass spectrometry (LC-ESI-MS) methodology which was able to 
monitor blood serum ganglioside levels in participants (n = 10) with different oesophageal 
diseases, but not the gangliosidoses. Other authors, [48], have developed a methodology for 
the observation of GM1 and GM2 gangliosides simultaneously in CSF using LC-MS-MS. 
This methodology used 30 human CSF samples in which GM1 and GM2 were ‘spiked’ and 
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recovered with a high accuracy, i.e. 98 and 102% respectively. More recently, [49], employed 
quantitative immunoassays to determine key biomarkers  in CSF and blood serum in 2 
infantile Sandhoff, 9 infantile Tay-Sach’s, 5 juvenile Sandhoff, 6 infantile GM1, 7 late 
infantile GM1 and 1 juvenile GM1 patients, and compared these to 100 healthy control 
participants. Of 188 metabolites tested, five key markers identified were epithelial-derived 
neutrophil-activating protein 78, monocyte chemotactic protein 1, macrophage inflammatory 
protein-1 alpha, macrophage inflammatory protein-1β, and tumour necrosis factor  receptor 
2, which were all upregulated in the CSF of gangliosidosis infantiles, and were also linked to 
inflammation within the central nervous system (CNS). In view of their rarity and severity, 
longitudinal metabolomics studies will, of course, take longer to perform. Markers which 
could be evaluated include those pertaining to CNS degradation, or lysosomal dysfunction 
such as quinolinate and N-acetylsugars respectively.  
Another investigation, [50], explored urinary N-acetylated storage compound biomarkers in 
patients with GM1 disease which arises from β-D-galactosidase deficiency. These researchers 
employed preparative TLC sequentially followed by 1D 1H NMR analysis, and found that 
the first of two bands investigated in this manner corresponded to an N-acetylated 
biantennary octasaccharide, and the second to an N-acetylated triantennary decasaccharide 
or tetraantennary dodecasaccharide [50]. The 500 MHz 1H NMR profile of a patient with 
this condition contained a series of N-acetyl-CH3 function singlet resonances within the 2.02-
2.04 ppm range at an analytical pH value of 2.50, that with the highest intensity being located 
at δ = 2.03 ppm. These results are consistent with elevations in the urinary concentrations 
of oligosaccharides with a D-galactosyl residue at their non-reducing ends.  
1H NMR spectra acquired on urine collected from a patient with Sandhoff disease 
demonstrated the excretion of oligosaccharides, specifically acetamido-CH3 function singlet 
resonances within the δ = 2.02-2.08 ppm range, the highest intensity one corresponding to 
a concentration of ca. 80 µmol/mmol of creatinine. Combined preparative TLC-1H NMR 
analysis provided evidence that these signals were at least partially ascribable to 
oligosaccharides with the structures β-GlcNAc-(1→2)-α-Man-(1-3)-[β-GlcNAc-(1→2)-α-
Man-(1-6)]-β-Man-(1→4)-GlcNAc (band 1), and β-GlcNAc-(1→2)-α-Man-(1-3)-[β-
GlcNAc-(1→4)][β-GlcNAc-(1→2)]-α-Man-(1-6)]-β-Man-(1→4)-GlcNAc (band 2).   
 
1.4 Future Perspectives for and Potential Limitations of Metabolomic 
Investigations for Monitoring LSDs 
 
Page 33 of 216 
 
Although [51] recently discussed some future perspectives for metabolomics in inborn errors 
of metabolism, these considerations could be further developed. For example, a thorough 
metabolomics analysis of the effects of ERTs and SRTs on patients with LLSDs could 
provide vital insights into the effectiveness of these clinical approaches by observing 
biomarkers in a multidimensional context, a simple example being the concomitant 
observation of elevated markers decreasing, and depleted markers rising in their biofluid 
concentrations. It is evident that new, robust, non-invasive treatment options need to be 
explored for LLSDs: in the case of neurological disorders, variants of these therapies are 
required to successfully cross the BBB. To enhance ERT, the use of nanoparticles to facilitate 
the ability of enzymes cross the BBB is also being explored, since they protect the enzyme 
delivered against its in vivo degradation [52]. Thus, metabolomics could play a role in 
ensuring that this methodology is effective, and perhaps also serve to validate candidate 
biomarkers. Moreover, nanoparticles are also being employed for the gene therapy trialling 
of non-viral vectors, and again metabolomics could facilitate the provision of insightful 
information regarding the effectiveness of such therapies [52]. However, one major potential 
drawback for the use of nanoparticles is that their long-term toxicity remains speculative, a 
process which again could be explored using metabolomics as a vital probing tool.  
Urine samples are yet to be analysed to the same extent as blood plasma/serum and CSF in 
these patients, and donations of this biofluid obviously constitutes a less invasive collection 
procedure. Although all biofluids and tissues have been probed in these works, plasma 
appears to be the biofluid of choice for such studies. Interestingly, no metabolomics studies 
have been performed on human saliva, which would be advantageous for virtually non-
invasive sampling purposes. In principle, saliva also has the potential to represent the full 
physiological status of the human body, just as blood serum or plasma samples can, it should 
be noted that many fully-characterised, established blood plasma markers are often present 
in saliva at much lower concentrations [44]. Salivary biomarkers have been found using 
metabolomics in diseases, such as cancer and diabetes [44]. However, the disadvantage of 
use of this biofluid for such investigations is that it may easily be compromised, i.e. influenced 
by external factors such as poor oral health/hygiene, and eating or drinking episodes prior 
to sampling. Hence, these investigations should be carried out with extreme care, particularly 
careful sample collection [53]. Moreover, very few studies have been performed on brain 
tissue from living participants in view of the inability to retrieve such samples. However, 
murine brain has been analysed as described above [15], [17], [45]. However, currently there 
remains a whole scope of unexplored biofluids, tissues and cells that can be investigated for 
LSDs, e.g. urine and CSF in Gangliosidosis. NP has been investigated by MS- and NMR-
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linked metabolomics investigations thoroughly, with a total of 24 publications arising from 
the study of the disease. Less metabolomics research has been performed on GD, however, 
with only 5 publications targeting the disease, respectively at the time of this report, and very 
little has been completed on Gangliosidoses. These are areas which could clearly be further 
investigated. It would also be of much interest to explore metabolic correlations of both 
biomarker and non-biomarker variables between differing sub-classes of the same disorder, 
i.e. NPA, NPB and NPC, and any similarities they may have with GD and gangliosidosis. 
This has shown to be extremely useful in other investigations to establish the specificity of 
the marker [54]. 
Lack of uniform studies across all LLSDs is evident within this review in terms of 
experimental design and statistical approach, not to mention the bioanalytical strategies and 
techniques employed for these purposes. More systematic metabolomics studies will provide 
a wealth of information regarding the significance of the current biomarkers identified, and 
also allow for more facile and expedient cross-validation of metabolites. Larger scale studies 
are also required, since they aim to provide much more representative dataset profiles. [34]’s 
study is a good example of this. As discussed above, it is also of much importance to use a 
biomarker or combination of biomarkers which are rigorous enough to avoid misdiagnosis, 
as demonstrated by [20], [22].  
LC-MS/MS is clearly showing some promise in detecting NPC disease, demonstrating an 
elevated level of blood plasma cholestane-3β5α6β-triol. However, there is a major 
requirement for such developments to be integrated into clinical practice, perhaps in 
combination with one or more specific biomarker for potentially confounding sterol 
disorders, or for NPC disease itself. A combination of the phenome, metabolome and 
genome could translate the research in metabolomics into practice to modernise medicine; 
however, for this to operate effectively, method development and validation are also crucial 
[6]. One of the major disadvantages of translating MV NMR datasets into medical practices 
is that the facilities employed for these purposes, such as NMR and LC-MS, have both high 
purchase and maintenance costs, and require specialist training for use, interpretation and 
subsequent data analysis. However, NMR technology is also showing some promise in 
benchtop instrumentation, which could be considered for clinical applications with the 
advent and development of water suppression sequences and automation now possible [55]. 
NMR approaches may prove to be invaluable as substantial technological advancements are 
being made in this field, with technologies such as hyperpolarisation increasing instrumental 
sensitivities. Emerging technology such as computational tools are also becoming a more 
integral part of metabolomics applications, and artificial intelligence technology could 
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effectively simplify and distinguish normal from unusual patterns of results acquired by 
metabolomics-based instrumentation.   
Another area of metabolomics research which is yet to be explored in depth is neonatal and 
prenatal testing for LLSDs. Some investigations have been performed on paediatric patients, 
and to date this offers some opportunities for further developments within this field [56], 
[57]. These diseases are often overlooked in view of their rarity, and hence diagnosis and 
prognosis are not established until later in the lifespan of the patient. Notwithstanding, 
currently available reports have emphasised that early detection of these diseases is a highly 
beneficial patient requirement, and hence early testing and diagnosis could indeed represent 
a life-saving process.  
In summary, despite some progress, metabolomics approaches have yet to influence 
diagnosis and monitoring of LLSDs in clinical practice. Clinical diagnosis is dominated by 
PCR-based genetic testing and enzyme assays, and hence using metabolomics to diagnose 
LLSDs is still in its infancy. Nevertheless, future opportunities in this area remain, most 
especially in an era where personalised medicine is becoming an increasingly greater practical 
likelihood. Future developments required for LLSDs include (1) systematic sample collection 
and handling, (2) further validation of at least some of the potential biomarkers suggested 
via the rigorous monitoring of their biofluid levels along with simultaneous co-ordinated 
assessments of clinical responses to treatment(s); (3) detailed correlations of biomarker 
concentrations with disease severity, and also demographic variables such as age, gender and 
diet, etc.; and (4) a further detailed review in order to ensure that biomarker(s) identified are 
solely specific to particular LLSDs. 
 
1.5 Conclusions 
 
To date, metabolomics techniques have only scratched the surface in terms of their 
applications to the lipidoses; however, to date they have provided some promising diagnostic 
and prognostic information for NPC-1 disease and its responses to different therapeutic 
treatments, which has revealed some promising biomarkers. In addition, more global 
experimental design and bioanalysis strategies may provide more valuable information, rather 
than limiting research to that focused only on a limited number of biomarkers as in pre-
targeted methodologies. Moreover, carefully-planned meta-analysis studies involving MV 
adjustments may also offer support for both targeted and untargeted LSD biomarker 
research.  This thesis aims to explore these developments further. 
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Chapter 2: Methodology 
 
2.1 Metabolomics  
 
There are over 200 ‘omics’ sciences in existence, in which metabolomics is a relatively new 
field of these and this involves the characterisation of small molecular ‘signatures’ or 
‘fingerprints’ which are associated with biological systems [58]. The metabolome itself 
consists of low-molecular-mass compounds which are present in certain cells at a particular 
phase in the organism studied [59]. All molecules are involved in metabolic processes once 
inside an organism, and metabolism is a set of reactions which cells perform for growth, 
maintenance, reproduction and death.  Disruption of these processes can cause problems 
within the system analysed. 
Metabolomics plays a key role in combination with genomics and proteomics, as illustrated 
in Figure 2.0 and promotes our understanding of cellular processes, diseases, and mutations, 
but the metabolomics approach is quite different, since these older ‘omic’s techniques are 
expensive, labour-intensive, and cannot easily contend with the thousands of biomolecules 
which are simultaneously identified, quantified and statistically differentiated [59]–[62]. 
Unlike genomics and proteomics, metabolomics focuses on biological fluids which express 
the pathological status of that organism at a particular point in time, which can change in a 
diurnal or more prolonged time-dependent manner in view of environmental factors, and 
therefore metabolomics investigations are very complex [59]. However, metabolomics 
strategies are very advantageous, providing  detailed information regarding cellular functions 
within the organism, and also the effects of xenobiotic exposure [62]. 
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Figure 2.0. Loop diagram representative of the relationships between genomics, proteomics 
and metabolomics. 
Metabolomics studies are vital in healthcare since they aim to observe disease-specific 
metabolic modifications, and in in particular highlighting specific biomarkers in a metabolic 
profile relating to disease, and enhancing disease diagnostics via providing knowledge 
regarding which biological pathways are being expressed [6], [63]. In addition, metabolomics 
analysis has potential to show the effectivity of the treatments prescribed alongside their  
downstream products, which can aid pharmaceutical research and development [63]. 
Metabolomics has alternative applications in nutrition, environmental studies, agriculture and 
food safety, but these are not explored in this particular research work [63], [64]. 
The growth of this field over the past 20 years is astonishing and ever-expanding, with a 
focus on an entire biological system rather than just a single cellular system [62].  
Metabolomics was first a relatively common practice in ancient Chinese medicine which 
noted different tastes, smells and colours of urine [64]. This biofluid, which is considered a 
waste product from the body, was further recognised as extremely useful in diagnosis of 
disease by the Egyptians, who noted that the smell, taste and colour of urine was different 
with different medical conditions and could be ‘mapped’ (Figure 2.1) [60]. Urine is composed 
of 95% (w/w) water, but also contains ions such as sodium, chloride, potassium, phosphate, 
sulphate, iodide, amides and also a number of amino acids and organic acids present at low 
concentrations [65]. Colour wheels were soon developed, which gave diagnostic information 
indicative of diseases; for example, a brownish colour would indicate jaundice [60].  
Although the ancient Chinese and Egyptians utilised these methodologies originally, 
metabolomics was first coined in 1940 by Roger Williams, and by using chromatography, he 
found a difference between the urinary profiles of schizophrenics when compared to those 
of healthy individuals [66]. Much later, Oliver in 1998 noticed differences in yeast cultures 
Proteomics
Metabolomics
Genomics
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with different genomes using microbiology, and termed this as metabolomics, a descriptor 
which was refined by Nicholson in 1999 [67].  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Egyptian urine wheel describing colours, tastes and smells of urine, published 
in 1506 by Ullrich Pinder in his book Epiphanie Medicorum. 
Urine gained even more diagnostic recognition when it was then used for diagnosis of the 
first genetic disease - alkaptonuria [60]. Nowadays, urine is collected in universal containers 
and more routinely used for dipstick tests which can instantaneously measure urinary glucose, 
bilirubin, ketone bodies, nitrates, leukocytes, haemoglobin etc. [60], (Figure 2.2) with more 
detailed urinalysis being utilised for renal conditions. Furthermore, it is frequently used as a 
metabolomics tool [60]. For example, increased urinary levels of taurine and creatine have 
been correlated with acute liver and testicular toxicity respectively, but metabolomics is not 
limited to just these examples, since there are many others [62]. The primary advantage of 
urine as a sample is that it is considered non-invasive for diagnostic purposes, has a simple 
collection procedure, and large volumes of it are readily available.  
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Figure 2.2. Typical dipstick test information derivable from human urine samples. 
Indeed, although urine demonstrated diagnostic application potential, blood has also shown 
to be extremely valuable for these studies. This biofluid, which is composed of plasma/serum 
and cellular matter, is predominantly water-containing, and has a primary function of 
transportation of cells and molecules including platelets, white and red blood cells, and 
proteins around the body [61]. Although blood is useful in metabolomics, it is more difficult 
to collect than urine, since it is collected by venepuncture by a trained healthcare specialist 
(phlebotomist).  
Both plasma and serum can be utilised for metabolomics analysis. Blood can be collected in 
combination with an anticoagulant, for example lithium heparin tubes or 
ethylenediaminetetraacetic acid (EDTA) tubes, and after centrifugation, plasma is collected. 
Without the anticoagulant, serum can be collected [61]. The primary responsibility of blood 
is to behave like the body’s ‘motorway’, transporting hormones, gases, nutrients and 
metabolic waste to appropriate organs [61].    
Blood has been analysed for over 70 years, and has profound clinical importance; indeed, 
reference ranges have been established for the majority of its components, and tests similar 
to those shown in Figure 2.2 have been developed for blood, and metabolomics analysis is 
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growing for both serum and plasma [61]. Some diseases are a direct influence of the condition 
of the blood such as cancers such as leukaemia, myeloma and lymphoma.  
Cerebrospinal fluid (CSF) studies are more infant than those involving blood and urine, 
although over the past 60 years reference ranges and metabolomics studies have been applied 
to CSF [63]. CSF is less commonly used as a sample for metabolomics purposes, since it has 
a more invasive sample collection nature, which is performed via lumber puncture [68]. CSF 
is located in the ventricles and subarachnoid space of the brain and spinal column, and has 
the primary function of protecting the brain from shock, but it also manages the nutrients 
and biomolecules filtered from the blood to the brain [63]. In view of its location, CSF is 
commonly utilised for diseases which affect the central nervous system (CNS), and plays an 
important role in biomedical research and clinical chemistry for diagnosing and monitoring 
diseases such as Parkinson’s and Alzheimer’s diseases, multiple sclerosis and brain injuries 
[63], [69]. LLSDs also affect the CNS, and CSF is yet to be analysed in metabolomics studies 
exploring such conditions as described in Chapter 1. 
At present, all biofluids, cell extracts, tissues and even organs are used in metabolomics 
research, and provide researchers with key information regarding the pathological status of 
patients, information which other ‘omics’ fields fail to fulfil [64]. More recently in 2004 the 
Human Metabolome project was launched in order for scientists to gain further 
understanding regarding metabolites in the human body, and in order to harmonise 
information gained across different bioanalytical platforms [65]. Databases have been 
developed to increase the ease of sharing information when new metabolites are found, and 
these include Biological Magnetic Resonance Bank (BMRB) and The Human Metabolome Database 
(HMDB), which integrates The Urine Metabolome Database (UMD) and The Serum 
Metabolome Database (SMDB), has the ability to enable scientists to identify thousands of 
compounds in a range of biofluids, this number continually growing as the sensitivity of 
techniques available increases, together with the number of diseases being analysed via this 
process [60], [65].  
Scientists are now further informed regarding pathways which molecules are attributed to 
with the creation of databases such as KEGG, BioCyc, Lipid Maps and Reactome [61], [65]. More 
recently, fully-automated NMR experimental and spectral profiling has been introduced in 
order to increase accuracy, precision, efficiency and speed of analysis, for example the use of 
Bruker’s Biorefecode2 which integrates NMR metabolites into the acquisition software [70]. 
These processes are all relatively new, and they are continuously developing in this growing 
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field in order to understand pathogenesis and drug metabolism, and also to harmonise such 
metabolomics data.  
Metabolomics can be described as targeted or non-targeted, dependent on whether specific 
metabolites are being observed or whether a collection of metabolites are being analysed, 
respectively. All biological samples have the potential to be used for metabolomics analysis, 
including blood (plasma, serum, erythrocytes, etc.), CSF, tissue, sweat, muscle and faeces. 
The focus sample for this study is urine, plasma and CSF. These biofluids are used in a 
multitude of methodologies in order to understand disease progression and drug 
pharmacology, as will be demonstrated in later chapters. 
Xenobiotics are also a particular focus, since this is an area which genomics and proteomics 
are unable to explore.  Indeed, the biological actions and effects of xenobiotics are able to 
be ‘fingerprinted’ via metabolomics investigations, and the metabolism of these can also be 
explored.  
 
2.1.1 Techniques 
 
As the field of metabolomics has grown, the techniques which are used have advanced 
tremendously, as has been demonstrated in a review of their growth since the early 1990s 
[64]; from colour wheels and tastes of biofluids back in the Middle Ages (Figure 2.1) to now 
utilising techniques such as MS and NMR in order to identify metabolites (both techniques 
are described in-depth in Sections 2.2 and 2.3) [60]. This combination of complementary 
techniques is applied in this study in view of their advantages and disadvantages. MS 
techniques are much more sensitive than NMR ones, i.e. the smallest metabolite and/or drug 
concentrations that can be quantified with MS are in the pico-molar level range, in 
comparison to NMR which has a sensitivity at the µM level [59]. In contrast, NMR has the 
greatest advantage of being non-destructive, and minimal sample preparation time is required 
[64]. NMR can also simultaneously detect multiple molecules in a sample, without prior 
separation, which is one of its greatest advantages. However, the cost of the instrument is 
considerably higher than that of MS, and signal overlap can sometimes be problematic [64], 
[71]. In addition, MS may not detect ions in view of matrix effects [64]. The exponential 
growth in the use of these techniques (Figure 2.3 and Figure 2.4) shows the difficulties of 
choosing between the methodologies and often a combination is preferred. 
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Figure 2.3. Growth in the fields of MS- (green) NMR- (blue) and combined NMR/MS 
analysis-based (red) metabolomics publications in the research field [64]. 
There are many variants of MS and other techniques which are widely applied in 
metabolomics research, and these are commonly described as hyphenated techniques, 
including LC-MS, Gas Chromatography – Mass Spectrometry (GC-MS), Direct flow 
Injection Tandem Mass Spectrometry (DFI/LC-MS/MS), Inductively-Coupled Plasma- 
Mass Spectrometry (ICP-MS), Ultra High Performance Liquid Chromatography-High 
Resolution Orbitrap Mass Spectrometry (UHPLC-HRMS), Electrospray ionisation mass 
spectrometry (ESI-MS), or alternatively HPLC with UV or Fluorescence detection (FD) 
systems [60], [64]. NMR analysis can also be used as a hyphenated technique, namely LC-
NMR. A combination of complimentary approaches is likely to increase the overall 
metabolite coverage, since each technique has some limitations as well as benefits [64].  The 
wide range of metabolomics instrumentation enables an analyst to acquire different 
information (dependent on the choice of methodology) in order to determine the nature and 
concentrations of biomolecules [59]. However, the wide range of techniques does cause 
difficulty in the harmonisation of data in this field, and the literature expresses a great need 
to develop all-inclusive reference resources [69] inclusive of research groups such as 
coordination of standards in metabolomics (COSMOS) specifically developed for this 
purpose. 
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Figure 2.4. Challenges of choosing between NMR and LC-MS [72]. 
Once data has been acquired using one of these ‘state-of-the-art’ bioanalytical techniques, it 
is then subjected to multivariate or multidimensional statistical analysis strategies. This 
methodology can be described as a biological derivative of chemometrics. With many 
metabolites being identified by a particular technique, such as NMR analysis for example, it 
is important to know which of these are significant in a particular disease process within the 
large dataset acquired. Multivariate statistics is employed in order to understand if the 
datasets between groups of data are significantly different or similar, and if so, which 
metabolites are contributing to these similarities or differences. The statistics will also 
provide information on how effective the performance of the tests applied and the 
significance of the overall result. Molecules or biomolecules with significant differences can 
be traced back through the cycles which they are derived from in order to further understand 
the disease or, for that matter, drug mechanism of action or pathway. This chapter aims to 
provide an in-depth review of the techniques described above, and their uses in 
metabolomics research approaches are explored throughout. 
 
2.2 Nuclear Magnetic Resonance 
 
NMR is a spectroscopic technique focusing on the observation of the magnetic properties 
of many different nuclei in different molecules. Unlike Ultraviolet-Visible (UV-Vis) and 
Infrared (IR) spectroscopies, which focus on the sole principle of Planck’s law, NMR relies 
on unique nuclei which possess magnetic properties in order to be detected. In addition, 
these nuclei must have an odd number of protons or neutrons, and are therefore NMR-
active. Planck’s law still applies, but it’s significance is secondary, since these molecules are 
excited by radiofrequencies, but under the influence of a magnetic field. The novelty of NMR 
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spectroscopy enables the chemist to gain information about molecules at both atomic and 
molecular levels [73]. 
The foundations of nuclei possessing a magnetic spin was first recognised by Pauli in  1924, 
and these ideas were then further developed by Rabi in 1939 who created the first frequencies 
involving a beam of lithium chloride [74]. Redfield then explored the theory of relaxation 
processes [75], and NMR was then developed from these principles by Bloch and Purcell 
from 1945-1970 who won several Nobel Prizes. Continuous wave (CW) methods were used 
to observe nuclei spin, experiments which use a permanent magnet/electromagnet and a 
radio frequency oscillator to produce two fields B0 and B1 respectively [76]. To produce 
resonance CW methodologies varied the B1 field or the B0 field to achieve resonance [76]. In 
essence the magnetic field is continuously varied and the peak is recorded on a oscilloscope 
or an x-y recorder [76]. However, these methodologies advanced, and at present pulse 
sequences are applied; this methodology is reviewed in more depth below [77].  
Characteristic nuclei with magnetic spin obtain a nuclear spin quantum number (I) and their 
own angular momentum (p) associated with it, and their relationships are established in  
equation (1) which is defined for each isotope [78]. This angular momentum (p) can be 
described as that about an axis, and has its own magnetic moment (µ) [78]. The link between 
these two parameters can be given by the nuclei’s gyromagnetic ratio (𝛾), as in equation (2). 
These developments are expressed here: 
(1)         𝑝 = 𝐼
ℎ
2𝜋
 
(2)           𝛾 =  
𝜇
𝑝
 
Every nuclei can be described as having a characteristic magnetic moment (e.g. 1H, 13C, 19F), 
but in order to be detected by NMR, the correct isotope needs to be observed, i.e. that which 
has odd number of protons or neutrons in the nucleus [78]. The characteristic nuclei have a 
spin of 
1
2
 and are classified as spin-half isotopes. Within the magnetic field the nuclei have its 
own magnetic influence too, since it is surrounded by negatively-charged electrons. 
Outside a magnetic field, nuclear spins are orientated randomly in space (Figure 2.5, Left). 
However, once the nuclei are placed in an external magnetic field, the nuclei will orientate 
with or against that field, once thermal equilibrium is reached [79] (Figure 2.5, Right). The 
nuclei, with a positive spin, will orientate with (parallel) the field and the nuclei with a negative 
spin, will orientate against (anti-parallel) that field. This can be described as the Zeeman Effect, 
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which describes this classic orientation of nuclei when exposed to a magnetic field, and this 
is illustrated in Figure 2.5. The parallel nuclei are at a lower (α) energy state in comparison to 
those anti-parallel to the field (β). However, almost equal proportions of the nuclei are 
distributed between both anti-parallel and parallel states, and this is known as the Boltzmann 
Distribution [78]. These ideas are illustrated in Figure 2.5, (3) and (4). 
 
 
 
  
 
 
(3)      
𝑁𝛽
𝑁𝛼
=  𝑒
−∆𝐸
𝑘𝐵𝑇  
(4)    𝐸𝛼 =  +
1
2
𝑣0,1 𝑎𝑛𝑑 𝐸𝛽 = −
1
2
𝑣0,1 
In equation (3), the number of protons in the β and α state are represented by Nβ and Nα, 
respectively. The difference in energy is represented by ΔE, the Boltzmann constant is 
represented by KB, and the temperature by T. In equation (4), the energy of β and α are 
denoted by Eβ and Eα respectively and frequency is denoted by ν. When a nucleus is in a 
homogenous magnetic field, it can be said to align along the z-axis or B0. In addition, nuclei 
are said to precess around this axis since complete magnetisation is not possible. This 
phenomenon is given by the Larmor equation, which defines the angular velocity of the 
precession movement.  
(5) 𝜔0 =  𝛾𝐵0 
Nuclei in the lower energy state can be transferred to the higher energy state (beta), a 
phenomenon known as a ‘spin-flip’ once the nuclei are irradiated with a pulse of 
radiofrequency. Energy is released when the nucleus ‘flips’ and can be measured as in normal 
spectroscopy using equation (5). The higher the radiofrequencies (measured in MHz) are, the 
more ‘spin-flips’ occur, which in turn produce a resonance and this is reflected by the 
Figure 2.5.  The Zeeman Effect: Arrows represent nuclei.  Left: Randomly orientated nuclei 
in space. Right: Magnetised nuclei showing an almost equal proportion of them between the 
anti-parallel and parallel spin states, if the magnetic field was north, the ascending arrows 
would be parallel to the field, and the descending arrows would be anti-parallel to the field. 
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Boltzmann Distribution. The energy, which is absorbed by the nuclei to perform this transition 
from a low energy state to a high energy state, is expressed by the Bohr condition, and this 
shows the application of Planck’s law: 
(6)   ∆𝐸 = ℎ𝑣 =
𝛾𝐵0
2𝜋
 
The relationship between the Bohr condition and the Boltzmann distribution show that a 
small population of excess nuclei are in the lower energy state [79]. However, this is vital to 
create an NMR signal, since this small population of nuclei become excited and create the 
NMR signal.  Due to only a small population of nuclei experiencing a change in energy, this 
renders NMR a relatively insensitive technique relative to MS. This small population 
difference creates a net magnetisation (M0) parallel to the magnetic field (B0). 
In order to produce an NMR signal, the magnetisation vector, M0, must be rotated from the 
z-axis towards to x or y plane [78]. In order for this to occur, nuclei are irradiated with a 
radiofrequency pulse orthogonal to B0, which oscillates at the Larmor frequency achieving 
the desired resonance [79]. The direction of the nuclei has changed from the z-axis to the x-
y-plane. The Larmor frequency can be defined as when the precessing orientations have the 
same energy as the resonance frequency of the system. This radiofrequency pulse is described 
as being a 90° pulse, since the magnetisation vector has translated 90°, as shown below in 
Figure 2.6 by the red arrows. Only when the magnetisation has been transferred to the x,y 
plane, can an electrical current be generated, which will be detected by the receiver coil, 
producing a resonance in the x-axis, also shown in Figure 2.6.   
 
 
 
 
 
 
 
Figure 2.6. Magnetisation transferring from the z-plane (B0) to the x-y plane enabling an 
electrical current to be generated [80].   
The resonance causes transitions between energy states in a manner which nuclei can be 
excited to the higher energy state. These are respectively described by equation (4) and Figure 
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2.5. Only a small quantity of nuclei will move from the lower to the higher energy state, and 
once in this latter state, this energy, which is absorbed, can induce a voltage, which is then 
detected by a coil of wire, and which can be amplified. The amplification of the voltage 
produces a free induction decay (FID), which shows a loss of energy over time as shown in 
Figure 2.7. 
 
 
 
 
 
Figure 2.7. Free induction decay (FID), showing an intense magnetisation on the left 
decaying on the right. 
The loss of energy in NMR is ultimately determined by two different parameters known as 
T1 and T2, which can be described as relaxation. Longitudinal (spin lattice) relaxation (T1) 
is the re-equilibration of α and β states by transfer of energy to the motion in the sample 
(lattice). The nuclei flip back to the z-axis, i.e. the spin flips back to non-excited positions, 
and therefore exponentially decays, similar to a half-life and is a first order process. This is 
also termed as thermal equilibrium and is important in small molecule NMR spectroscopy. 
Transverse (spin-spin) relaxation (T2) is the interaction of spins between molecules and 
unbunching of spins in the x-y plane. Some nuclei precess fast, whilst some nuclei precess 
slower, dependent on the size of the molecules.  
In summary, the novelty of using a magnet ensures that the results are acquired in a different 
manner to alternative spectroscopic techniques such as UV-Vis and IR as noted above. The 
energy emitted by the nuclei changing energy states creates energy within the detector coil; 
this then creates a FID, which arises from a series of cosine waves [78]. These waves are then 
processed mathematically, using Fourier transform (FT), to create an NMR spectrum [78]. 
An NMR spectrum is shown as ppm/Hz along the horizontal axis and intensity along the 
vertical axis. Using ppm is more universal, since it enables the user to compare results arising 
from all instruments. 
In order to analyse NMR spectra, some basic principles need to be outlined in order to 
understand the information spectra can provide. Ethanol will be used as a typical example of 
how to analyse a basic NMR spectrum. Ethanol is composed of 2 carbons, 6 hydrogens and 
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an oxygen which is identical to that of dimethyl ether as shown in Figure 2.8. These principles 
will outline how the two molecules can be distinguished via NMR spectroscopy. 
 
 
 
 
Figure 2.8. Molecular structures of ethanol and dimethyl ether. 
 
Number of Signals shows the number of hydrogen nuclei chemical environments that are 
present in the sample - this is dependent on the chemical components of the molecule. Spin-
spin coupling is also characteristic for high-resolution spectra, and provides information 
regarding the spin of directly adjacent, surrounding nuclei. The measure of the strength of 
the interaction between two nuclei is known as the coupling constant. Magnetically-
equivalent nuclei do not show any splitting. However, it is important to note that chemically-
equivalent nuclei may be magnetically inequivalent. As shown in Figure 2.9, ethanol produce 
triplet and a quartet signals, which arise from spin-spin coupling. The orientation of the 
nuclei in their different positions is shown in Figure 2.10. This is also known as multiplicity, 
which follows the (n+1) rule based on Pascal’s triangle for simple molecules. This 
phenomenon occurs due to different energy levels exerting an influence on the signal. The 
observation of the -CH3 group producing a triplet is attributable to the neighbouring 2 
hydrogens on the adjacent carbon and the different sub-levels within that nucleus. Likewise, 
Figure 2.9. 1H NMR spectrum of ethanol (left) and dimethyl ether. 
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the -OH group gives rise to a singlet resonance since the hydrogen will undergo rapid 
chemical exchange, which removes the potential coupling. 
Chemical shift is crucial in NMR; the scale of the NMR is described as being in ppm (or Hz) 
and shows the location of the signal. The frequency x-axis scale, in ppm, is uniform across 
all NMR spectrometers, regardless of frequency of the instrument. The precise chemical shift 
value of a resonance is dependent on what class of nuclei is resonating, and is proportional 
to the magnetic field that is applied to the nucleus. Below is a guide to 1H NMR chemical 
shift values (Figure 2.11), which illustrate basic ideas regarding expected shifts. Hydrogens 
bonded to more electronegative nuclei (e.g. those within carboxylic acids, aromatic 
molecules, etc.) tend to resonate downfield, whereas less electronegative nuclei tend to 
resonate upfield (e.g., alkanes). Such chemical shift phenomena are present because the 
electrons around the nuclei have a shielding effect against the applied magnetic field, and the 
nucleus effectively becomes magnetically shielded or deshielded. This can be represented by 
the Larmor Frequency.  
 
Figure 2.11. Simple guide to NMR chemical shift values [81]. 
Figure 2.10. Spin-apin coupling of a triplet and quartet showing the different orientations 
of the nuclei. 
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Integration of NMR spectra enables the user to quantify the concentration of molecules from 
spectra. This information can be extracted from the intensity of the signal, but it is also vital 
to account for the number of hydrogens attached to them producing this signal. Integration 
involves analysis of the area underneath resonances. The NMR spectra therefore provides 
quantitative information regarding hundreds of metabolites in the case of biofluids. 
This is an outline of the very basic rules of NMR spectroscopy and takes into account the 
principles for most first-order systems, also known as AX, AMX and A2MX systems in which 
hydrogen nuclei are chemically- and therefore magnetically- equivalent. However, the 
coupling of nuclei and how they interact with one another becomes more complex with 
larger molecules with different types of nuclei, which are not chemically or magnetically 
equivalent, but share the same three-dimensional ‘space’. Nuclei themselves are small 
magnets, and once placed in a magnetic field, their own magnetic field affects surrounding 
nuclei which ‘disobey’ these basic rules and create different splitting patterns outside of the 
n+1 rule. More complex formations of resonances can occur, and these are created from 
non-first order systems, such as AA’XX’ AB and ABX ones.  
Nuclei which are the focus for this thesis are primarily 13C and 1H, since biofluids are 
predominately composed of organic molecules, as indeed are most drugs. However, NMR is 
not limited to observing 13C and 1H; metal ions can also be analysed as part of metabolomic 
analysis, using chelating agents such as Ethylenediaminetetraacetic acid (EDTA). 
Furthermore, phosphorus (31P) and fluorine (19F) NMR probes can also be utilised. All these 
nuclei possess a nuclear spin quantum number (I) of  
1
2
 which can both be analysed by NMR 
spectroscopy. It is easy to elucidate metabolites with the use of NMR, however; more 
specialised techniques such as LC-MS or LC-MS/MS are required when observing some 
molecules, if they are present at only limited quantities in biological fluids and this will be 
explored in the following chapters. 
The main advantages of NMR for metabolomic analysis is that it provides a non-targeted 
metabolomic, near global approach, which is able to detect a combination of hydrophilic and 
lipophilic metabolites, dependent on pulse sequence and extraction methodologies applied 
[68]. Furthermore, samples do not require pre-preparation in most cases, and the quantitative 
analysis is fast, non-invasive, non-destructive and reproducible [68]. In addition, only small 
sample quantities are required, which overall renders NMR as the methodology of choice.   
The following sections will review specific NMR pulse sequences which are applied to 
biological fluids throughout the practical chapters. Biological fluids require different 
experimental and acquisitional conditions in order to produce desired results, since the 
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biomolecules present are generally of limited quantities. Larger molecules could ‘hide’ the 
smaller ones which would impact analysis, so overcoming this obstacle is further explored. 
Furthermore, this section aims to provide an insight into techniques which enable the 
identification of such molecules, which is of much importance when distinguishing 
biomarkers.  
 
2.2.1 Water Suppression  
 
Saturation of the water signal is particularly important for biomedical NMR analysis, 
especially when considering biofluids. Some biological samples, such as urine, contain up to 
95% (w/w) water, in addition to many thousands of biomolecules [60]. However, the 
presence of such a high quantity of water is troublesome to spectroscopists, since it hides 
valuable information from surrounding metabolites which resonate at a similar frequency. 
This is problematic, as small concentrations of metabolites could be missed entirely, and so 
techniques have been developed in order to overcome this issue. Without resolution of this 
problem, such metabolites would be masked by the overlapping solvent signal. 
A standard pulse sequence consists of using a 90° pulse and data acquisition, the FID is 
recorded and then FT is applied to produce the spectrum. However, for water suppression 
overcoming this issue requires a change in pulse sequence to minimise the signal. The most 
employed NMR techniques applied for water suppression in metabolomics are NOEPR 
(Nuclear Overhauser Effect pulse with Presaturation during relaxation and mixing time) and 
PRESAT (Presaturation). These techniques are usually used succinctly as a NOESY-
PRESAT and provides an untargeted metabolomics approach and in combination aim to 
enhance the signal of the small metabolites whilst eliminating the solvent signal.  
The PRESAT experiment is composed of two pulses with a low radiofrequency which 
selectively saturate the water signal by irradiating during the relaxation delay. These long 
pulses targeted at the order of solvent T1 ensure that the nuclei are not allowed to relax and 
therefore a signal, in turn, is suppressed. If the nuclei do not relax, they cannot be detected 
via NMR. Any group which chemically interchanges with water such as molecules with -OH, 
-NH groups will be suppressed too. NOEPR focuses on reducing the solvent signal during 
the recycle delay and mixing time as the pulse sequence is similar to the NOESY 
experimental. The sequences are structured below: 
(7) 𝑃𝑅𝐸𝑆𝐴𝑇 [𝑃𝑟𝑒𝑠𝑎𝑡(𝑅𝐷) − 90°] 
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PRESAT is where the duration of the pulse is inversely proportional to the width of the area 
excited which in turn means the longer the pulse signal, the narrower the spectral bandwidth. 
(8) 𝑁𝑂𝐸𝑃𝑅[−90° − 𝑇1 − 90°𝑡𝑚 − 90] 
NOEPR is where T1 is a short delay and tm is the mixing time in which the water is 
specifically irradiated which reduces the signal by enhancing the population difference in 
nearby nuclei [82]. 
These techniques are utilised together throughout this thesis in order to gain the results 
acquired in a manner which is simple and robust [78]. Although other water suppression 
techniques can be utilised such as Water suppression enhanced through T1 effect. 
WATERGATE and Excitation pulse sequences are other methodologies which can be 
utilised for water suppression. 
 
2.2.2 Carr-Purcell-Meiboom-Gill (CPMG) Pulse Sequence 
 
CPMG was first developed by Carr and Purcell and later refined by Meiboom and Gill. 
CPMG pulse sequence is a 1H NMR which is specifically used for pre-extracted plasma in 
this study, in order to reduce the signals occurring from proteins and lipids [82]. Proteins and 
lipids produce a large baseline and the CPMG pulse sequences aims to reduce this. The pulse 
sequence focuses on the small molecules, which are of most interest in untargeted 
metabolomics studies [83]. The larger molecules are allowed to relax first, as they have small 
T2 values, prior to detecting the small molecule resonances [83].   
For the CPMG pulse sequence, a standard 90° pulse is applied and the maximum 
magnetisation is reached and over time the magnetisation decays. The loss of total 
magnetisation is a result of spin-spin relaxation and each nuclei obtain their own magnetic 
field. In turn, nuclei precess at different Larmor frequencies. Another 180° pulse is applied 
after a period of time (τ), which enables individual nuclei to be refocused and attain 
homogenous magnetisation.      
(9) CPMG [90ox - τ - 180
o
y - τ - 1
st echo - τ - 180oy - τ - 2
nd echo - … (τ - 180oy - τ)n 
2.2.3 Total Correlation Spectroscopy  
 
1D TOCSY can be performed as a targeted metabolomic approach in order to gain more 
information regarding the molecules structure and bonds. This technique shows relayed 
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correlations between nuclei which are up to 2-3 hydrogen bonds apart, sometimes 4 bonds 
apart [78]. If a nucleus is excited, other nuclei are excited through spin-spin coupling which 
produces resonance. For more extensive information regarding molecular structure 2D 
NMR techniques are usually employed as these provide a larger picture of the entire sample.  
 
2.2.4 2D NMR 
 
The use of 1D NMR alone sometimes cannot provide enough information regarding small 
molecules and their bonds. 2D NMR is often used in conjunction in order to investigate and 
confirm molecular structures which reinforce the specificity of the technique[84]. 2D NMR 
Spectroscopy operates by excitation of nuclei at particular frequencies in order to correlate 
those with alternate nuclei more than three bonds away. This gives a bigger picture of how a 
molecular structure is composed. 2D NMR plots across horizontal and vertical axes, the two 
different axes can be two different nuclei (heteronuclear) or two of the same nuclei 
(homonuclear), dependent on the experiment chosen. The key difference between 1D NMR 
and 2D NMR is that they are plotted by two frequencies instead of one frequency defined as 
F1 and F2. A cross-peak is created by a co-ordinate style plot. The coordinates which are set 
along the diagonal are a connection of the same molecule. The NMR needs to record a 1D 
NMR spectrum prior to the 2D NMR spectrum in order for this to be loaded into the 
frequency domain. The 2D experiments follow the general scheme of 4 stages (Figure 2.12). 
 
Figure 2.12. 2D Experiments Scheme. 
The main goal of 2D NMR techniques is to overcome issues regarding overlapping 
resonances to confirm molecular identity [68]. The main techniques which are going to be 
utilised include 2D COSY, which observes nuclei through H-H correlations (coupled 
protons) and is able to monitor relationships between hydrogens 2-3 bonds apart and 2D 
TOCSY to observe all correlations.  
  
Preparation
Evolution 
(T1)
Mixing
Detection
(T2)
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2.3 Liquid Chromatography-Mass Spectrometry 
 
Some molecules cannot be detected by NMR and more sensitivity is required in order to 
view these molecules in limited concentrations. When this is the case, LC-MS is a hybrid 
technique which is aimed at the polarity and molecular weight of molecules. The theory of 
HPLC had been initially developed in 1941 by A. J. P. Martin and R. L. M. Synge [85] and it 
was not until over 25 years later in 1966 C. Horvath and S. Lipsky utilised HPLC as a 
technique [86]. In contrast, the roots of MS were established much earlier, Prouts hypothesis 
recognised the significance of molecular weights in the early 19th Century [87]. However, it 
was not until 1919 the first mass spectrometer was built by F. W. Aston [88]. It would also 
be important to note in 1918 prior to F.W. Aston, A.J. Dempster reported on his mass 
spectrometer and established the theory and design, but his discovery was used for 
applications to allow the development of the atomic bomb and nuclear power [89]. This 
contrasts hugely with the work of F.W. Aston who primarily focused on different isotopes 
and developed the whole number rule, he ended up becoming a fellow of the Royal Society 
and received a Nobel Prize in Chemistry.  
The combination of using LC and MS together as a technique was first developed in 1968 
by Victor Tal’Rose and was further developed by Hewlett Packard in 1979 [90]. This had 
come a long way from initial theories in the 19th Century and the progress over a few hundred 
years was a rather large leap.  
The LC component is a separation technique, dependent on the column used, LC will 
separate molecules by the use of a mobile phase and a stationary phase. If a polar column is 
used, molecules which are polar in the sample will ‘stick’ to the column. In contrast if a non-
polar column is used, molecular which are non-polar will ‘stick’ to the column. The principle 
of the technique is based on Van De Waals forces of interaction between molecules. HPLC 
contrasts with LC due to the high pressure being exerted onto the sample which ranges from 
50-350 bar whereas, LC alone relies on the force of gravity. The length of the column effects 
the resolution of the results, the longer the column the better the resolution, but other 
parameters such as flow rate, temperature are also important. 
The use of different phases in HPLC are categorised into two types normal-phase and 
reversed phase [91]. Normal phase HPLC uses the polar column and the column is typically 
packed with silica particles and a non-polar solvent is utilised [91]. Reversed-phase HPLC 
uses the non-polar column and the column is packed with silica particles too however, they 
typically have long hydrocarbon chains attached to make the column non-polar [91]. For 
reversed phase HPLC a polar solvent is usually utilised [91]. Reversed-phase is typically 
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utilised in these studies as the molecules found in urine are typically polar and therefore will 
pass through the column more quickly.    
After separation, the sample can be passed through a mass spectrometer which will 
bombards the molecules with electrons in order to create ions. The liquid is transformed into 
an aerosol in order to be suitable for mass spectroscopy analysis. The ions are then detected 
and various detectors are used. In the case of quadrupole, the ions travel through 4 
quadrupoles and dependent on the ionic strength of the ion, different ions will be detected 
at different stages. There are positive and negative ions produced as part of this process and 
the mass spectrometer can be tuned to observe negative ions or positive ions. The mass to 
charge ratio of the ions can be associated with different molecules as these are characteristic 
to a particular structure which are useful for building up a compound. Mass spectrometry 
also provides information regarding molecular weights too and a trace of the overall 
molecular weight of a target compound can typically be seen. 
The mass spectrometer operates in two different modes SCAN mode and SIM mode.  The 
SCAN mode observes the entire array of molecules which are in the solution whereas the 
SIM mode will look for a target molecule. There are advantages and disadvantages of the 
two different modes, SIM mode is more sensitive and useful for quantification purposes, 
whereas SCAN mode takes into account the entire sample composition.      
 
2.3.1 Preparation Techniques 
 
Although NMR and MS are highly multicomponent techniques and some samples need little 
or no preparation prior to analysis, on occasion, some samples do require preparation. The 
preparation of a sample may be necessary in order to concentrate the sample, in order to get 
more information regarding the content of the sample or it may involve splitting the contents 
of the samples into lipophilic and hydrophilic species. Different preparation techniques have 
advantages and disadvantages and some used in this thesis are outlined below.  
Solid Phase Extraction 
Solid Phase Extraction (SPE) is a technique which is often used in conjunction with both 
NMR and LC-MS and is an excellent preparation technique which removes compounds in 
liquids dependent on the chemical properties. It functions similarly to HPLC by pressing 
the liquid (mobile phase) through a syringe within a solid (stationary phase) which either 
has a hydrophilic or hydrophobic surface, enabling certain molecules to pass through.  
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Syringe Filtering  
Syringe filtering is useful for removal of matter prior to LC based methods and is composed 
of a circular filter and a syringe which combined will let a liquid pass through however, 
particles will not. The size of the membrane within the circular filter determines what size 
molecules will pass through. 
Freeze Drying 
Samples can be freeze dried in order to remove water from the sample so the sample can be 
reconstituted into a different solvent, or concentrated. This process is completed by rapid 
freezing under a vacuum which removes ice via sublimation. The molecules that remain can 
be reconstituted into a solvent which is more lipophilic such as chloroform or methanol 
which can provide further information. 
Centrifuge 
Centrifuging is another methodology to remove solid matter from the sample. This works 
by rotating the samples at a high speed which causes the liquid matter to suspend and the 
solid matter to move down to the centre. The liquid supernatant can then be extracted and 
used for analysis. In biofluid NMR analysis, removal of solids from cellular matter ensures 
shimming is optimal.  
 
2.4 Multivariate Statistics 
 
When handling colossal and complex datasets from untargeted metabolomic approaches, 
which include a plethora of metabolites at a range of concentrations, which are generated 
from NMR, it can be difficult to interpret and understand the significance of the data 
acquired. Multivariate statistics have integrated into analysis of NMR, due to the number of 
data points produced from the output of analysing complex biofluids. Multivariate (MV) 
statistics aids in dealing with large datasets into visual formats which are more comprehensive 
for the analyst by recognition of patterns in the data. The combination of using a scientific 
technique alongside statistics in this manner is termed chemometrics. The following section 
explores some of these visual formats and their uses in aiding interpret the complex datasets. 
Prior to use of these techniques it is important the data is prepared using normalisation, 
referencing and scaling these will be described in more depth in later chapters. All univariate 
and MV forms of statistical analysis will be performed using XL STAT 2016, MetaboAnalyst 
4.0, ROCCET and MetATT software. 
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2.4.1 Principle Component Analysis 
 
Principle Component Analysis (PCA) is arguably as the most widely applied and useful 
multivariate statistic for metabolomics [62]. The main aims of PCA are to establish patterns 
in large datasets concentrating on similarities and differences in the data via PC ‘clusterings’ 
and enables to the user to detect outliers which are statistically significant [84]. The data will 
cluster and the classification of each of the groups can be evaluated [84]. It is a unsupervised 
tool and therefore unbiased which is advantageous in non-targeted metabolomic studies [92]. 
Thus, the technique aims to find the maximum variance in a data set (X) without considering 
the class (Y) [92]. PCA operates by examination of the interrelations among a set of variables 
in order to identify a new structure of those variables namely principle components (PCs) or 
scores which have a weight or loading [84], [92]. PCA performs a linear transformation of 
the starting variables with appropriate weighting coefficients and the tool attempts to retain 
as much variance as possible with each PC remaining uncorrelated with each other [62], [84]. 
The primary component in the PCA will retain the greatest variance and subsequent 
components will contain less and less until there is no variance [84].  
From the data matrix given, usually an NMR dataset matrix is created in the case of 
metabolomics, eigenvectors and variance are established and utilised to produce the PCA 
plot. The eigenvectors are formed of the non-singular portion of the sample covariance 
matrix (S) for the column. The eigenvalue will reflect the number of variables associated with 
the principle component. For metabolomics, a set of metabolites which are negatively or 
positively correlated will form a PC. A second set of metabolites which are correlated will 
form a second PC and PCA will compare these two sets of loadings.  
 
2.4.2 Partial Least Squares-Discriminant Analysis and Orthogonal Partial Least 
Squares Discriminant Analysis 
 
Partial Least Squares Discriminant Analysis (PLS-DA) previously nominated as Projection 
to Latent Structures is another statistical tool commonly used in metabolomic analysis 
however, this tool is supervised unlike PCA and considers the class memberships [92]. PLS-
DA optimises the separation between different groups of samples, by maximising the 
covariance between independent variables and discovering a new linear subspace between 
explanatory variables [59]. The advantages of this approach is that the technique is able to 
handle highly collinear and noisy data which is attributed to NMR and LC-MS outputs [59]. 
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PLS-DA enables complex datasets to be visualised through easily interpretable scores plot 
that can show separation between groups [59].  
This technique does not impose orthogonality and requires X scores to be uncorrelated, 
closer to the PLS regression. PLS creates scores and loadings described as latent 
structures/variables which summarise the set of X and Y values. The production of latent 
variables by this method consist of linear combinations of the original variance that preserve 
as much between X and Y as possible.  
The problem with PLS-DA is that variation which is not directly correlated with the variables 
is still present in the scores which is problematic when the number of classes increases. In 
contrast, Orthogonal Partial Least Squares Discriminant Analysis (O-PLS-DA) addresses 
these issues by incorporation of an Orthogonal Signal Correction filter into the original 
model which separates the predictive variation from the uncorrelated variation. 
PLS is a supervised technique which takes into consideration the groups and can potentially 
overfit if the dataset is small and cross validation is required in order to confirm the strength 
of the test. A permutation test is usually performed to ensure the test is employed correctly 
testing the multivariate independence of disease classification and prognostic stratification 
groups [84]. A Q2 value gives the accuracy of the test. 
Variable importance in projection (VIP) score is a weighted sum of squares of the PLS 
loadings and will show the regions causing the most significance in the correlations or lack 
of correlation between the PCA score [92].  
 
2.4.3 Computational Intelligence (neural networks) 
 
Computational Intelligence techniques, including Optimisation Algorithms and Machine 
Learning Algorithms (supervised and unsupervised neural networks) can be employed in 
order to recognise metabolic classification patterns for each of the disease and disease 
severity classifications [93]. In addition, reinforcement learning algorithms can be used to 
identify classification and have been previously applied to the medical research domain [93]. 
Optimised algorithms will be used to select the most discriminatory biomarker variables from 
the datasets for use in constructing machine learning classification models. Supervised 
learning techniques will then classify the diseases. Feed forward and cascade forward 
networks can be formed trained with backpropagation in order to classify disease groups 
[94]. Different algorithms have been previously applied in metabolomics including, but not 
Page 59 of 216 
 
limited to Levenberg-Marquardt, Bayesian regularization, Broyden–Fletcher–Goldfarb–
Shanno Quasi-Newton, Resilient, scaled conjugate gradient, conjugate gradient with 
Powell/Beale restarts, conjugate gradient with Fletcher-Powell, conjugate gradient with 
Polak-Ribiére, one step secant, variable learning rate gradient descent, gradient descent with 
momentum and gradient descent [95]. These algorithms can be multilayer or single layer 
networks [95]. Deep learning is being used more frequently to observe metabolomics data; a 
feed forward network has shown promise in distinguishing estrogen receptor positive and 
negative breast cancer tissue samples for example.  
 
2.4.4 Support Vector Machines 
 
Support vector machines (SVM) is also used for classification purposes and indeed is a 
supervised technique. The SVM classification uses non-linear decision functions in the input 
space in which both a higher dimensional feature space is mapped [92]. Features are 
separated by a maximum margin hyper plane [92]. Cross validation error rates are applied to 
features which are based on their relative contribution in the classification [92]. Non-
important features are removed and thus a series of SVM models are created [92]. The best 
ranking model can be used and is ranked by its frequency [92].  
 
2.4.5 Self-Organising Maps  
 
Self-Organising Maps (SOMs) are utilised in order to explore self-similarities between the 
spectra acquired and hence clustering’s - arising from each source of variation involved [84]. 
SOM’s are unsupervised neural networks using a grid method which consists of nodes [92]. 
The model is trained to represent subsets of data, as the model clusters random values and 
the user specifies the expected dimension of the grid [92]. Aggravated expression profiles are 
then formed from the k-means and SOM which are presented in the form of a line graph on 
top of each other using feature values [92].    
 
2.4.6 Heatmaps 
 
The concept of heatmaps is dated back to Loua in 1873 who shaded in a matrix which was 
drawn and coloured by hand [96]. Cluster matrices were then developed in 1914 by Brinton 
which reveal more structure [96]. The advances since then are vast, many computer software 
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include this statistical tool and its applications are recognised in various fields, from 
accounting to science.  
Heatmaps are a visual tool which are applied to represent data, which will be put into a matrix 
and colours will reflect the values in a hierarchical cluster structure. Heatmaps appear as 
colourful tiles on a rectangle matrix and hierarchical cluster trees are marked on the margins. 
The creative history of the heatmap is reflected in its presentation and is a crucial tool for 
MV statistics. Colours usually reflect patterns of increases and decreases in metabolites across 
the matrix whereby red represents increase and blue represents decreases. The intensity of 
the colour will also depict the quantity of increases or decreases whereby, a more neutral red 
would indicate a slight increase, whereas a strong red would indicate a strong increase. 
Heatmaps are used in metabolomics in order to distinguish and increase or decrease in 
metabolites across the samples relative to each other and are an extremely useful visual tool.  
 
2.4.7 Classification Trees 
 
Classification trees are able to construct non-linear relationships and are subcategorised into 
adaboost, bagging or random Forest (RF). RF’s generate many decision trees which are 
constructed by randomly selected variables from a bootstrap sample at each branch and were 
first introduced by Brieman [59], [92]. One third of the bootstrap samples are left out during 
the construction of the trees for the purpose of being used as a test sample, in order to obtain 
an unbiased estimate of the classification (OOB) out-of-bag error [92]. Variable importance 
can be measured by increasing the OOB error [92]. 
This technique can also handle large datasets, measure predictor variables, a measure of 
internal structure of the data and also able to handle missing values [59]. RF produces an 
internal unbiased estimation of the generalisation error and is robust to outliers as described 
and is also supervised like PLS-DA [59], [92].  
 
 
2.5 Summary 
 
Overall, metabolomics is a growing field and gives an insight into the pathology of different 
biological systems which can aid in personalised patient care, diagnosis, therapy and overall 
outlook of patients. The versatility of the subject enables research to also delve into discovery 
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of potential biomarkers or characteristic features in diseased patients. Therefore, it is crucial 
to expand the research in this particular field as the information it may provide is profound. 
MVA ensures that the large data quantities are manageable and understandable. This 
combination of techniques and technology are at the forefront of chemometrics and 
metabolomics. A final figure, (Figure 2.13), shows the work flow of metabolomics data from 
acquisition to results and encapsulates the experimental design.  
 
Figure 2.13. Metabolomics Experimental Design ideas adapted by [1]. 
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Chapter 3: 1H NMR-Linked Metabolomics Analysis of Urine 
and Blood Plasma Collected from Gaucher’s Disease Type 1 
Patients: Challenges Associated with Xenobiotics and 
Experimental Design 
 
3.0 Abstract 
 
Background: 1H NMR metabolomics provides potential scope as a non-invasive approach 
to discover candidate biomarkers for, and further understanding of metabolic pathway 
perturbations in Gaucher’s Disease Type 1 (GD1). GD1 is a complex multisymptomatic 
disorder affecting multiple organs, including the liver, spleen, skeleton and brain. In order to 
further understand GD1 and assess the effectiveness of specific treatments for GD1 
(imiglucerase, velaglucerase alfa and eliglustat) a metabolomics approach was utilised.  
Methodology: Age- and sex-matched plasma and urine samples were provided from fasted 
and unfasted controls, and unfasted GD1 participants. 1H NMR datasets were acquired using 
a 700 MHz cryoprobe facility. 1H NMR spectral data was processed, integrated and then 
prepared for multivariate metabolomics analysis using normalisation and scaling techniques. 
Since the fasting status unfortunately differed between the two cohorts, so all metabolites 
known to be affected by fasting status, such as glucose etc., were removed from the dataset 
prior to statistical analysis.  Drugs such as acetaminophen, ibuprofen and acetylsalicylic acid 
were taken by the GD1 cohort which also resulted in removal of many 1H NMR bucket 
regions from the urinary 1H NMR profiles. However, no xenobiotic signals in plasma spectra 
acquired were detectable.  
Results and Discussion: No significant differences between the urinary profiles of GD1 and 
control participants were found. However, some significant metabolic differences in their 
plasma samples, including downregulated high-density- and low-density-lipoprotein 
triacylglercol, and upregulated lactate, 3-D-hydroxybutyrate and acetone levels were 
observed. The influence of the differences in fasting status and potential biochemistry 
changes due to the diseases status of the participants is discussed.  
Conclusions: 1H NMR-linked metabolomics analysis can successfully distinguish between 
GD1 and control plasma profiles, and these results provide insight regarding new 
metabolomic markers for GD1. Further work could aim to validate the findings by the 
synchronous observation of both untreated and treated GD1 participants in order to confirm 
findings. Alternatively, an animal model system could also be employed in order to retain 
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consistency in the experimental design and reduce variability introduced from xenobiotics 
such as drugs or dietary supplements.   
 
Keywords: Nuclear Magnetic Resonance; Metabolomics; Lysosomal Storage Diseases; 
Gaucher’s Disease; Blood Plasma; Biomarkers  
 
3.1 Introduction 
 
In this pilot investigation, conventional 1H NMR metabolomics approaches were employed 
in order to identify new, and potentially valuable, biomarkers for Gaucher’s Disease Type 1 
(GD1) in human blood plasma and urine, particularly those which correlate with disease 
severity and progression. Such an investigation may provide further understanding of GD1 
pathogenesis through the identification of defects in key metabolic pathways involved.  This 
1H NMR-based strategy has been supplemented by the application of newly-developed 
metabolic pathway and quantitative metabolite set enrichment analyses. The 1H NMR dataset 
matrix was also interpreted using both multivariate and univariate statistical approaches in 
order to further understand dataset variation and its contribution towards validation of 
potential biomarkers. These software-based approaches served to provide much valuable 
information regarding biomolecular connectivities, and hence the biological/metabolic 
pathways involved in the pathogenesis of GD1. This methodology also permitted the 
recognition of metabolic ‘signatures’ that may enhance our understanding of the pathogenic 
mechanisms of GD1 at the molecular, biochemical and cellular levels. Furthermore, such 
metabolomic profiling has provided valuable insights into the effectiveness of enzyme 
therapy, as a current treatment.  
 
3.2 Specific Aims  
 
• To observe the metabolic profiles and patterns of blood plasma and urine collected 
from GD1 patients, and compare these with those of healthy controls with the 
outlook of improving the diagnosis of these patients; these studies will involve the 
seeking and identification of candidate biomarkers which may be useful for the   
future monitoring of clinical progression. 
Page 64 of 216 
 
• To further understand perturbations in and disturbed metabolic pathways in GD1, 
with a particular focus on identifying how such modifications may be involved in its 
chemopathological mechanisms. 
• To further understand the impact of treatment outcomes of enzyme replacement and 
substrate reduction therapies on GD1 metabolome. 
 
3.3 Materials and Methods 
 
3.3.1 Approval for Research  
 
All control samples were collected with informed consent and approved by the appropriate 
Research Ethics Committee at De Montfort University (DMU) in accordance with the 
declaration of Helsinki 1975 (revised 1983). Samples from GD patients were provided by the 
Department of Pharmacology, University of Oxford. 
 
3.3.2 Human Plasma Collection 
 
Twenty-two control participants were recruited directly from DMU who were fasted for a 
12-hour period, whilst 28 participants with GD1 (4 further control participants were 
recruited by Prof. Platt’s team at the University of Oxford). Blood samples were collected by 
a fully trained phlebotomist via venepuncture on-site at DMU, and all blood samples were 
collected in lithium heparin collection tubes. Whole blood samples were centrifuged for 15 
min. at 4,300 rpm and 4°C on-site and the plasma was frozen at -80°C and ready for 1H 
NMR analysis.  
Control participants were provided with a participant information sheet and signed a consent 
form. Control participants also provided information such as diet in the form of a food diary, 
demographic information such as BMI, along with their use of supplements and medications. 
All samples were anonymised on collection and numerically coded. Blood plasma was 
collected into heparinised tubes in order to avoid NMR analytical complications arising from 
the use of those containing EDTA or citrate anticoagulants. The complications of adding an 
EDTA anticoagulant include its complexation of Ca2+ and Mg2+ ions, and this has been 
demonstrated in several works elsewhere [26], [97]. Samples from the University of Oxford 
were provided by participants who were not fasted but were collected, centrifuged and stored 
in the same manner.  
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Class Gaucher Disease Control Total 
Mean Age 
Range (Years) 
54.17 
33-77 
39.88 
21-64 
47.29 
21-77 
Males 12 16  28 
Females 16 10 26 
Total 28 26 54 
Table 3.0. Breakdown of age and genders of healthy control, and GD1 (OMIM #230800) 
plasma and urine samples. 
Samples collected represent those from a near aged-matched cohort with a similar ratio of 
females to males. In the GD group, all except one sample were GD1 with the remaining 
sample being Type 3 GD (GD3), which is excluded from this table (OMIM #231000).  
 
3.3.3 Human Urine Collection  
 
Nineteen fasted control participants were recruited directly from DMU. An additional 29 
unfasted ones with GD1, along with 4 unfasted control participants were recruited by the 
University of Oxford. Urine samples from DMU were collected by participants after ~12 
hour fasting period, was the first pass of the day and midstream urine collection. They were 
collected onsite at DMU in sterile universal containers and stored at -80°C until ready for 
analysis. Control participants provided the same information as described above in the blood 
plasma section 3.3.2. Samples were collected in the same manner at the University of Oxford, 
although samples were collected from unfasted participants. The urine provided was from 
samples time-matched to the plasma ones. However, some participants did not provide a 
urine sample. 
Class Gaucher Disease Control Total 
Mean Age 
Range (Years) 
55.27 
33-77 
44.17 
31-64 
50.36 
31-77 
Males 12 8 20 
Females 17 15 32 
Total 29 23 52 
Table 3.1. Breakdown of age and genders of healthy control and GD1 urine samples. 
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3.4 1H NMR Analysis 
 
3.4.1 1H NMR Sample Preparation of Human Plasma 
 
Samples were prepared using 450 µL of plasma, 50 µL of sodium azide, 50 µL of phosphate 
buffer (pH 7.0) and 50 µL of D2O containing no added 3-(trimethylsilyl)propionic-2,2,3,3-d4 
acid, sodium salt (TSP) internal standard. Samples were analysed at the University of Oxford 
using the Bruker AVII 700 MHz NMR equipped with a 1H TCI cryoprobe (Chemistry 
Department, University of Oxford) at an operating frequency of 699.989 MHz and a probe 
temperature of 298 K. Spectral acquisitions involved the collection of 65536 data points 
using 32 scans across a spectral width of 15.99 ppm. For the plasma, the CPMG sequences 
was used which is also previously described in Chapter 2, section 2.2.2) in order to suppress 
the broad protein signal envelope which obscures the visibility of many low-molecular-mass 
metabolite resonances (Appendix 1). Samples were loaded onto an automated sample belt 
using a sample changer. 
 
3.4.2 Plasma NMR Data Preprocessing 
 
All samples were referenced and aligned to alanine -CH3 at δ = 1.47 ppm, baseline corrected 
and phased. Once this was completed, samples were then bucketed using ACD Labs 12.0. 
Manual bucketing requires the analyst to observe NMR signals visually and bucket 
accordingly, with prior knowledge of signal multiplicity. This is an important step since 1H 
NMR chemical shifts can vary, and depend on temperature, pH and ionic strength. It was 
noted that histidine signals shifted slightly in the spectra, probably a consequence of small 
variations in pH, and therefore manual bucketing was considered to be the most appropriate 
method. Uniform bucketing was not performed, since this can lead to further problems such 
as signal splitting, which would have been the case for histidine. Intelligent bucketing can 
also be performed; however, this can additionally give rise to split signals. The raw integral 
buckets were then imported into MicrosoftTM Excel to create 1H NMR data matrices. Any 
buckets attributable to baseline noise or water were removed prior to multivariate and 
univariate statistical analyses. 
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3.4.3 1H NMR Sample Preparation of Human Urine 
 
Samples were analysed using the same facility described above with the same operating 
frequency and probe temperature. Spectra acquired collected 65,536 data points using 32 
scans across a spectral width of 15.99 ppm. For the urine samples, NOSEY Presaturation 
(noesygppr1d) was used as previously described (Chapter 2, section 2.2.1) targeting the intense 
water signal located at δ = 4.70 ppm. Samples were loaded onto an automated sample belt 
using a sample changer. 
 
3.5.4 Urine NMR Data Preprocessing 
 
All samples were baseline-corrected, phased and aligned to TSP. Once this was complete, 
spectra acquired were then bucketed using ACD Labs 12.0 using two different methods, 
manual bucketing and intelligent bucketing. For intelligent bucketing, buckets had a width 
of 0.02 ppm and 50% width looseness. The buckets were then imported into Microsoft Excel 
and the data was normalised to TSP. Any buckets attributed to baseline noise, drugs and 
their metabolites, supplements, urea (δ = 5.80 ppm) or water (δ = 4.70 ppm) were removed.  
 
3.5 Results 
 
3.5.1 1H NMR Plasma Profile Results  
 
1H NMR profiles were assigned using the Bruker Topspin 4.0.2 software module; spectra 
acquired were referenced to alanine-CH3 (δ = 1.47 ppm), overlaid and labelled (Figures 3.0-
3.2). The water signal located at δ = 4.70 ppm was eliminated from the figures. This process 
used articles [61], [98]–[100] and HMDB in order to confirm the assignments of signals from 
their chemical shift values, coupling patterns and coupling constants. No assignments were 
attributed to drugs ingested in the plasma profiles, despite GD1 participants being on various 
medications, because the drugs are in concentrations too low for detection by 1H NMR. 
  
 
 
 
 
 
 
 
 
Figure 3.0. Labelled 700 MHz CPMG 1H NMR spectra of GD plasma sample from 0.75 ppm-2.95 ppm; [1] very low density lipoproteins (vLDL)/ low 
density lipoproteins (LDL) / Triacylglycerol (TAG)-CH3; [2] Iso-Leucine-CH3; [3] Leucine-CH3 [4] Valine-CH3; [5] L-Threonine-CH3/3-Hydroxybutyrate-
CH3; [6] vLDL/LDL -(CH2)n- [7] L-Lactate-CH3; [8] Alanine-CH3; [9] TAG–CH2CH2-CO; [10] Lysine-CH2/Arginine-CH2; [11] Arginine γ-CH2; [12] Acetate-
CH3; [13] TAG-CH2CH2CH=; [14] Acute-phase glycoprotein molecularly-mobile carbohydrate side-chain N-acetyl-group-CH3 functions; [15] Glutamate-β-
CH2; [16] CH2CO / Acetone-CH3; [17] Acetoacetate-CH3; [18] Glutamate-β-CH2 /3-Hydroxybutyrate-CH2; [19] Pyruvate-CH3; [20] Glutamine-β-CH2; [21] 
Citrate CH2A/CH2B; [22] Albumin Lysine/TAG-CH=CH-CH2-CH=CH-. 
Chemical Shift (ppm) 
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Figure 3.1. Labelled GD plasma sample using CPMG from 3.00 ppm-4.70 ppm; [23] Creatine/Creatinine-CH3; [24] unassigned; [25] Dimethylsulphone-CH3 
[26] HDL-Phospholipid choline headgroup-N+(CH3)3; [27] D-Glucose-C3-CH/Taurine-CH2; [28] Trimethylamine oxide (TMAO)-CH3; [29] unassigned; [30] 
unassigned; [31] D-Glucose-C5-CH/Taurine-CH2; [32] L-Proline-CH; [33] D-Glucose-C6-CH; [34],[35] D-Glucose-CH; (dd)  [36] Glycine-CH2; [37] Valine-
CH; [38] Threonine-CH; [39] Lipid N-CH2; [40] D-Glucose-C4/C11-CH; [41] Galactose-CH; [42] D-Glucose-C6/C11-CH; [43] D-Glucose-C11-CH; [44] D-
Glucose-C11-CH; [45] D-Glucose-C11-CH; [46] D-Glucose-C11-CH; [47] D-Glucose-C11-CH; [48] Creatine-CH2; [49] L-Histidine-C7-CH; [50] Creatinine-
CH2; [51] L-Lactate-CH; [52] 3-Hydroxbutyrate-CH; [53] Dihydroxyacetone-CH3 (tentative assignment) ; [54] β-Glucose-C1-CH. 
 
 
Chemical Shift 
(ppm) 
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Figure 3.2. Labelled GD plasma sample using CPMG from 5.10 ppm - 8.50 ppm; [55] α-Glucose-C1-CH; [56] TAG-CH=CH-; [57] Urea-CO-NH2; [58] L-
Tyrosine-β/ζ-CH; [59] L-Histidine-β-CH; [60] L-Tyrosine-γ/ε-CH; [61] L-Phenylalanine-β/ζ-CH; [62] L-Phenylalanine-γ/δ/ε/-CH; [63] tentative broad 
protein aromatic residue-CH; [64] tentative broad protein aromatic residue-CH; [65] Formate-CH.
Chemical Shift (ppm) 
3.5.2 Statistical Analysis of the 1H NMR Profiles of Blood Plasma 
 
Numerous statistical approaches were applied to this dataset. MetaboAnalyst 4.0, which 
provides a number of multivariate statistical outputs (including PCA, PLS-DA, O-PLS-DA 
and univariate options such as ANOVA, t-test and fold-change analysis). The software also 
provides clustering and visualisation tools to create dendrograms and heatmaps. This 
software is also able to classify sample groups by the random forest (RF) and support vector 
machine (SVM) techniques, and these statistical and machine learning methods have been 
previously described in Chapter 2.  
Data filtering was performed initially in order to remove variables which are unlikely to be 
of use to modelling data, such as those which contain constant values across the dataset. 
Normalisation aims to adjust for the dilution factors involved in experiments [101], and in 
this instance the constant sum-normalisation (CSN) approach was applied. Creatinine 
normalisation was not performed as it is not used for plasma [101] and, in any case, there are 
evident differences in fasted and unfasted samples, and thus would therefore not represent 
a suitable reference substance [102]. TSP was not added to these samples since it can interfere 
with the matrix by binding to plasma proteins [103] and therefore would be unsuitable as an 
internal standard for normalisation, unless TSP was added via a capillary. Data was then 
transformed using the cubed root transformation, and scaled by Pareto scaling which is 
generally recommended for metabolomics data [84]. This method of normalisation will be 
applied for all of the plasma datasets throughout this work, unless otherwise specified.  
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Figure 3.3. (a) PCA scores plot of plasma samples collected from GD1 (green) and fasted 
and unfasted control participants (red). This diagram shows a plot of PC2 vs PC1 accounting 
for 20 and 39.8% of the dataset variation respectively. 95% confidence ellipses are also shown 
for both participant classifications. Outliers are highlighted in orange in the control group 
and yellow circles highlight unfasted control samples. (b) PLS-DA scores plot of GD1 
plasma (green) vs control plasma (red). PC3 vs PC2 vs PC1 represent 14.9, 28.0 and 26.6% of 
the total dataset variation respectively. This plot shows some clear discrimination between 
GD1 and control participants. Cross-validation, utilising a 10-fold leave-one-out cross 
validation (LOOCV) methodology, gave a Q2 value of 0.70 on a four-component model. 
Permutation testing, using 2000 permutations, gave p < 0.0005.  
PCA is primarily employed to obtain an overview of the degree of separation within the two 
groups. In addition, PCA can observe clustering between the different classifications in order 
to detect any outliers in the dataset. The PCA plot of control vs GD1 plasma profiles shows 
(a) 
(b) 
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some distinction between the two groups with respect to PC1 and PC2 scores, and revealed 
no major outliers apart from a single control and a single GD1 group samples (Appendix 2). 
The former’s participant was male, aged 34, with a history of smoking, slightly higher BMI 
than normal (25.5). The latter profile was from a GD1 participant who was male, 69 years 
old and on a combination of velaglucerase alfa, hydroxocobalamin, cholecalciferol and 
calcium carbonate.  
The control sample that appears as an outlier highlighted in orange (Figure 3.3 (a)) clearly 
has lipid disturbances within their plasma 1H NMR spectrum (Appendix 2). 1.20-1.30 ppm 
was a significant bucket region on the PCA biplot which scored positively for this sample. 
The outlier attributable to the GD1 participant highlighted in orange arose from an extreme 
elevation of citrate in the plasma, which is possibly ascribable to a different type of collection 
tube used (such as one containing a citrate anticoagulant), and so this sample was also 
removed from the study.  
It can be observed that the unfasted control samples coded 501, 502, 503 and 504 are 
overlapping somewhat with the unfasted GD1 group, instead of the remaining ones in the 
fasted control group (Figure 3.3, (a)). PCA is an unsupervised methodology, which would 
suggest that most of the separation observed is due to the fasting status. Interestingly, one 
sample with GD3 had a different profile to the rest of the control samples in addition to the 
GD1 profiles, and was clearly distinguishable (data not shown). This suggests that 
metabolomics analysis with GD3 could provide some interesting metabolic differences. 
However, with only one sample, it is difficult to establish if this is common across an entire 
GD3 cohort, and more samples would be required in order to confirm this statistical 
difference. GD3 is predominantly neurological, and therefore different to GD1 which is 
predominantly non-neurological. 
PLS-DA shows two clear sub-groups for the GD1 participants (Figure 3.3, (b)). Some GD1 
participants are within close proximity to the control participants in this analysis, however. 
Indeed, this could represent disease severity, whereby patients with more severe conditions 
are further away from the control group and vice-versa. Alternatively, this could represent 
dietary differences within the GD1 cohort. Food diaries were only obtained for the fasted 
cohort and not the GD1 cohort. Similar statistical tests were performed for the different 
treatments of GD1, however, and these were insignificant (Appendix 5). Further statistical 
tests were performed to investigate the impact of participants’ age, the results of which were 
also insignificant and did not account for the sub-clustering noted herein (Appendix 5). PLS-
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DA testing demonstrated that the two cohorts were clearly distinguishable (Figure 3.3, (b)).  
Cross-validation, utilising the 10-fold leave-one-out cross validation (LOOCV) 
methodology, gave a Q2 value of 0.70 on a four-component model (Figure 3.3, (b)). 
Permutation testing, using 2,000 permutations, gave p < 0.0005 (Figure 3.3, (b)). These 
validation tests show that the PLS-DA model is performing efficiently, and that there is a 
clear difference between the two cohorts in the study. The variable importance in projection 
plot (VIP) showed from the PLS-DA results were then assigned (Table 3.3). However, it is 
difficult to ascertain whether the differences herein are ascribable to the fasting and non-
fasting of participants, or to the disease pathology. However, considering the VIP 
information (Table 3.3) and PCA scores plot, it can be considered that the majority of the 
metabolites are elevated in view of the differential fasting status of the two groups of 
participants. 
δ/ppm Elevated or 
decreased in 
GD1 
Assignment (multiplicity) 
0.78 – 0.90 ↓ LDL/vLDL-TAG-CH3 (broad) 
1.91 – 2.01 ↓ TAG-CH2CH2CH= (broad)/Acetate-CH3 (s) 
2.32 – 2.35 ↑ 3-Hydroxybutyrate-CH2 (m) 
2.97 – 3.02 ↓ Albumin lysine residue-ε-NH2 (t) 
3.16 – 3.22 ↓ HDL-Phospholipid choline headgroup-N+(CH3)3  
3.29 – 3.31 ↑ Glycerol-CH2OH (m)  
3.62 – 3.64 ↑ Lipid Unassigned (broad) 
3.91 – 3.92 ↑ Creatine-CH2 (s)/Unassigned (broad)  
3.93 – 4.00 ↑ L-Histidine-CH (m)/Phenylalanine-CH (m) 
4.05 – 4.08 ↑ Glyceryl backbone of TAGs-CH2OCOR (broad) 
4.08 – 4.13 ↑ Lactate-CH (q)/3-D-Hydroxybuyrate-CH (m) 
4.22 – 4.26 ↑ Threonine-CH /Glycerol backbone of TAGs (m) 
4.26 – 4.34 ↑ Glyceryl backbone of TAGs CH2COR (broad) 
4.41 – 4.46 ↑ Unassigned Lipid (broad)  
4.62 – 4.65 ↑ β-Glucose-C1H (d) 
7.33 – 7.38 ↑ Unassigned-CH (t) 
7.38 – 7.43 ↑ L-Phenylalanine-aromatic-CH (m) 
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Table 3.2. Elevated and depleted metabolites in GD shown by the VIP plot with 
corresponding bucket regions inclusive of the top 15 most significant metabolites. 
Abbreviations: GD1, Gaucher’s Disease Type 1; TAG, triacylglycerol; HDL, high-density-
lipoprotein. Multiplicities are indicated in brackets: multiplet, triplet, doublet and singlet are 
denoted as (m), (t), (d) and (s) respectively.  
Glucose, L-phenylalanine and myo-inositol were removed from the PLS-DA analysis since 
differences between their normalised levels may arise from those observed between fasting 
and non-fasting participants. These data were then used in subsequent multivariate analysis 
performed. 
 
Figure 3.4. (a) PLS-DA scores plot of GD1 plasma (green) and healthy controls (red) with 
the removal of buckets pertaining to glucose, myoinositol and phenylalanine showing PC3 
vs PC2 vs PC1 axes representing 13.4, 27.0 and 28.1% of the dataset variance respectively. 
Performance using LOOCV 10-fold methodology gave Q2 = 0.66, and from permutation 
testing using 2000 permutations, the (p value obtained was 0.0005). This plot shows some 
clear discrimination between GD1 and control participants. (b) PCA plot of GD1 plasma 
(green) and control scores (red). This diagram shows that PC1 and PC2 account for 41.9 and 
23.8% of the dataset variation respectively. 95% confidence ellipses are also shown for both 
participant classifications. 
 
On removal of significant metabolites directly associated with differences observed between 
fasted and unfasted plasma, a clear separation between these two classifications is always 
observed, irrespective of the multivariate analysis technique employed for testing. The same 
four unfasted healthy control samples are scoring/responding in the same manner as the 
unfasted GD1 participants in the PCA scores plot (Figure 3.4). This effect could be 
attributable to dietary differences. The PLS-DA plot is able to distinguish between metabolic 
profile on removal of the significant metabolites found in observed differences between the 
fasted and unfasted participant profiles such as glucose, myo-inositol and phenylalanine, 
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suggesting that other metabolites contribute to the differences observed between fasted and 
unfasted plasma samples.   
Figure 3.5. (a) Receiver operating curve (ROC) analysis, with the inset showing the number 
of variables (Var.) in the first column, area under curve (AUROC) in the second column, and 
95% confidence intervals (CIs) in the third column. The sensitivity is plotted on the y-axis vs 
selectivity on the x-axis. The highest AUROC value of 0.968 was obtained using 10 variables, 
each one representing an ISB region. (b) Cross-validation matrix showing samples on the y-
axis and predicted class probabilities on the x-axis. (c) Random forest classification of GD1 
plasma vs healthy control plasma samples; the green and blue curves representing healthy 
control and GD1 participants. The red line represents the overall model respectively. The x-
axis shows the number of trees built in this model, and the error level (prediction error) is 
shown on the y-axis. ROC curve analysis can easily distinguish between plasma samples 
collected from GD1 and control participants using very few variables (Figure 3.5, (a)). The 
most specific ROC curve test was only using 10 variables which are selected using SVM, 
which provided an AUROC value of 0.968 and 95% confidence intervals of ±0.0882 (Figure 
3.5, (a)). A cross- validation matrix of the ROC Curve shows some cross-over between 
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participants, since one GD participant is misclassified within in the control group and one 
control sample is misclassified in the GD1 group (Figure 3.5, (b)). The outlier in this group 
is one of the unfasted samples, as noted above. This cross- validation gave a 94.6% accuracy 
with 20 features (Figure 3.5, (b)).  
The RF approach gave an out-of-bag (OOB) error value of only 0.0714 using 500 trees and 
7 predictors. Out of 26 controls, 2 were incorrectly classified as GD1, and out of a total of 
30 of these, 2 were incorrectly classified as controls using this statistical methodology (Figure 
3.5, (c)). This may be a reflection of the disease severity, fasting status or high dimensionality 
of the dataset. Some metabolites may not appear significant in a multivariate model when 
indeed they are significant, and can be identified in alternative multivariate statistical 
methodologies instead, or could be found to be statistically significant in univariate models.  
Power analysis aids with study design, and ensures that cohort sample sizes are sufficient to 
detect any metabolic differences observable. Since LSDs are rare, it is important to determine 
how many samples would be required to provide statistically significant results. Power 
analysis is not only dependent on sample size but also the magnitude of the effect of interest 
in the population, along with the statistical significance criterion used in the test. Using a 
false discovery rate (FDR) setting of 0.1 and a maximum group size of 1,000, power analysis 
revealed that around 600 samples per group would be required to prove the significant 
differences found here. However, this is taking into consideration the experimental factors 
at present which differ i.e. diseased samples are non-fasted and the controls are fasted. Less 
samples may be required if the experimental factors were identical, and therefore it is 
considered important to repeat this analysis with identical sampling strategies; however, this 
is challenging in view of the severity of the disease and clinical conditions.  
The top 15 significant metabolites in each multivariate statistical test performed are listed in 
Table 3.3. Interestingly, some methodologies consider the same metabolites statistically 
significant, for example the 4.26 – 4.34 ppm bucket region, and other metabolites are only 
statistically significant for a single bucket variable, for example the 2.20 – 2.25 ppm chemical 
shift region (Table 3.3).  
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δ/ppm 
Elevated 
or 
decreased 
in GD 
Assignment (multiplicity) 
Statistical Test 
PLS-
DA 
VIP 
value 
ROC 
Curve RF 
4.41 – 
4.46 
↑ Unassigned (broad) 2.71 ✓ 
  
4.26 – 
4.34 
↑ TAG glycerol backbone (broad) 2.50 ✓ ✓ 
4.08 – 
4.13 
↑ 
Lactate-CH (q) / 3-D-
Hydroxybuyrate-CH (m) 
2.03 
  
✓ 
4.22 – 
4.26 
↑ 
Threonine-CH /TAG-glycerol 
backbone (m) 
1.77 ✓ ✓ 
0.78 – 
0.90 
↓ 
TAG-LDL/vLDL-terminal-CH3 
(broad) 
1.55 ✓ ✓ 
1.91 – 
2.01 
↓ 
TAG-CH2CH2CH= (broad) / 
Acetate-CH3 (s) 
1.54 
  
✓ 
3.62 – 
3.64 
↑ Unassigned (broad) 1.40 ✓ ✓ 
2.32 – 
2.35 
↑ Glutamate-β--CH2 (m) 1.35 ✓ ✓ 
2.76 – 
2.80 
↑ 
TAG unsaturated fatty acids (broad) -
C=CH-CH2-CH=C 
1.34 ✓ ✓ 
7.16 – 
7.19 
↑ L-Tyrosine-γ/ε-CH (s) 1.20 
    
1.20 – 
1.30 
↓ 
vLDL/LDL-bulk-chain-(CH2)n- 
(broad) 
1.18 
    
4.03 – 
4.05 
↑ Creatinine-CH2 (s) 1.17 ✓ ✓ 
2.97 – 
3.02 
↓ Unassigned (m)  1.13 ✓ ✓ 
7.79 – 
8.01 
↑ Histidine-CH (s) 1.13 
    
0.94 – 
0.96 
↑ Leucine-CH3 (d) 1.11 
    
2.35 – 
2.37 
↑ Pyruvate-CH2 (s) 
1.09 
✓ ✓ 
1.45 – 
1.48 
↓ Alanine-CH3 (d) 
1.03 
✓ ✓ 
2.90 – 
2.92 
↑ TMAO/Unassigned (broad)  
  
✓ 
  
2.63 – 
2.69  
↓ 
C=CCH2C=C (broad)/Citrate 
CH2A/CH2B (d)   
✓ ✓ 
3.33 – 
3.35 
↑ Unassigned (broad)  
  
✓ 
  
2.20 – 
2.25 
↑ Acetone-CH3 (s) / CH2CO (broad) 
    
✓ 
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Table 3.3. Top 15 statistically significant buckets, showing up- or downregulations in GD1, 
and for which statistical tools show that these metabolites are significant. VIP Scores are 
reported in the PLS-DA column. Abbreviations: GD1 Gaucher’s disease, type 1; HDL, 
High-density-lipoprotein; LDL, Low-density-lipoprotein; TAG, Triacylglycerol; VIP, 
Variable Importance Parameter. 
 
3.5.3 Univariate Statistics Performed on Plasma Profiles  
 
1H NMR profile frequency buckets which were found to be significant in univariate testing 
were then assessed using box plots and ANOVA (Appendix 3). The PCA loadings plot 
identified elevations in 4.08 – 4.13 (-0.06, 0.24), 4.26 – 4.34 (-0.12, 0.13), 4.41 – 4.46 (-0.16, 
0.09), and 4.22 – 4.26 (-0.07, 0.09) ppm bucket regions (PC1 and PC2 loadings are shown 
respectively in brackets), from observation of the extreme loadings on PC1 and PC2. These 
are also displayed as box and whisker plots (Appendix 3). These bucket regions are 
attributable to lactate-CH (q)/3-D-hydroxybuyrate-CH (m), TAG glycerol backbone (broad), 
unassigned broad singlet (s), and threonine-CH (m). The ROC curve analysis identified 
bucket regions attributable to TAG glycerol backbone, TAG-LDL/vLDL-terminal-CH3, 
TAG unsaturated fatty acids and TAG-CH2CH2CH= (broad)/Acetate-CH3 (s) to be 
significant bucket regions, with the minimum AUROC value for these particular predictor 
variables to be 0.823 (Appendix 3). Both univariate test results agree with the above 
multivariate statistical analyses which were performed. 
 
3.5.4 Enrichment Analysis on Plasma Dataset 
 
Enrichment analysis considers disturbed metabolites in the GD1 plasma dataset, and 
compares it to that of the healthy controls. Such differences are then explored with special 
reference to these datasets that are defined by disease or biological locations. This helps to 
identify correlations with multiple metabolites that might be disturbed in a disease or 
location. Metabolite set libraries used include the location-based set including organs, tissue 
and sub-cellular locations, and the disease associated metabolite set (Blood) containing 344 
reported metabolite sets in blood. 
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Location-Associated Enrichment Analysis 
Enrichment analysis using Metaboanalyst 4.0 revealed skeletal muscle as the most significant 
organ impacted in the metabolite dataset (FDR corrected p-value 2.76 x 10-8) in view of an 
upregulation in creatine/creatinine, glutamine, arginine, leucine and pyruvate in GD1 disease. 
The skeletal muscle manifestations in GD1 are well documented in the literature [104]–[107]. 
Moreover, the second most significant location was revealed to be the muscle (FDR-
corrected p value 3.49 x 10-7). The third and fourth most significant organs were the spleen 
(FDR-corrected p value 6.01 x 10-7) and bladder (FDR-corrected p value 1.95 x 10-6). 
Significance of the impact of splenomegaly in GD1 is also frequently reported [104], [107]–
[109]. Muscle is a less well documented manifestation of GD, but more recently, correlations 
have been established between GD1 and myopathy, although this has been variable amongst 
patients with this disorder [110]. All three of these organs are features that are affected by 
GD1 disease pathology.  
Other locations that were identified as significant included the bladder, epidermis, placenta, 
intestine, peroxisome, pancreas and prostate. It is unsurprising that other organs are 
significant, in view of the age of the GD1 patients, and the number of medications that the 
patients are taking, which suggests that there are other age-related metabolic changes and 
possibly age-related diseases. The liver was also significant, but to a lesser extent, and this 
organ often inflamed in GD1 [104]. It would be unsurprising to observe the liver as a 
significant organ, due to the number of drugs the patients were taking. Nevertheless, GD is 
a heterogeneous multi-symptomatic disorder, hence metabolic disturbances are variable from 
patient to patient. Additionally, due to the other medications the participants are taking, it 
cannot be omitted that some of the other organs are impacted because of pharmacological 
related changes.     
Disease-associated Enrichment Analysis 
Critical illness, early markers of myocardial injury, cirrhosis, rhabdomyolysis, diabetes, N-
acetyl glutamate deficiency, heart failure and inflammatory diseases were all significant in the 
disease associated enrichment analysis performed (FDR corrected p-value < 0.01181). 
Cirrhosis metabolomics profiles correlating with the study herein is unsurprising due to 
hepatomegaly observed in GD1 patients [111]. Furthermore, rhabdomyolysis is a condition 
related to muscle injury which also correlates with the disease pathology that observed in the 
form of myopathy in GD1 patients [110].  
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Metabolites affected by gender (FDR corrected p-value = 2.88 x 10-7) and age-related (FDR 
corrected p-value 2.88 x 10-7) metabolites were two of the most significant metabolite sets in 
enrichment analysis. The participants are predominantly sex- and age-matched, and hence 
this finding was unexpected.  
 
3.5.5 1H NMR Urinary Profile Results 
 
1H NMR profiles acquired were referenced to TSP, overlaid and labelled using literature 
sources  [60], [112] and reference to the HMDB. All the GD patients involved in the study 
were on a combination of medications, which may have an effect on NMR spectra in two 
different manners. Drugs and their metabolites may produce resonances which overlap with 
metabolite ones, and therefore need to be removed in order to not appear as an anomaly 
following multivariate/univariate statistical analysis. In addition, metabolomics studies which 
considered the drugs and supplements taken by the patients were monitored, so changes in 
endogenous biomolecule metabolism arising from drug interactions or other xenobiotics 
could be ascertained in depth, together with the impact this may have on the results acquired. 
A literature review performed herein established whether the drugs and their metabolites 
were typically excreted in urine, and if so, their corresponding urinary concentrations. 
Additionally, it was observed how, if at all, drugs impacted on the metabolomic profiles 
observed, and how this would impact on the study performed here. Drugs and their 
metabolites were removed from 1H NMR spectra when detectable by removal of the bucket 
regions containing such xenobiotic resonances. 
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Figure 3.6. (a) 700 MHz 1H NMR spectra of typical GD1 and control urine samples using 
the NOESY PRESAT pulse sequence from 0.35-0.75 ppm, highlighting the region where 
Chemical Shift (δ/ppm) 
 
Chemical Shift (δ/ppm) 
 
Chemical Shift (δ/ppm) 
(a) 
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bile acids C18-methyl function resonances appear. (b) Corresponding spectrum of a typical 
GD1 urine sample using NOESY PRESAT from 0.85-9.20 ppm. Abbreviations: [1] 
Isoleucine-CH3; [2] Leucine-CH3; [3] Valine-CH3; [4] Methylsuccinate-CH3; [5] 2-
Oxoisovalerate-CH3; [6] Amino-isobutyrate-CH3; [7] 3-D-hydroxybutyrate-CH3; [8] Lactate-
CH3; [9] Lysine-γ-CH2; [10] Alanine-CH3; [11] Adipate-C3-CH2; [12] Amino adipate-CH3; 
[13] Acetate-CH3; [14] Lysine-β-CH2; [15]  N-Acetyl-X-CH2; [16] Glutamine-γ-CH2; [17] 
Acetone-CH3/Unassigned; [18] Unassigned; [19] Acetoacetate-CH3; [20] Hydroxygluterate-
δ-CH2; [21] Pyruvate-CH3; [22] Glutamate-γ-CH2; [23] Citrate-CH2A/CH2B; [24] 
Dimethylamine-CH3; [25] Trimethylamine-CH3; [26] Dimethylglycine-CH3; [27] 
Creatine/Creatinine-CH3; [28] Malonate-CH3; [29] L-Histidine-CH2; [30] D-Glucose; [31] 
Trimethylamine N-oxide(TMAO)-CH3; [32] Taurine-CH2-NH3+; [33] Trimethylamine-CH3; 
[34] D-Glucose-CH; [35] Cystine-γ/ζ-CH; [36] Taurine-CH2-SO3; [37] 3-
Hydroxyphenylacetate-CH2; [38] Mannitol-γ-CH; [39] Phenylacetylglutamine-CH2; [40] 4-
Methyloxyphenylacetate-CH2; [41] Lysine-β-CH; [42] Mannitol-CH2; [43] Creatine-CH2; [44] 
Glycolate-CH2; [45] Hippurate-CH2; [46] Creatine-CH2; [47] Pyroglutamate-CH; [48] 
Lactate-CH; [49] Tartrate-CH; [50] Dihydroxyacetone-CH3; [51] β-Glucose-CH; [52] Urea-
CO-NH2; [53] 2-Furoylglycine-γ-CH; [54] Indoxylsulphate-C6/C9-CH; [55] 
Indoxylsulphate-C2-CH / Phenylalanine-C2/C6-CH; [56] Phenylalanine-C3/C4/C5-CH; 
[57] Indoxylsulphate-C2-CH; [58] Indoxylsulphate-CH / Benzoate-CH; [59] Hippurate-
C3/C5-CH; [60] Hippurate-C3/C5-CH; [61] 1-Methyl-Histidine-CH; [62] Hippurate-
C2/C6-CH; [63] Histidine-β-CH; [64] Hypoxathine-C2/C7-CH; [65] 1-Methylnicotinamide-
α-CH; [66] Quinolinate-C6-CH; [67] Formate-CH; [68] Trigonelline-C4/C6-CH; [69] 1-
Methylnicotinamide-CH; [70] Trigonelline-β-CH; [71] N-Methylnicotinamide-CH. 
 
Not all assignments could be finalised in view of the complexity of urine as a biological 
sample, since there are over 200 1H NMR-detectable biomolecules therein [60], in addition 
to overlap problems sometimes encountered with signals arising from drug resonances and 
their corresponding metabolites. Further analysis using 2D NMR techniques would be 
required to confirm all resonance assignments. 
Acetaminophen and it’s metabolites (Appendix 4) are excreted in human urine, and this is 
already extensively established in the metabolomics literature [113], [114]. These are 
examples of signals which are required to be removed prior to metabolomics analysis, or 
alternatively the samples collected from participants receiving this particular medication can 
be removed and hence excluded from the analysis. In view of the number of drugs the 
participants are receiving, all of the samples were kept in the model and the metabolite 
resonances that arose from drugs and their metabolites were removed. If fewer participants 
were on medication, these participants could be removed, and the study could be performed 
with a smaller number of participants. Additionally, an aspirin metabolite, salicyluric acid, 
was also identified in human urine (Appendix 4), and this has been confirmed by reference 
to the HMDB and further literature [113]. Interestingly, although a patient was receiving 
ibuprofen, resonances attributable to this drug that have previously been reported in the 
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literature were not observed [115]. The half-life of ibuprofen is ~2 hours and this may be the 
reason that the parent compound or its metabolite resonances were not observed, i.e. it is 
rapidly excreted in the urine. Although the medications of all individuals participating in the 
study were obtained, the time of administration of the drugs was not provided, information 
which would help in this metabolomics investigation if it was required to investigate drug 
metabolism further. 
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3.5.6 Statistical Analysis of Urinary 1H NMR Profiles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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Figure 3.7. (a) PCA scores plot of control (red) vs type I GD (green) urinary profiles 
showing that PC1 and PC2 represented 27.2 and 16.5% dataset variance respectively. 95% 
confidence ellipsoids are also shown for both participant classifications.  An ’outlier’ sample 
from a patient receiving eliglustat therapy is circled in blue. (b) Potential eliglustat resonance 
in 1H NMR profile labelled [I] which corresponds to its terminal-CH3 function, but this could 
also be attributable to pregabalin’s-CH3 resonance. Aromatic hippurate signals are shown on 
the inset image with resonances located at δ =7.54, 7.56 and 7.82 ppm.  
PCA analysis shows no clear distinction between controls and GD1 (Figure 3.7). There is 
one outlier in the data in the GD1 disease group outside the confidence ellipses which is the 
only patient taking eliglustat. Eliglustat is primarily excreted in the faeces in view of poor oral 
absorption, but has also been observed in the urine to a lesser extent and has been described 
as having unharmful oxidised metabolites [116], [117]. On further observation of the scores 
for the PCA plot and the corresponding spectrum a large resonance at δ = 0.899 ppm that 
was loading positively on PC2. A large elevation in hippurate was also observed, which could 
be a response to the eliglustat, since this is the highest level of hippurate found in any of the 
1H NMR spectra acquired here. These aromatic signal bucket regions and the doublet at δ = 
3.95 ppm were also scoring positively on PC2. Further confirmation using 2D NMR would 
be required in order to confirm the rest of the drug metabolites signals. This particular 
participant was also receiving pregabalin therapy, and this drug also has a methyl group with 
a similar chemical shift value to that of eliglustat at δ = 0.90 ppm [118] and therefore it is 
proposed that this signal is from either one of these drugs. 
 
 
 
 
 
 
 
 
Figure 3.8. PLS-DA scores plot of control vs Type I GD showing a plot of PC3 vs. PC2 vs. 
PC1 representing 12.6, 14.1 and 16,8% of dataset variance respectively. 10-fold cross-
validation was performed, and a model containing 3 components gave a Q2 =value of -0.07. 
However, permutation testing was also performed, and this gave a p-value of 0.068 (not 
significant) with 2,000 permutations using separation by distance.  
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PLS-DA did not distinguish between control and GD1 urinary profiles. It appears that some 
control participants are loading in a similar manner to that of GD1 participants (Figure 3.8). 
Regardless, the model appears to be performing poorly and the cross validation of the data 
showed poor accuracy and precision showing that the model was overfitting. Furthermore, 
the permutation test showed that the model was insignificant.   
SVM was applied to this dataset and it was found to provide a 51.16% error rate with five 
variables, this was the lowest error rate which shows that SVM is not suitable for trying to 
classify between these two groups. A range of different validations were used including 
bootstrap, 10-fold cross validation and LOOCV. k-Means clustering and self-organising 
maps were also unable to distinguish between the groups. 
Univariate analysis was also completed, and this found no statistically significant metabolites 
in all the tests performed, including fold-change analysis, t-tests and volcano plots. 
Multivariate Modelling of Gaucher Disease Treatments 
Multivariate modelling of the two different treatment types were explored in order to 
distinguish if they had any significant impact on metabolic patterns in urine.  
PCA analysis showed a clear outlier in the initial analysis. This may be because this participant 
is the only individual taking omeprazole and there are clear resonances that could be 
attributable to this drug. However, full identification would be required by 2D NMR 
strategies. The PCA analysis shows no real separation in the group (Appendix 5). This outlier 
was removed before further supervised analysis.  
A PLS-DA scores plot showed no significant difference between metabolites in the two 
different treatment types employed herein, since there was no separation observed between 
confidence ellipses (Appendix 5). The PLS-DA analysis revealed low levels of accuracy and 
precision. Additionally, cross-validation provided a p-value > 0.05. Upon permutation, the 
test could not distinguish accurately between the two groups. Similarly, sPLS-DA and O-
PLS-DA approaches confirmed no distinction between the two groups.  
With the use of SVM analysis and using 37 variables, the lowest error rate was 45.8% using 
all three combinations of validation methods including LOOCV, bootstrap and 10-fold cross 
validation. This was the lowest percentage error reported amongst all the variables. RF could 
not distinguish between sample groups either, with OOB error at 0.538 using 1,000 trees and 
7 predictor variables. 
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Fold change, t-test and volcano plot revealed no significant differences in metabolites in 
urinary profiles on comparison of the two different treatments. 
Multivariate Modelling of the Impact of Age in GD participants 
Additional analysis was performed to explore if age groups could be distinguished in the 
GD1 patient cohort. Disease severity index scores were not provided as part of the dataset, 
and therefore age was considered as one of the variables that could help indicate the 
metabolic age and severity of the disease in the participants. The average age of the cohort 
was 50 years, so the cohort was split into groups of below and above 50 years. 
No significant differences were noted in GD participants using PCA or PLS-DA. The PLS-
DA model did not find a significant difference between the two groups in view of the poor 
Q2, R2 and accuracy scores reported.  There appears to be one main outlier in the group in 
the PCA plot and this is the participant taking eliglustat, rather than the other two receiving 
enzyme medications for GD treatment. It was found that no significant differences were 
found in terms of age of participants using computational intelligence techniques such as 
SVM, which provided a 58.7% error with 9 variables and this was with all forms of validation 
testing. In univariate testing, one metabolite was significant when using fold-change testing, 
and it was a trigonelline bucket region (δ = 9.10-9.15 ppm); this is a metabolite of caffeine, 
which is often found to be elevated in coffee drinkers [119]. k-Means clustering was unable 
to distinguish between the different age groups, but interestingly the three clusters that were 
formed included the eliglustat participant on its own.  
 
3.6 Discussion 
 
3.6.1 Potential Plasma Biomarkers  
 
Metabolites linked to GD pathology  
Lipoproteins are responsible for the transportation of lipids in the circulatory system [120]. 
HDL removes lipids from cells, and therefore high levels of HDL are associated with 
decreased risk of cardiovascular events [120]. Conversely, high levels of LDL are commonly 
associated  with an increased risk of such events [120]. Interestingly, buckets relating to 
HDL-, LDL- and vLDL-TAGs are all decreased in the GD1 plasma profiles, despite the 
fasting period involved for the healthy control participants, since all these acylglycerols can 
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be obtained from the diet and GD participants were not fasted, unlike the control ones. This 
is the first time these lipid disturbances have been observed via 1H NMR analysis. These 
lipoproteins are responsible for transporting cholesterol. Low levels of HDL cholesterol 
reverse cholesterol removal, and this may lead to disturbances in cholesterol transport and 
its deposition; this biomolecule is one of the major contributors of gallstones in GD1 patients 
[121].  
Unlike LDL and vLDL cholesterol, HDL cholesterol has been shown to decrease after 
eating, and therefore the depletion may be exaggerated here in this study due to the GD1 
patients being non-fasted [122]. Nevertheless, all these markers have been previously 
recognised as depleted in GD1 patients in view of metabolic changes [123], [124], and serve 
as evident lipid disturbances in the GD1 plasma profiles acquired. On average, GD1 patients 
are older than the control participants within this study (Tables 3.0 and 3.1), which would 
predispose to higher levels of LDL cholesterol in this group [125]; However, this is not the 
case here. Indeed, the inverse effect was observed for HDL cholesterol, which diminishes 
with age, and therefore the results acquired here could be ascribable to the slight difference 
in age ranges between GD1 and control participants, since the age-matching of the two 
groups for comparison is imperfect [125]. Additionally, multivariate modelling was 
performed in order to determine if metabolic differences were distinguishable by age, but 
this effect was not found to be significant.  
Low HDL cholesterol is associated with an increased risk of cardiovascular problems, whilst 
increased HDL is associated with longevity of life [125], [126]. However, a previous study 
on GD participants showed that low HDL cholesterol does not correlate with atherosclerosis 
assessed by artery intima-media measurements [127]. Low levels of HDL cholesterol are 
already recognised as a marker to diagnose patients of Ashkenazi Jewish ancestry with GD1; 
however, confirmatory testing of GD1 is almost always performed with leukocyte 
glucocerebrosidase assays [128].  
LDL cholesterol was also found to be low in GD participants who are on average slightly 
older than the control participants. This is interesting, since typically LDL cholesterol should 
be higher in older participants and so it could be expected LDL cholesterol to be elevated in 
GD1 as a result of non-fasting [122]. Indeed, vLDL cholesterol was also found to be low in 
GD1 patients.  
It has been previously hypothesised why these disturbances occur in GD1 patients, with 
potential causes being ascribable to: (i) malnutrition; (ii) displacement of cholesterol with 
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glucosyl ceramide; and (iii) reduced synthesis in the liver [123]. The most likely cause of 
disturbances in LDL/HDL cholesterol levels are believed to be attributable to a reduction 
in the level of the apolipoprotein B100 and apolipoprotein A1, and an elevation in 
apolipoprotein E in the liver, which are responsible for LDL and HDL biosynthesis [124]. 
Alternatively, this could be attributable to a lack of ABCA1, similarly to NPC, or LCAT 
proteins which control cholesterol trafficking [127]. Both NPC and GD exhibit liver 
inflammation and a disrupted cholesterol transport [26], which could give rise to these 
depleted plasma markers. 
There has previously been described the relationship between gallstones and low HDL/LDL 
cholesterol in GD1 patients, gallstones were correlated with low HDL/LDL cholesterol and 
elevated severity score index, also they were found to be composed mostly of cholesterol 
[121]. Previous studies have suggested these disturbances are also present in β-
glucocerebrosidase (GBA) carriers [129], and have suggested that these markers are inversely 
correlated with disease severity [123]. Upon treatment with ERT, patients’ HDL cholesterol 
levels are elevated, but do not normalise, and LDL cholesterol levels remain unchanged [130]. 
Although this preliminary study has not included carriers, this may be an interesting addition 
to see whether metabolomics could distinguish between all three groups. However, this is 
the first time that these disturbances have been detected using an 1H NMR metabolomics 
approach in conjunction with other potential biomarkers. 
Chronic liver disease and cirrhosis were found to be in the top 5 leading causes of death 
pertaining to GD1 patients [131]. Elevated lactate has been previously described as a 
biomarker for acute liver failure [132], which would corroborate with disease profiles here as 
GD1 participants have hepatomegaly and an elevation in plasma lactate levels. Hypoxia and 
cirrhosis are also highly correlated to elevations in lactate. Furthermore, necrosis is common 
in GD1 patients, which is also highly correlated to elevated lactate levels in plasma, and is 
more prominent in patients that have not been treated with ERT within 2 years of diagnosis 
[133]. Decreases in HDL and elevations in lactate together, formulate the hypothesis that 
there is a shift from aerobic glycolysis to anaerobic and lipid metabolism, which is also 
observed in the blood serum of patients with acute-on-liver failure [134]. Elevations in lactate 
and creatinine have also been previously correlated with cirrhosis [134], [135], and both are 
upregulated in the GD1 profiles observed in this study. Moreover, lactate has also been 
observed to be elevated in plasma of malnourished children [136] and patients with anaemia, 
sepsis and trauma [137]. Malignancy has also been found to be the top cause of death in 
GD1 patients [131], and this is correlated with elevated lactate levels [137]. Blood lactate is a 
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biomarker that has been recognised for mortality, and upregulations of this marker is 
inversely correlated with survival, and has been shown in numerous studies [138]. Overall, 
lactate is a non-specific marker and it could be linked to numerous disorders in GD1. 
Tyrosine and phenylalanine were also upregulated in GD1 patients which have been 
previously found to serve as early markers of liver injury [134], [135]. In addition, acetone, 
which is a ketone body, was also increased in GD1 plasma profiles (Table 3.3), which also 
indicates liver injury, which would fit with GD1 pathology. However, upregulations of 
acetone in plasma have also been correlated with many other conditions, such as 
uncontrolled diabetes [139], chronic renal insufficiency [140] and pancreatic cancer [141], for 
example. Amino acid disturbances have been found in patients with chronic liver disease, 
including upregulations of both tyrosine and phenylalanine [142].  
Formate plays a key role in disrupting the mitochondrial electron transport chain and energy 
production by the inhibition of cytochrome oxidase activity [99]. This is the terminal acceptor 
of the electron transport chain [99]. Consequently, cell death can occur in view of depletion 
of adenosine triphosphate (ATP), which reduces the energy requirements of cells, and hence 
functions cannot be maintained [99]. This could support the hypothesis that mitochondrial 
dysfunction is occurring in GD1 [143]. The elevation of formate in the blood plasma is 
showing the bodies response attempting to remove the excess formate from within the cells. 
Again, this could be another key biomarker for GD. 
Histidine is a metabolite which suppresses inflammation [99]. This metabolite is observed to 
be elevated in GD1 blood plasma (δ = 3.93 – 4.00 ppm) using multivariate analysis (Table 
3.3). However, phenylalanine also resonates within this bucket region. Phenylalanine, as 
noted above, is considered as having little clinical significance with the exception of 
elevations being observed in patients with chronic liver disease.  
3-D-hydroxybutyrate (3-HB) increases with fasting, exercise [144], ketogenic diets and calorie 
restriction [145]. 3-HB has also been demonstrated to be elevated after eating [122]. Thus, 
the increase in unfasted GD1 patient’s plasma may be significant. 3-HB is often used as a 
source of energy when blood glucose levels are depleted; however, this ketone body was 
found to increase despite the blood glucose levels in participants being significantly elevated.  
Moreover, the HDL-phospholipid choline headgroup resonance is significantly decreased in 
GD1 patients. Choline is synthesised in the body of humans, but can also be obtained from 
dietary sources. This effect was observed despite the fasting status of GD1 patients. Choline 
is an important molecule for liver function and skeletal muscle [146], and a depletion in 
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choline can cause liver damage [147]. Skeletal muscle contains large amounts of choline and 
a small amount of acetylcholine, its precursor. Both the liver and bone marrow dysfunction 
are involved in GD1. This could show viability as a potential biomarker for GD1. 
A bucket attributable to leucine (δ = 0.94 – 0.96 ppm) is elevated in GD participants. This 
bucket is slightly overlaid by the lipid resonance, but this resonance without inclusion of the 
leucine signal is observed to be reduced in GD rather than increased, which contrasts with 
the lipid signal. Leucine is an essential branched-chain amino acid, and breaks down in a 
ketogenic manner producing acetoacetate and acetyl-CoA [99]. Leucine was shown to be 
elevated in GD participants and this could be linked to changes in the mitochondria and 
possibly links to other metabolic changes described herein. Alternatively, leucine can be 
obtained from the diet and this may be the reason why it is elevated in GD1 patients. 
Alanine is downregulated in GD profiles on observation of the bucket region 1.46 – 1.48 
ppm. Alanine is a non-essential amino acid and is synthesised by the body, and can be 
acquired from DNA breakdown or conversion of pyruvate [148]. Interestingly, alanine 
decreases on fasting, and GD1 participants are unfasted hence this may be a marker of 
interest for this disease. Additionally, alanine can be obtained from the diet, so an elevation 
in alanine in GD participants is expected, and not a decline. Depletion of alanine could 
indicate a disruption in the citric acid cycle, glycolysis and/or glucogenesis.   
The bucket region 2.35 - 2.37 ppm is attributable to pyruvate, which is elevated in GD plasma 
profiles. Pyruvate is a product of glycolysis and may be upregulated in view of a lack 
of/disturbance with pyruvate dehydrogenase in this disease. This could also serve as a 
potential marker in GD1, in combination with other metabolic markers described herein.  
The bucket region 2.20 – 2.25 ppm is attributable to acetone and a CH2CO resonance which 
appear elevated in the GD cohort and was statistically significant in one of the multivariate 
tests. Acetone may represent a significant metabolite, as generally lipids are downregulated 
in GD and high levels of acetone are often correlated with diabetes and ketoacidosis. 
In rat serum it was demonstrated that anaemia has an impact on metabolic pathways [149]. 
Indeed, an elevation in vLDL cholesterol, LDL cholesterol, acetone, tyrosine, valine, 
histidine, lipid and TMAO levels and a reduction in succinate, choline, creatine, glutamine, 
arginine and α-ketoglutarate was observed in rat serum [149]. Some of these metabolite 
irregularities correlate with our findings since increased tyrosine and lipid levels were 
observed, and decreased choline levels too. However, not all metabolites are changing in the 
same manner as those observed in [149]. 
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Metabolites linked to Parkinson’s Disease, Niemann Pick Disease Type C and 
Gaucher’s Disease 
 
It has been previously proposed [2], [143] in the literature that an improved understanding 
of GD1 would enable a better understanding of Parkinson’s Disease (PD) since frequently, 
carriers of GD alleles and GD patients are at a higher risk of developing PD. Hence, 
metabolites that were significant biomarkers in GD1 with those observed for PD were 
compared, in order to distinguish any differences or similarities.  
Pyruvate and myo-inositol found to be elevated and citrate and acetate were depleted in both 
GD1 and PD [150]. Other metabolites which were significantly different in PD included 
elevations in glucitol and propylene glycol, and depletions in galactitol, ascorbate, threonate, 
glycerol, methylamine, ethanolamine, suberate, isocitrate, glutarate, trimethylamine and 
malate [150]. Upregulations in pyruvate have also been observed in the CSF of Alzheimer’s 
patients [151], [152]. Pyruvate has been suggested as a marker in PD1, and it was 
demonstrated that 46 genes interact with the pyruvate dehydrogenase, but two in particular 
were established as those linked to this disease, namely NPFF and PDHB [150]. The former 
gene, NPFF is associated with inflammation modulation, neuroendocrine function and 
cardiovascular regulation, whereas the latter is involved in mitochondrial dysfunction and the 
activity of pyruvate dehydrogenase [150].  
Citrate is a metabolite that is part of the TCA cycle, and is also readily available in the diet 
[99]. Citrate (2.63 – 2.69 ppm) was depleted in GD1, which could be attributable to several 
reasons. Citrate is observed to rise upon fasting in plasma profiles [153]. However, another 
hypothesis is that the depletion of citrate correlates with the noted disruption of pyruvate 
dehydrogenase [150]. A final hypothesis links citrate to bone metabolism, whereby 
hypocitricemic conditions could be linked to the lack of calcium content in the bones [154], 
a process giving rise to osteopenia, osteoporosis joint pain, arthritis and joint damage in GD 
patients [155]. 
Myo-inositol is produced by the human body from glucose. Therefore, it was removed from 
the statistical analysis since prior analysis involved comparisons between fasting and non-
fasting participants. Nevertheless, the elevation of myo-inositol observed in the initial 
analysis (data not shown) may be significant in GD pathogenesis. In PD, it was observed 
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that myo-inositol was elevated in the basal ganglia under exercise conditions [156]. This 
upregulation could be relevant, since it has been previously hypothesised that the polyol 
metabolic pathway could thus be causing mitochondrial dysfunction [150], which has been 
previously demonstrated to occur in GD1. 
Interestingly, metabolic perturbations that have been demonstrated in Niemann Pick Disease 
Type C1 (NPC) have also been observed in GD in this work [26]. In NPC1 disease, it was 
observed that plasma HDL is downregulated [26], which is also observed in GD, suggesting 
that potentially this is an unspecific biomarker for both LSDs. It is evident and clear that 
lipid disturbances are a feature in both disorders. 
 
3.6.2 Potential Biomarkers for GD1 in Urinary Profiles 
 
From the results acquired, it can be noted that there are no potential biomarkers for urine to 
be further considered. It is promising that the impact of GD1 enzyme replacement therapy 
may be providing 1H NMR profiles that are similar to the controls, and this may provide a 
reason as to why GD biomarkers in the urine are not observable, since all patients were 
undergoing some form of treatment. However, without having a substantial cohort of 
untreated GD participants it would not be possible to confirm if the urinary metabolic status 
resembles that of the control or treated GD cohort. Additionally, in view of the comparison 
of fasting and non-fasting samples, there may be a more significant impact if both cohorts 
were collected under the same, preferably non-fasting, conditions. 
Interestingly, no bile acids (BAs) between 0.66 – 0.69 ppm (Figure 3.6) were observed as 
reported  in NPC1 [13]. This was described previously as being possibly ascribable to liver 
trauma [13], and NPC1 and GD1 conditions exhibit similar symptoms, so it was 
hypothesised that a similar biomarker patterns in the urine may be found. No BA pattern 
that was distinct to GD1 was observed, and it was hypothesised upregulated BA 
concentration may have arisen from inflammation of the liver. This is promising for the 
NPC1 investigation as this may indicate that this specific bile acid pattern is unique to NPC1 
and cholesterol disturbances. A previously unassigned δ = 0.76 ppm iso-propyl-CH3 doublet, 
was observable in both controls and GD1 participants. However, BAs are often present in 
low concentrations in healthy human urine anyway and are directly impacted as a result of 
fasting or non-fasting regimens. 
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3.6.3 Xenobiotics 
 
A combination of xenobiotics assigned, which were found in human urine in this study are 
listed in Appendix 4. Additionally, with patients taking 30 different medications, this renders 
metabolomics studies extremely challenging. On sample collection, most GD1 patients were 
on an average of 4 different types of drugs, with the range of medications including enzyme 
treatment, antibiotics, analgesics etc. Thus, this makes it challenging to effectively monitor 
metabolic responses arising from the ERT alone, for example. Henceforth, the complications 
of drug administration to the metabolomics analysis of human urine is outlined. Moreover, 
conditions (co-morbidities) that are related to the drugs will be explored, since such 
conditions may exert an impact on the results. All controls patients were not receiving 
treatments, unless otherwise specified. 
Some of the participants in the study were receiving drugs for GD treatment. This includes 
the enzymatic drugs imiglucerase (n = 14) and velaglucerase alfa (n = 11) which tackle the 
disease by means of ERT; with elevated enzyme, the glucosylceramide substrate is reduced 
in concentration. Eliglustat (n = 1) partially inhibits the enzyme glucosylceramide synthase 
producing less glucosylceramide. Some participants (n = 5) in this study were not receiving 
enzyme-related treatment. As shown in the previous Figures, metabolomics investigations 
were unable to distinguish between participants on different types of enzyme-related 
medication. However, it remains a possibility that all the treatments were working efficiently, 
and therefore no metabolic changes in the urine were observed. Some changes in urinary 
profiles may have been expected in view of previous literature reports which have shown 
that urinary lipid metabolites, namely monohexosylceramides, showed significant differences 
when compared to those of controls [157], an observation suggesting disturbances in the 
lipid profiles of these participants. However, these elevations in monohexosylceramides were 
found to decrease upon treatment, and their levels returned to normal [157]. The lipid 
concentration in the urinary profiles was not observable by 1H NMR analysis in this study 
since it is below the limit of detection. With only 5 participants untreated with some form of 
GD1 medication, it is very difficult to create a urinary metabolomics medication sub-set in 
view of a small sample size in each group. The significance drawn from this sample size 
might not be accurate or precise, and could be subjected to multivariate models that overfit 
datasets. Additionally, the true effects of eliglustat are also difficult to evaluate with only one 
participant in this group. 
Page 96 of 216 
 
 
A number of participants were also receiving antibiotics including clarithromycin (n = 2), 
phenoxymethylpenicillin (n = 7) and azithromycin (n = 1). From our studies in feline urine 
(Chapter 4) azithromycin was undetectable in any of the urinary profiles examined, since this 
particular antibiotic is excreted in the bile and kidneys. Similarly, phenoxymethylpenicillin 
undergoes metabolism through the kidneys. Other penicillins have been observed in human 
urinary profiles by NMR analysis [158]. Clarithromycin undergoes hepatic metabolism [159], 
and from the work performed on feline urine, it was not possible to identify this drug in the 
urinary profiles. Moreover, no antibiotic resonances were identified in urine profiles in the 
GD1 patient spectra. Participants receiving these drugs did not appear to be ‘outliers’ in 
either of the plasma or urinary multivariate scores plots.  
Salbutamol (n = 1) and beclomethasone (n = 1) were also used as treatments for GD patients, 
and are both used for managing asthma. NMR metabolomics profiling has been previously 
performed on urine samples collected from patients with no asthma, stable asthma and 
unstable asthma [160]. Urine metabolites which were critical in the model were those related 
to the TCA cycle inclusive of 2-oxaloglutrate, succinate, fumarate, 3-hydroxy-3-
methylglutarate, threonine, cis-aconitate and trans-aconitate [160]. This cohort did not control 
the time of urine collection, nor diet before collection, which may have impacted the overall 
results acquired. Nevertheless, samples from GD1 patients receiving these medications were 
not ‘outliers’ in the present study comparing GD1 and controls. It is unknown how drugs, 
such as salbutamol and beclomethasone, impact on the urinary and plasma profile in GD1 
participants and asthma patients more generally, since such metabolomics studies are yet to 
be performed.  
Analgesics are often prescribed to GD1 patients since it is a multiorgan disorder which varies 
in severity. The GD1 participants were receiving the following therapies: etoricoxib (n = 1) 
and fentanyl (n = 1); co-codeamol, paracetamol and codeine (n = 2); co-dydramol, 
dihydrocodeine tartrate and paracetamol (n = 1); acetaminophen (n = 5); aspirin (n = 1); and 
morphine (n = 1). Control participants (n = 2) were also receiving acetaminophen treatment.  
Both aspirin and acetaminophen have been previously analysed in urine using 1H NMR 
analysis [113]. The impact of the resonances from these drugs and their metabolites 
appearing in the 1H NMR spectra (Figures 3.14 and 3.15) unfortunately precludes these 
spectral regions in view of their overlap or potential overlap with those of endogenous 
metabolites.  Aspirin (O-acetylsalicylate), which can be used as an analgesic, can also be used 
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for cardiovascular disease or stroke. Neither O-Acetylsalicylate, nor its metabolites, were not 
observed in the 1H NMR plasma profiles.  
Tramadol (n = 1) was employed to treat a single GD patient. Its metabolism have been 
previously extensively explored, and it has several metabolites, including O-
desmethyltramadol, N-desmethyltramadol and N,O-desmethyltramadol, which are formed 
in the liver [161]. Tramadol has been previously observed in the urine of dogs and cats using 
mass spectrometry [162]. Despite extensive analysis of tramadol’s metabolic pathway, it is 
unclear how it impacts upon the metabolism of humans, if at all.  
A single GD patient received morphine treatment. Metabolomics studies focused on 
morphine administration have been performed in rats, and significant changes were observed 
in the urine and plasma [163]. Rat plasma was observed to change after morphine addiction, 
with depleted levels of 3-hydroxybutyrate, L-tryptophan and cystine, and elevated levels of 
n-propylamine [163]. The GD patient receiving morphine therapy was not found to be 
statistically significantly different in the plasma profiles comparably to the remainder of the 
GD cohort. Many metabolites in the rat urine changed as a result of morphine administration 
and morphine addiction, including TCA and amino acid metabolites, amongst others [163]. 
However, no significant differences were observed in this GD patient’s urine versus control 
urine samples. Overall, analgesics are an essential part of managing pain and palliative care 
in GD. This creates challenging human metabolomics models for GD1.  
Omeprazole (n = 2) and esomeprazole (n = 1) were taken by GD1 participants, and are 
frequently used to treat gastroesophageal reflux disease (GERD), and to avoid side-effects 
arising from strong pain relief.  
In a previous study, human patients with cirrhosis showed different metabolic urinary 
patterns to corresponding controls, and the differences observed included hippurate, 
dimethylamine and lactate [164]. On administration of omeprazole, hippurate was 
significantly reduced in urinary profiles of cirrhosis patients [164]. Additionally, lactate was 
observed as elevated in the urine of both controls and patients when compared to 
participants receiving omeprazole [164]. Finally, dimethylamine was seen to be significantly 
reduced in the urine of the cirrhosis cohort [164]. However, in this study, no significant 
differences in the GD1 profiles arising from the administration of omeprazole was observed 
in multivariate testings in plasma but an outlier was observed in urine. The study reported in 
(63) did not analyse human plasma samples, and to date the metabolic differences in human 
plasma have not been observed using omeprazole. However, one study which analysed blood 
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serum samples in rats following administration of aspirin and a combination of aspirin and 
omeprazole [165] observed no disturbances in the citric acid cycle, but did find some 
disturbances in beta-oxidation with a depletion in 3-D-hydroxybutylate [165]. No significant 
differences in the plasma of the GD1 cohort were observed, and these samples were not 
observed as outliers. 
Methotrexate (n = 1) has been used to treat a GD1 patient in this investigation. Methotrexate 
has previously been explored in a 1H NMR metabolomics investigation which evaluated the 
treatment outcome and the corresponding metabolic changes in urinary profiles in 30 rats 
[166]. A total of 13 biomarkers for successful treatment were proposed, including urate, 
taurine, histidine, methionine, glycine, tryptophan, uracil, TMAO, methionine, aspartate and 
α-oxoglutarate [166]. Despite this, the GD1 participant being treated with methotrexate did 
not exhibit any ‘outlier’ characteristics in multivariate scores plots of the plasma or urinary 
datasets. 
Benzydamine (n = 1), ibuprofen (n = 1) and naproxen (n = 1) have been used to treat GD1 
patients. Ibuprofen and its corresponding metabolites have been well documented in human 
urine [115], [167]. However, ibuprofen metabolites were not observed in the urinary profiles 
of GD1 patients, and this may be because of the drug’s rapid metabolism (half-life ca. 2 hr). 
In the metabolic profiling of rat urine using 1H NMR analysis, naproxen was found to induce 
metabolic increases in creatine, creatine phosphate, betaine and kynurenate, and a reduction 
in choline [168]. Additionally, naproxen dosage depends on how significant these differences 
are. For example, significant changes in citrate levels are only observed on comparison of 
vehicle vs. high dose-administered rats. In this study, no significant differences between GD 
urine in multivariate testing was observed, and nor were there any ‘outliers’ arising from the 
taking of non-steroidal anti-inflammatory drugs.     
Some patients with GD were also taking bendroflumethiazide (n = 1) candersartan (n = 1) 
hydrochlorothiazide (n = 1) losartan (n = 1) and co-amilofruse (n = 1), which is a 
combination of amiloride [169] and furosemide. Losartan metabolism has been investigated 
using 1H NMR in human plasma profiles, and showed a metabolic response in biomolecules 
such as upregulated vLDL/LDL lipids, creatine, creatinine, lactate, citrate and α-glucose in 
addition to downregulated HDL lipids, glycine, phosphorylcholine and choline [170]. These 
markers were indicative of pharmacometabolomic effects arising from this treatment. 
Moreover, losartan was transformed to its bioactive metabolite EXP3174 [170].  
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Citalopram (n = 1) and amitriptyline (n = 3) were taken by small numbers of the GD1 
patients in the cohort. Selective serotonin reuptake inhibitors  (SSRI’s) have been previously 
subjected to metabolomics analysis and elevated glycine has been proposed as a response 
biomarker for these conditions in human plasma samples [171]. However, the study did not 
explore the biomarkers as a response to treatment outcome and if glycine was depleted as a 
result of such administration, which is required for validation purposes. A 1H NMR 
metabolomics study has been performed on the urinary profiles of patients receiving 
citalopram, and it was found that the metabolic disturbances caused by major depressive 
disorder returned to control levels [172]. Twenty-four out of twenty-six urinary metabolites 
monitored by UPLC-Orbitrap-MS have also been observed to return to normal levels after 
administration of citalopram in rats with mild stress [173]. It would be expected metabolic 
disturbances would be observed in urine as a result of administration of citalopram herein. 
No significant differences in the GD1 urinary profiles were observed; however, this is a 
consideration that should be observed in future investigations. Glycine was not observed to 
be a significant metabolite in the plasma profiles in these particular GD patients, nor did this 
GD patient appear as an ‘outlier’ in multivariate analysis scores plots.  
Quinine sulphate (n = 1) has been administered in a GD1 participant in this study, and is 
often used for muscle cramps. Quinine sulphate is metabolised in the liver and excreted in 
urine, and a total of 10 metabolites have been previously identified by GC-MS in human 
participants [174]. Quinine sulphate can cause hypoglycaemia, but regardless, glucose was 
removed from the multivariate analysis performed on plasma samples, and this participant’s 
sample was not an ‘outlier’ in this metabolomics investigation. 
Pregabalin (n = 1) is a treatment that manages a range of conditions including epilepsy, 
fibromyalgia, restless leg syndrome and generalised anxiety disorder, and was administered 
to one of the GD1 patients. This participant, however, did not appear as an outlier in 
multivariate analysis scores plots for the plasma profiles.  
Warfarin (n = 1) was used to treat one GD1 participant. Plasma has been analysed in 
participants receiving warfarin and it demonstrated that ethanolamides, a group of lipids 
responsible for procoagluation, were significantly upregulated [175]. This was not observed 
in this investigation, and this sample did not appear as an ‘outlier’ amongst the plasma 
samples.  
Zoledronate (n = 2) is used to treat various bone diseases, including osteoporosis, which is 
frequently prevalent in GD1 patients [176], amongst other bone-related conditions. No 
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resonances attributable to this therapeutic agent in the plasma profiles acquired. Zoledronate 
is metabolised by the kidneys and excreted in urine without any structural changes, although 
it was not observed in the 1H NMR spectra. 
Loperamide is an opioid-receptor agonist used to treat diarrhoea and was prescribed to treat 
a GD participant in this cohort. Loperamide is only excreted in small amounts in the urine 
and is considerably metabolised via first-pass metabolism. Serum biomarkers have been 
found in rats that are indicative of loperamide ingestion [177]. Depletion of acetate, glucose, 
glycerol, lactate, succinate, taurine, alanine, glutamate, glutamine and glycine were observed 
in the blood serum of loperamide-treated rats [177]. Hence, administration of this particular 
drug may impact the results of the plasma acquired in this study for this participant. However, 
this participant did not appear as an ‘outlier’ in any of the metabolomics scores plots 
generated. Additionally, metabolic changes demonstrated in rats were not observed in this 
human trial.  
Some of the GD participants were on cholesterol-lowering drugs, namely simvastatin (n = 
2) and pravastatin (n = 1). For participants to be prescribed these drugs, they are likely to 
have high cholesterol levels, and potentially be overweight with high BMI values, and are 
older and/or have a higher risk of cardiovascular disease, specifically stroke, heart attacks, 
coronary heart disease and angina. All of the above conditions and factors are required to be 
taken into account prior to a metabolomics investigation; however, this information was not 
provided for the GD1 group.  
In a metabolomics study monitoring rat plasma by 1H NMR, simvastatin-treated rats were 
observed to have higher levels of LDL/vLDL-TAGs, 3-D-hydroxybutyrate, glutamine, O-
acetyl glycoproteins, lactate, choline/phosphocholine, and depleted levels of alanine, 
polyunsaturated fatty acids, glutamate, arginine, monounsaturated fatty acids, valine, proline 
and pyruvate, when compared to corresponding controls [178]. Other studies have been 
performed in order to assess the impact of weak and high simvastatin toxicity with 1H NMR 
monitoring of rat urinary profiles [179]. The biomarkers found include allantoin, 2-
oxoglutarate and TMAO, which were all increased in the urine upon treatment with 
simvastatin [179]. Since the present GD1 urinary metabolomics investigation was 
insignificant, this may contribute towards further overlap of multivariate scores between 
controls and GD1 participants. 
Serum cholesterol levels were also demonstrated to be lowered in pravastatin-treated 
participants [180]. Additionally, changes were observed in apolipoproteins B and a 
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combination of these with apoliproteins A1. Statins therefore may have a positive impact on 
GD1 participants as the disorder is a LSD, and lipids for the most part are found to be 
lowered on administration of statins [181]. This could exacerbate the significance of what is 
observed in GD1, since if plasma cholesterol is low in GD1 participants, and it is further 
lowered upon receiving pravastatin, this might explain some of the metabolomics analysis 
overlap between control participants and GD participants. However, in view of the small 
sample size of the number of participants taking statins, a full metabolomics investigation 
would have to be performed in order to validate this hypothesis.   
Participants in the GD1 group were taking estradiol (n = 2) and norethisterone (n = 1), 
whereas healthy controls were not receiving any hormone treatment or contraceptives. 1H 
NMR metabolomics investigations have been previously performed in plasma and urinary 
profiles, observing the effects of menstrual cycle phase, which found no separation based on 
urinary metabolites [182]. There were a range of participants who participated in this study, 
and these included a variety of ages,  and some of these participants were taking oral 
contraceptives [182]. However, these participants did some show variations in plasma 
between two phases of the menstrual cycle, with the menstrual and luteal phases being 
significantly different that were significant [182]. This included a significant decrease in 
metabolites such as glutamine, glycine, alanine, lysine, serine and creatinine, and elevations 
in acetoacetate and vLDL-TAGs [182]. On comparison with data collected here, only alanine 
is depleted in GD1 plasma, and no significant changes in any other metabolites were 
observed. Elevation in the creatinine/creatine resonance was also observed in the GD1 
patients. However, this observation differs from the depletion of metabolites observed in 
the menstrual cycle study. [182]. In a study that compared sex and contraceptive use, it was 
shown that women receiving oral contraceptives showed lower levels of glycine, proline, 
histidine, lysine, hydroxyproline and orthenine, along with increased levels of isoleucine 
[183]. GD datasets did not exhibit any of the changes described above in the plasma profiles. 
No outliers were observed arising from hormone treatment. 
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Biofluid Drug and 
dose 
Metabolites  Pathways 
disturbed and 
impacted 
metabolism  
GD1 
metabolites 
Plasmab Morphine  
addiction 
3-Hydroxybutyrate (↓), l-
tryptophan (↓), cystine (↓), 
n-propylamine (↑) 
(↓) β-Oxidation 
pathway from 
fatty acids and/or 
ketone production 
from acetyl-CoA 
Some biological 
implications 
unknown 
n/a 
Urineb Morphine 
addiction 
(↑) 2-Ketoglutaric acid, 
fumaric acid, malic acid 
and l-threonine 
(↓) Glutamate, isoleucine, 
valine, aspartic acid, 
oxamic acid, 2-
aminoethanol, 
indoxylsulphate, creatinine 
n/a 
Urineb Naproxen 
Toxicity 
(↑) Creatine, creatinine 
phosphate, betaine, citrate, 
cis-aconitate, kynurenate 
(↓) Choline  
Energy 
metabolism 
decreased 
mitochondrial 
function and 
gastric injury 
n/a 
Plasmaa Losartan Glycine, 
phosphorylcholine, 
choline, creatine, 
creatinine, lactate, citrate 
alpha-glucose and lipids  
Glycine, serine 
and threonine and 
glycolysis or 
gluconeogenesis 
metabolism  
 
Plasmab Simvastatin  (↑) LDL/vLDL-TAGs, β-
hydroxybutyrate, 
glutamine, O-acetyl 
glycoproteins, lactate, 
choline/phosphocholine  
(↓) Alanine, 
polyunsaturated fatty 
acids, glutamate, arginine, 
monounsaturated fatty 
acids, valine, proline 
pyruvate 
Lipid metabolism 
ketone bodies 
gluconeogenesis  
(↓) 
LDL/vLDL 
Urineb Simvastatin 
toxicity  
(↑) Allantoin, 2-
oxoglutarate, TMAO 
Free radical 
damage, oxidative 
stress, 
inflammatory 
response  
n/a 
Seruma Pravastatin (↓) All cholesterol types 
except HDL* 
Reversal of 
cholesterol 
transport 
(↓) All 
cholesterol 
Seruma Warfarin (↑) Ethanolamides Procoagluant n/a 
Serumb Loperamide (↓) Alanine, glutamate, 
glutamine, glycine, acetate, 
glucose, glycerol, lactate, 
succinate and taurine 
TCA cycle 
 
n/a 
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Table 3.4. Impact of administration of drugs on biofluids, inclusive of what metabolites are 
affected in humansa and ratsb and considering a combination of NMR- and MS-determined 
metabolites. Corresponding metabolic pathway that are disturbed are also shown. *scaled 
against a baseline measurement rather than corresponding control participants. 
Drug metabolite(s) Chemical shift 
(δ/ppm) 
Urine metabolite(s) 
Acetaminophena 2.15 
6.90 
 
 
7.25 
Glutamine-CH2 
3-(3-Hydroxyphenyl)-
3-hydroxypropanoic 
acid-CH 
 
Acetaminophen glucuronide derivativea 2.15 
3.63 
 
3.91 
5.11 
7.13 
7.34 
Glutamine-CH2 
Myo-insitol-
CH/Glycerol-CH2 
Creatine-CH2 
 
 
Tartrate-CH 
Acetaminophen sulphate derivativea 2.18 
7.27 
7.45 
Acetone-CH3 
Indoxyl sulphate-CH 
Imidazole-CH 
Acetaminophen L-cysteinyl derivativea 1.84 
2.15 
3.28 
4.30 
7.50 
Aminoadipate-CH2 
Glutamine-CH2 
Taurine-CH2 
Choline-CH2 
Indoxyl sulphate-CH 
Acetaminophen N-Acetyl L-cysteinyl 
derivativea 
2.15 
3.35 
3.99 
6.99 
7.26 
7.51 
Glutamine-CH2 
Methanol-CH3 
Phenylalanine-CH 
3-Methylhistidine-CH 
Indoxyl sulphate-CH 
Indoxyl sulphate-CH 
Salicyluratea 3.96 
3.97 
7.02  
7.49  
7.78  
 
Phenylalanine-CH 
Histidine-CH 
Hippurate-CH 
Table 3.5. A summary of drug resonances found in humana and animalb urinary profiles in 
this study and the corresponding bucket region elevated and the corresponding urinary 
metabolites which would not be able to be quantified in view of interfering drug/drug 
metabolite resonances.   
 
3.6.4 Diet and Dietary Supplements 
 
Diet has an impact on 1H NMR metabolomics and this has been shown in various studies 
[184]. Participants in the control group included a range of diets which were documented 
using a food diary. None of the participants in the control group had taken supplements with 
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the exception of one participant taking magnesium supplementation. GD participants were 
taking vitamins and this can impact the metabolic pathways. Herein, it is described what 
supplements were taken and how this can potentially have affected the results.   
Cod liver oil is a very well-known supplement and has been previously evidenced for being 
beneficial for heart disease in population studies [185]. However, metabolomics studies have 
not been performed on cod liver oil and there is some evidence that suggests cod liver oil 
has no influence on disease [186]. Nevertheless, it has been demonstrated that seafood diets 
give rise to a higher level of TMAO in urinary profiles whereas, guanidinoacetate and 3-
methylhistidine are reduced in non-seafood diets [187]. This may have an impact when 
conducting a metabolomics investigation whereby some of the GD participants (n = 2) are 
taking cod liver oil supplements, known for improving cardiovascular health. Cod liver oil is 
known to lower total cholesterol and LDL cholesterol levels in the blood, which is believed 
to be due to elevated expression of cholesterol receptors [188]. A depletion in cholesterol in 
plasma was observed across the whole GD cohort and not just the two GD participants 
receiving cod liver oil.  
Vitamins are frequently taken by many groups of diseased cohorts as they can be taken due 
to a deficiency and other medical reasons such as pregnancy or digestive disorders. It can be 
difficult to isolate the impact of a vitamin on the metabolism and often vitamins are used in 
combinations with other minerals, such as calcium, magnesium, and drugs. 
Folic acid, folate or vitamin B9 (n = 2) is another supplement taken by the GD cohort. The 
intake of folic acid has been shown to significantly elevate plasma homocysteine and urinary 
malondialdehyde and lymphocyte DNA hypomethylation in postmenopausal women [189].  
Elevation in plasma homocysteine can lead to an elevation in taurine as demonstrated in rats 
[190]. Additionally in diabetic rats, 20 urinary metabolites were found to be significantly 
altered as a result of folic acid supplementation including urinary metabolites such as creatine, 
nicotinurate, n-acetyl-tyrosine spermine, 5-hydroxyindoleacetate, Indolylacryloylglycine, 4-
(2-Aminophenyl)-2,4-dioxobutanoic acid, hydroxyphenylacetylglycine, suberic acid, 2-Oxo-
4-hexenoic acid, 5-oxo-7-decenoic acid, ω-oxo-capric acid, ethyl oxalacetic acid, hydroxy-
cyclohexenoic acid, monoethylhexyl phthalic acid and cis-stilbene oxide [191]. These 
metabolites demonstrated potential changes in the gut microbiota [191]. No significant 
differences in the patients GD urine were observed, across 30 different patients, these 
metabolic changes observed in the literature are unlikely to make a significant change to the 
study. Although a potential elevation in taurine in plasma was observed, these buckets were 
Page 105 of 216 
 
 
shared with those of glucose and required to be removed from the investigation, thus do not 
impact the plasma results herein. Other B vitamins that were taken in this study by the GD 
cohort include cyanocobalamin (n = 1), thiamine (n = 1) and hydroxocobalamin (n = 4). 
Overall, these B vitamins boost energy metabolism but the participants do not appear as 
outliers in the statistical testing.  
A number of vitamin D’s were taken in the GD group including ergocalciferol, vitamin D2, 
calcitriol, vitamin D, calcium carbonate and vitamin D3. Vitamin D is often taken in order to 
strengthen teeth and bones and therefore in GD, where the symptoms are bone pain for 
example, it is an important vitamin to be supplementing. To date, no metabolomic studies 
have been performed on vitamin D that could explain some of the changes observed herein.  
One participant in the control group was taking magnesium vitamin supplement. This 
participant was not observed to be an outlier in the statistical tests on urine or plasma profiles 
suggesting no dramatic changes in metabolism. Although this could be further investigated 
in a larger metabolomics investigation as magnesium is observed to play a role in energy 
metabolism.  
 
3.6.5 Implications of comparing fasted with non-fasted participants plasma  
 
Many studies have previously explored the effect of fasting and non-fasting participants and 
it has been shown that even acute dietary changes can affect the metabolism [192]–[194]. 
Glucose and amino acids have been shown to give a difference between fasting and non-
fasting participants [194]–[196]. Thus, it is crucial further experiments are performed with 
fasted GD participants to validate these findings to ensure a rigorous metabolomic study.  
Removal of buckets in plasma profiles pertaining to glucose, phenylalanine and myo-inositol 
was important, as although these metabolites could be due to clinical significance, they are 
more likely to be upregulated due to simple differences between fasting and non-fasting 
participants [197].  
Glucose was elevated in the GD participants plasma (Table 3.3), which is expected, due to 
the lack of fasting from these participants in comparison to the healthy controls [102], [122]. 
Glucose is a precursor for myo-inositol, if glucose is elevated, consequently further myo-
inositol is produced in a two-step reaction via glucose-6-phosphate [148]. Phenylalanine is 
also expected to be elevated due to being an essential amino acid that is required to be 
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obtained from diet and therefore is likely to be of little clinical significance [102]. 
Phenylalanine converts to tyrosine by phenylalanine hydroxylase, hence why both of these 
metabolites may also be increased in the plasma. Tyrosine however, can also be synthesised 
by the body similar to formate, both of which are elevated. Tyrosine is not found in high 
concentrations throughout the body, as normally it is rapidly metabolised and one study 
suggests it is higher in fasting individuals as opposed to non-fasting individuals [102]. 
However, tyrosine is elevated in GD patients, the non-fasting individuals in this case. Large 
concentrations of tyrosine usually indicate a need for more vitamin C, which is crucial to 
bones and in GD, bones are impacted as a result of the disease.  
Histidine is another essential amino acid which is elevated in GD. This metabolite in serum 
from fasting participants has been shown to be both higher [102] and lower [122] in fasting 
participants however, the former is evident here. Histidine is attributable predominantly from 
dietary sources but elevated levels of plasma histidine have been previously associated with 
numerous pathological conditions such as tremors, ataxia and psychosis [148]. Therefore, it 
is challenging to identify herein whether this metabolite is elevated due to the different 
experiment conditions or alternatively the disease pathogenesis.  
Leucine is a precursor of 3-HB and is elevated typically in fasting participants serum [102] 
and it is an essential amino acid which can only obtained through the diet. Thus, an elevation 
in leucine would cause the elevation of 3-HB. Leucine is elevated in our statistical analysis 
performed (Table 3.3), which could be due to comparing non-fasting and fasting participants. 
Leucine has not previously been described or identified as a marker for GD.  
Fasting is known to have an effect on urinary metabolites including an increase in 3-HB [60]. 
Furthermore, diet is also shown to have an effect on metabolites within urine; mannitol is 
said to increase with the intake of carrots, asparagus and apples [60], trans-ferulic acid 
increases with the intake of breakfast cereals and chocolate [60], betaine/proline decreases 
with low prevalence of dietary fruits [60], [184], dimethyl sulfone increases with intake of 
onions [60], methyl histidine increases with intake of meat [60], ethyl glucoside is elevated 
following the ingestion of rice, wine and sake [184]. Hence, it is important to take into 
consideration these other metabolites which may be impacted. 
Urinary metabolic profiles can also be impacted by drinks as well as food. Urinary profiles 
have been correlated with age and this has previously been demonstrated due to a higher 
intake of caffeine [112], [119]. No significant differences in the profiles were observed herein 
and elevated trigonelline levels were not reported in the GD participants. 
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3.6.7 Populations 
 
The GD cohort and cohort of participants from DMU were different populations. The 
INTERMAP study highlights the impact of population differences in metabolome inclusive 
of changes in gut microbial-host metabolites, amino acids, dietary related metabolites, energy 
metabolism, and TCA intermediates in urine [184]. This can be correlated with systolic and 
diastolic blood pressure [184], which was not taken as part of the study herein but it is 
important to consider in future metabolomics investigations. Not only were differences 
found between populations such as East and West of the world but also within populations 
[184]. The north and south of China had significantly different urinary metabolites. These 
were believed to be derived from different dietary patterns, blood pressure and BMI and this 
is reflected in the occurrence of CVD and mortality rates [184]. This study explored the 
impact of environmental differences which could be potentially why differences are observed 
between GD1 and control cohorts. 
 
3.7 Conclusions 
 
A clear distinction between GD and control plasma profiles has been established using 1H 
NMR combined with MVA. There are evident lipid disturbances in plasma profiles which 
have been previously reported in the literature that corroborate with the findings in this 
study. Furthermore, upregulated metabolites such as lactate, creatinine and depletion in 
tyrosine and phenylalanine may indicate liver dysfunction. 
This 1H NMR metabolomics strategy is able to easily distinguish from control and GD1 
patients, despite the fasting period. However, it is important to consider the drawbacks and 
implications of these findings due to comparison of fasting and non-fasting participants in 
addition to GD1 patients being on a plethora of drugs which are highlighted herein.  
No distinction was made between urinary profiles in controls and GD1 patients using 1H 
NMR. These participants were receiving enzyme treatment, which has previously been 
shown to affect the urinary lipid metabolome in GD, but no other pathways herein have 
been explored using a 1H NMR approach, such as the amino acid metabolism for example. 
Despite this the results are interesting as, the potential effectiveness of enzyme treatment in 
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GD is demonstrated, as the multivariate and univariate analysis is not statistically significant 
in GD profiles compared to the control profiles.  
Herein, it was also explored how drugs also present challenges in human metabolomic studies 
as some elements of experimental design cannot be controlled such as drug administration. 
Moreover, metabolomics studies have not been performed on all drugs and predominantly 
animal models have been used to investigate the impact of drugs on metabolites. Animal 
models allow for uniformity in experimental design which is not always possible in human 
studies which makes exploring drugs using these models practical. It is also challenging to 
isolate the impact of a single vitamin or supplement when extensive studies have not been 
performed on corresponding controls or the disease group. It is very well known that diet 
and nutrition can impact metabolomics outcomes but, due to a limited sample sizes, these 
issues were not explored further. 
 
3.8 Proposal for future research investigations 
 
From this work complications of uncontrollable human variables into a metabolomics 
investigation are described. This creates complexity in the models and variance can be due 
to a number of factors including treatment, age, sex etc. It would be essential to replicate this 
study with an animal model with treated, untreated and control animals whereby it is easier 
to control the conditions exposed to the subjects. Alternatively, it would be desirable to have 
samples from fasted GD1 participants where possible on no medication that would cause 
interference with the spectrum. However, due to the patients being in critical condition in 
some instances this may not be possible, but this introduces further variables in a 
metabolomics investigation including the aforementioned drug signals present in spectra and 
the changes in metabolism. Another investigation that would validate findings herein would 
be to observe human plasma and urine samples from GD1 participants prior- and post-ERT 
or other therapies such as Eliglustat. 
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Chapter 4: A 1H NMR Metabolomics Investigation of 
Niemann Pick Disease and Hydroxypropyl-β-Cyclodextrin 
Therapy in an Animal Model System 
 
4.0 Abstract 
 
Background: Niemann Pick Disease Type C (NPC) is a rare, neurodegenerative, lysosomal 
storage disorder which alters the storage and transport of cholesterol and sphingolipids. 
Hydroxypropyl-β-Cyclodextrin (HPβCD) has been proposed as a treatment for NPC in view 
of its cholesterol encapsulation and removal properties.  
Methodology: A 1H nuclear magnetic resonance (NMR) metabolomics investigation was 
performed to assess metabolic responses from felines suffering with NPC, along with the 
metabolic effect of HPβCD treatment. Urinary profiles were acquired using a 400 MHz 
NMR spectrometer analysing control (n = 35), untreated NPC (n = 22) and HPβCD- treated 
NPC felines (n = 95). Three HPβCD treatment approaches were used: two intrathecal 
methods were administered using a 120 mg dose, one initiated at 3 weeks pre-
symptomatically (n = 36), and another initiated at 6 weeks, post-symptomatically (n = 36). 
The third approach involved subcutaneous injection of 1,000 mg/kg and 120 mg doses 
intrathecally, and this was initiated at 3 weeks of age (n = 23).  
Results and Discussion: More than 80 metabolites were detectable in the feline urine 
spectra, including short-chain organic acid anions, branched chain amino acids, N-
acetylamino acids, N-acetylsugars, and notably nicotinate and nicotinamide pathway 
metabolites, amongst others. Partial Least Squares-Discriminant Analysis (PLS-DA) was 
unable to distinguish between control and NPC felines. However, on removal of the younger 
felines (< 10 week ages), in which disease progression was not as established and hence pre-
symptomatic, PLS-DA was able to successfully distinguish between these restricted 
groupings. Significant differences were not found when comparing the treated and untreated 
NPC felines using the intrathecal 120 mg dose both pre- and post- symptomatically. 
However, for felines treated by subcutaneous injection (SQ) of 1,000 mg/kg and intrathecal 
injection (IT) of 120 mg of HPβCD initiated at 3 weeks of age, significant differences were 
observed. Significant metabolites included felinine, creatine/creatinine, hippurate, 
phenylacetylglycine, trimethylamine oxide, betaine and taurine, together with others. These 
urinary results were compared to results obtained on blood plasma in order to assess the 
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outcomes of different treatment models, and further understand the metabolic pathways 
involved. 
Conclusions: 1H NMR metabolomics profiling can successfully distinguish between 
treatment approach outcomes in the 1H NMR urinary profiles of felines. 1H NMR 
metabolomics is unable to distinguish between NPC feline samples and controls; however, 
post-symptomatic changes can be observed when evaluated against control felines. 
Treatment with a combination of SQ (1,000 mg/kg) and IT (120 mg) of HPβCD initiated at 
3 weeks of age was deemed to be the most effective course of treatment. Removal of the SQ 
1,000 mg/ kg and IT 120 mg HPβCD treatment group from the complete dataset did not 
reveal any significant urinary metabolic differences between the other treatment regimens 
and untreated controls. Metabolic modifications observed in the post-symptomatic NPC 
urinary profiles indicate disturbances in both gut microbiota and cholesterol/sterol 
metabolism. These disturbances appear to be reversed on treatment with SQ (1,000 mg/kg) 
and IT (120 mg) injections of HPβCD. 
Keywords: Nuclear Magnetic Resonance, Hydroxypropyl-β-Cyclodextrin, Niemann Pick 
Disease Type C1, Lysosomal Storage Diseases, Urinary Analysis, NMR-Linked 
Metabolomics, Metabolism. 
 
4.1 Introduction  
 
Niemann Pick Disease Type C (NPC) (OMIM 257220) is a rare, neurodegenerative lysosomal 
storage disorder which alters the storage and transport of cholesterol and sphingolipids in 
view of a mutation in either the NPC1 (95%) or NPC2 (5%) genes [2]. Humans and animals 
afflicted with this disorder present symptoms including, but not limited to, vertical 
ophthalmoplegia, dementia, ataxia, dystonia and hepatosplenomegaly. These developments 
are potentially fatal at an early age, which can occur as early as 24 weeks in felines, and 
0.1years in humans [198]. The median age of death for humans with NPC disease is 13 years 
[198]. At present, NPC disease is diagnosed using the Filipin test which is required in 
duplicate to validate findings, and consists of an invasive skin biopsy procedure [199], 
followed by a genetic test to confirm the presence of this condition. Miglustat is currently 
the only approved treatment for NPC disorders, which inhibits the enzyme glucosylceramide 
synthase, and hence prevents sphingolipid production and slows down lysosomal lipid build-
up and hence in turn, neurodegeneration, amongst other symptoms [200]. Such lipid 
Page 111 of 216 
 
 
deposition is not limited to sphingolipids, since cholesterol trafficking is also perturbed in 
NPC disease, a process leading to substantially higher cholesterol levels. 
There is an urgent requirement to seek improved diagnostic and treatment monitoring 
strategies for NPC and other lysosomal storage disorders. Indeed, NMR-based 
metabolomics has recently been used in the study of NPC in order to search for new 
biomarkers [13]. Moreover, the urinary excretion of treatments such as miglustat have been 
monitored using such an NMR approach [201]. Metabolomics is the study of low-molecular-
mass biomolecules under different environments e.g. healthy control versus diseased humans. 
Unlike genetics, the metabolome is able to provide a ‘snapshot’ of the status of the organism 
at a particular point in time. Therefore, metabolomics is also extremely valuable for the 
discovering of biomarkers for the monitoring of disease progression and treatments 
effectivity. Metabolomics methodologies can either be targeted or untargeted; targeted 
approaches observe specific pre-defined metabolites which are usually known to be related 
to disease pathology or aetiology, whilst untargeted approaches view all possible global 
metabolites, including unknown ones. NMR analysis is an untargeted technique, which offers 
many advantages since it is able to detect and quantify a very wide range of metabolites 
simultaneously, in order to recognise any unusual molecular ‘signatures’. It is also a high-
throughput and non-destructive bioanalytical strategy.         
HPβCD has been proposed as a treatment for NPC1 disease in animals [202]–[204], with the 
first human clinical trials on this novel therapeutic agent are now in progress [205]. HPβCD 
is a cyclic oligosaccharide which has a hydrophilic exterior and a hydrophobic interior; these 
properties allow this molecule to internally encapsulate lipids such as cholesterol. Dependent 
upon its concentration in vivo, HPβCD is also able to remove (transport cholesterol away) 
from the body, although the mechanism of this process is not completely understood [206]. 
Indeed, animal studies are now making it possible to further understand the mechanisms of 
HPβCD as a therapeutic agent in NPC [207] in addition to Alzheimer’s disease [208], and 
this drug has shown much promise in current trials. However, to date the effect of HPβCD 
on the human or mammalian metabolomes is unknown. Thus, in this pilot investigation, 1H 
NMR-based metabolomics was employed in order to identify new, potentially valuable 
biomarkers for NPC disease in felines, particularly those which correlate with disease severity 
and progression. Furthermore, this investigation aimed to observe the potential use of 
HPβCD as a therapeutic treatment regimen in these felines using three different dosing 
methods. In view of the longitudinal status, urine samples collected were standardised, and 
repeated urinary collections were made throughout increasing time-periods. In this manner, 
Page 112 of 216 
 
 
the capability of these techniques to prognostically stratify these experimental animals was 
explored. Indeed, these software-based approaches served to provide valuable information 
regarding biomolecular connectivities, and hence the biological/metabolic pathways 
involved in the pathogenesis of NPC diseases.  
 
4.2 Methods 
 
4.2.1 Approval for Research   
 
Cats were raised in the animal colony of the School of Veterinary Medicine, University of 
Pennsylvania, under NIH and USDA guidelines for the care and use of animals in research. 
The experimental protocol was approved by the University of Pennsylvania Institutional 
Animal Care and Use Committee. 
 
4.2.2 Animals and Drug Formulations 
 
Domestic shorthair felines were housed and retained under the same conditions reported 
elsewhere [204], and were of the same line of breed [204]. The felines were raised at the 
School of Veterinary Medicine, University of Pennsylvania, under National Institutes of 
Health (NIH) and United States Department of Agriculture (USDA) guidelines for the care 
and use of animals in research, within an animal colony. The University of Pennsylvania 
Institutional Animal Care and Use Committee approved this experimental protocol (NIH 
OD P40-10939). Guidelines for the care of use in animal research were adhered to, and 
which are established under the NIH and US Department of Agriculture. All animals were 
maintained at 21°C with ad libitum food and water. 12-hour light cycles were used with air 
changes 12-15 times per hour. Both classes of HPβCD for IT and SQ administrations were 
formulated as described in [207], and doses administered are listed below. The dose of 120 
mg HPβCD IT and 1,000 mg/kg SQ was determined from the body weight and brain weight 
of the animals, respectively, as in [204]. Felines were administered with IT injections every 2 
weeks, and SQ injections every week, and animals were weighed at 2-week intervals.  
 
4.2.3 Sample Collection 
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A total of 33 felines were involved in this study, with urine collection occurring at different 
ages. Animals were fasted for 8 hr. prior to sample collection, and then urine was collected 
when felines were under propofol anaesthesia for cyclodextrin administration. The feline 
urine was taken at different increasing intervals, and grouped into 8, 10, 16, 20, 24, 52 and 
72 week time-points. For multivariate (MV) analysis, the 50 and 72 week samples were 
combined in view of a lack of samples at these age ranges, and these were all labelled as 50 
weeks. Typically, felines with NPC disease die at a mean age of 21 weeks [207]. 
Two different types of HPβCD, Sigma for SQ injections, and Kleptose for IT injections, 
were used throughout these studies. Two sets of felines were treated pre-symptomatically 
(initiated at 3 weeks of age) using either 120 mg IT HPβCD alone, or a combination of 1,000 
mg/kg SQ and 120 mg IT HPβCD injection every 2 weeks. These two treatments are 
considered clinically the same. A final set of felines were treated post-symptomatically 
(initiated at 16 weeks of age), using 120 mg IT HPβCD injection every 2 weeks. 
Some felines were on complementary medication including antibiotics, which can affect the 
metabolome. Clavamox (CLX) was used as an antibiotic throughout this study (n = 10 
samples), which is a composite of the potassium salt of clavulanic acid (CLAV) and 
amoxicillin (AMOX).  Metronidazole (MET) and Azithromycin (AZI) were also used 
throughout these studies (n = 4 and n = 3 samples respectively). Full details regarding the 
metabolism and excretion of these drugs are detailed in Appendix 2. 
 
Sample Type Number of cats Male:Female  Samples 
Control Untreated 7 4:3 35 
NPC Untreated 5 1:4 22 
NPC Treated with Cyclodextrin/Kleptose IT 
120 mg early (initiated at 3 weeks of age) 
6 3:3 36 
NPC Treated with Cyclodextrin/Kleptose IT 
120 mg late (initiated at 16 weeks of age)  
7 5:2 36 
NPC Cyclodextrin treated with combination 
SQ (1,000 mg/kg) and IT 120 mg early 
6 4:2 23 
Table 4.0. Urine samples collected from feline groups and analysed. 
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4.2.4 Sample Transportation 
 
Feline urine samples were donated from the School of Veterinary Medicine, Department of 
Clinical Studies, Philadelphia and abided by the Importation of Animals Pathogen Order 
1980 and the Specified Animal Pathogens Order (2008), as per the Council Directive 
82/894/EEC (as amended) on the notification of animal diseases within the EU. These were 
transported to De Montfort University, Leicester on dry ice and immediately stored at -80°C 
on arrival, until ready for analysis; 152 urine samples were received which are summarised in 
Table 4.0. 
Plasma samples were also collected taken by the University of Philadelphia research group 
involved, and a clinical chemistry panel was performed on these samples at their School of 
Veterinary Medicine.  
 
4.2.5 Sample Preparation  
 
Urine samples were thawed at room temperature followed by centrifuging a 500 µl aliquot 
and removing 450 µl of the corresponding supernatant. Phosphate buffer (Acros Organics) 
at pH 7.00 (50 µl) was added to the supernatant, in addition to 0.05% (w/v) sodium azide 
(50 µl) (Sigma Aldrich) and 10% (v/v) D2O (55 µl) (Sigma Aldrich) containing (w/v) 0.05% 
3-(trimethylsilyl) propionic-2,2,3,3-d4 acid (TSP) (Sigma Aldrich) was then added to the 
solution. This was then thoroughly rotamixed and added to newly-purchased 5-mm diameter 
NMR tubes ready for analysis. 
 
4.2.6 Sample Analysis 
 
All spectra were acquired using a 400 MHz Bruker Avance I (AVI) NMR (Leicester School 
of Pharmacy, De Montfort University, Leicester, UK) spectrometer operating at a frequency 
of 399.93 MHz. The samples were analysed using the water suppression technique 
(noesygppr1d) in order to saturate the water signal (δ = 4.80 ppm) in the urinary samples, with 
irradiation at the water frequency during the recycle and mixing time delays. 32K data points 
were acquired using 128 scans and 2 dummy scans, 3 µs pulses, over a sweep width of 4,844 
Hz and a receiver gain of 128. The auto-sampler ensured that the samples were continuously 
delivered throughout the analysis period. Chemical shifts were referenced to TSP, and NMR 
Page 115 of 216 
 
 
spectra were assigned considering chemical shifts, coupling patterns, integral ratios and 
coupling constants of resonances therein.  
Some additional spectra were acquired using a 600 MHz Jeol-ECZ NMR (Leicester School 
of Pharmacy, De Montfort University, Leicester, UK) spectrometer operating at a frequency 
of 600.17 MHz. The samples were analysed using the water suppression technique 
(single_pulse_wet) in order to saturate the water signal (δ = 4.80 ppm) in the urine samples, 
with irradiation at the water frequency during the recycle and mixing time delays. 16K data 
points were acquired using 64 scans and 4 dummy scans, 6 µs pulses, over a sweep width of 
15 ppm and a receiver gain of 36. The auto-sampler ensured that the samples were 
continuously delivered throughout the analysis period.  
Experiments were performed in order to provide confirmatory identification of molecules 
within the biofluid samples which include the application of 2D-TOCSY and 2D-COSY 
techniques. These were acquired using the 600 MHz Jeol facility using a presat COSY and 
TOCSY pulse sequences. The COSY spectra were acquired using 4 pre-scans; 1280 x points 
and 256 y points; sweep width of 11.28 kHz; an offset of 4.69 ppm; and total number of 
scans of 2,048. The receiver gain was optimised to 66 and the relaxation delay was 1.5 
seconds. The 2D TOCSY was acquired using 4 pre-scans; 1024 x points and 256 y points; 
sweep width of 11.28 kHz; an offset of 4.69 ppm and a total number of scans 2048. The 
receiver gain was optimised to 62 and the relaxation delay was 1.5 seconds. Temperature 
remained constant throughout the duration of the experiments and the samples were not 
spinning.  
 
4.3 Metabolite Assignments 
 
Metabolites were assigned using the literature available [209], [210], the human metabolome 
database (HMDB) [65] and Chenomx using the above features of spectra described above. 
However, at present there is no database for feline metabolites for metabolomics 
investigations. 
 
4.4 NMR Data Preprocessing for Statistical Analysis 
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All samples were referenced, aligned, baseline- and phase-corrected. Once this was complete, 
the samples were then manually bucketed using ACD Labs 12.0. The buckets were imported 
into excel to create spreadsheets containing 1H NMR data matrices. Any buckets attributed 
to baseline noise, drugs or water were removed. The total number of buckets for the study 
was 133.  
 
4.5 Data Normalisation, Scaling and Transformation  
 
Raw integrals were  constant sum normalised (CSN), Pareto-scaled and cube-root 
transformed prior to statistical analysis using MetaboAnalyst 4.0 [211]. CSN has been found 
to be recommended for urinary metabolomics datasets; other recommended normalisation 
strategies include probabilistic quotient normalisation [212].  
 
4.6 Results  
 
4.6.1 400 MHz 1H NMR Urinary Profiles Acquired Using noesygppr1d 
 
The 400 MHz single-pulse 1H NMR spectra of these biofluids contained many prominent, 
sharp signals assignable to wide range of low molecular-mass biomolecules (Figures 4.1 and 
4.2). Indeed, more than 80 metabolites were detectable in the spectra acquired on feline urine, 
and these included a range of biomolecules such as short-chain organic acid anions (e.g., 
acetate, formate, lactate, pyruvate and 3-D-hydroxybutrate); amino acids, including glycine, 
alanine, glutamate, glutamine, lysine, taurine, valine etc., together with N-acetylamino acids; 
carbohydrates, most especially NPC disease-relevant N-acetylsugars; and also nicotinate and 
nicotinamide pathway metabolites, amongst others. In addition to the amino acids above, 
the β-amino acid felinine was also assigned, which is exclusively found in feline urine; 
confirmation of the identity of resonances for this feline-specific metabolite is shown in the 
2D NMR profiles of feline urine (Appendix 10). 
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Figure 4.1. Average stack plots of the 1H NMR profiles of NPC and control felines in red 
and blue, respectively, from 0.00 - 9.50 ppm. U1-U9 represent unknown metabolites, with 
the broad U6-U9 resonances presumably representing those of protein aromatic amino acids. 
Abbreviations: 1-MH, 1-methylhisitidine; 1-MN, 1-methylnicotinamide; 3-HB, 3-
hydroxybutyrate; DMA, dimethylamine; DMG, dimethylglycine; I-3-L, indole-3-lactate; IS, 
Indoxyl sulphate; LAC, L-acetylcarnitine; NAC, N-acetyl groups; PAG, phenylacetylglycine; 
p-creatine, phosphocreatine; TMA and TMAO, trimethylamine- and trimethylamine-N-
oxide-N(CH3)3 respectively. 
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Figure 4.2. Average 1H NMR profiles of NPC felines versus those treated with 1,000 mg 
HPβCD. Metabolite differences are assigned only. Abbreviations: 3-HB, 3-D-
hydroxybutyrate; DMG, dimethylglycine; IS, indoxyl sulphate; I-3-L, indole-3-lactate; NAC, 
N-acetyl groups; PAG, phenyl-acetyl-glycine. 
Comparison of different age and sex groups between control and NPC felines 
For the first time, the age and gender of felines have been considered as part of a 
metabolomics investigation.  
 
Figure 4.3. 8 significant bucket regions found by ANOVA involving comparisons of gender 
and disease status. Shown are mean±SEM plots for hippurate, taurine/betaine and 
felinine/lactate, which were found to be statistically significant (p < 0.05) This includes all 
datasets from 8–24 weeks for both control and NPC feline urine samples. Bottom right inset: 
Time series two factor analysis PCA scores plot of control vs. untreated NPC Felines at 8, 
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10, 16. 20 and 24 weeks. PC1, PC2 and PC3 represent 22.6, 13.8 and 12.6% of the total data 
variation respectively.  
A univariate analysis of variance (ANOVA) approach was initiated on investigation of the 
feline urine in the control and NPC groups. Both Fishers and Tukey’s test using parametric 
ANOVA showed 8 metabolites to be significant (Figure 4.3). The Kruskal Wallis test was 
also employed, and false discovery rate (FDR)-corrected statistic values were considered 
using a p-value of 0.05. These showed no significant metabolite variables. Upon employment 
of parametric ANOVA, no bucket regions were revealed to be significant. However, on 
separation of disease status and the age 8 weeks bucket regions, significant differences were 
found, and these may be related to growth and hormonal changes. These included buckets 
pertaining to hippurate, felinine and betaine/taurine (Figure 4.3). That containing combined 
taurine, betaine and TMAO signals are clearly elevated in the NPC group over those of the 
controls. However, the taurine δ = 3.43 ppm triplet resonance did not appear as significant 
in this test. This therefore suggests that it may not be taurine that is giving rise to this 
significant difference, but the other two metabolites (betaine and TMAO). Betaine has 
another resonance located at δ = 3.89 ppm, but this is in a relatively crowded region of the 
spectra and of a much lower intensity, and therefore may not appear as being statistically 
significant. TMAO only has one resonance (δ = 3.25 ppm), which is incorporated within this 
bucket region. 2D COSY analysis revealed no other correlations other than that with taurine 
between the signals in this bucket region.  
All of the buckets incorporating hippurate resonances (δ = 3.95, 7.54, 7.62 and 7.82 ppm) 
appeared as significant buckets, and the same pattern was exhibited throughout, i.e. hippurate 
was elevated in controls and female NPC felines, and depleted in male NPC ones. Felinine 
was observed to be elevated in controls versus NPC disease across all bucket regions, with the 
exception of that with the neighbouring hippurate signal, i.e. NPC females were observed to 
have higher felinine levels. This can be attributable to the overlapping hippurate signal in this 
bucket region. The signal attributable to felinine at δ = 1.33 ppm shares the same bucket 
region as that of the lactate-CH3 signal. However, the felinine triplet was divided across two 
buckets in order to overcome this problem, and facilitate the identification of felinine as the 
contributing factor for this significance, rather than that for lactate-CH3. Additionally, the 
other lactate signal located at δ = 4.13 ppm did not show significance using this test, and this 
provided evidence that the felinine signal was the significant metabolite involved.  
Principal component analysis (PCA) was performed considering two variables, the age of the 
feline upon sample collection, and the felines disease status, either control or NPC disease 
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(Figure 4.3, bottom right inset). PCA enables the outliers in this investigation to be removed 
for further statistical analysis, of which it appears that the younger felines are separating from 
the older ones, since the former group appear to be scoring more negatively on PC3. This 
PCA plot shows differences within age groups and between control and untreated felines, an 
observation suggesting that distinctions within the dataset are not only attributable to disease 
status, but also to age. Therefore, further investigation regarding which metabolites were 
affected by age and disease status were performed. Data showing differences between age-
related metabolites is displayed in Appendix 9 in the form of heatmaps and overlaid average 
spectral profiles.   
Multivariate analysis showed no significant differences between the four groups investigated, 
i.e. male controls, female controls, male NPC disease and female NPC disease. Pre-
symptomatic felines were analysed at < 16 weeks of age. ANOVA showed no significant 
metabolites using the same testing criteria as above. This indicates that the severity of the 
disease is not also distinguishable by gender, and the changes observed in hippurate and 
felinine noted above are ascribable to disease status only.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. PCA scores plot of control felines (n = 35) vs. untreated NPC felines (n = 22) 
showing PC1 and PC2 representing 22.0 and 13.8% of the total dataset variance respectively 
from 8 - 24 age weeks, showing differences only between males and females. 95% confidence 
ellipses are shown for each group.  
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Figure 4.4 shows a comparison of males with females in both the NPC and control groups. 
There is only one outlier in this dataset, a male loading just outside the 95% confidence 
ellipse range. Two clusters are present, and this is attributable to disease status, since each 
individual point was checked to observe which scoring values were representing each sample. 
This demonstrates that the disease is not dependent on the sex of the feline, even though 
there is some variabilities between sexes.  
Partial least squares- discriminant analysis (PLS-DA) cross-validation of the model showed 
a poor model fit and poor measure of consistency on comparison of genders (data not 
shown). Two sub clusters were observed in the data which were composed of a combination 
of disease and controls however, the controls were more prominent in one cluster and the 
disease was more prominent in the other cluster. However, as the model was invalid further 
testing had to be performed in order to distinguish whether the variability was due to disease 
or sex. So, a further strategy was performed with gender-only clusterings (Appendix 9). 
Figure 4.5. (a) PLS-DA plot of control felines (red) (n = 35) and untreated NPC felines 
(green) (n = 22) showing PC1, PC2 and PC3 representing 12.7, 14.2 and 11.2% of the dataset 
variance respectively. Q2 = 0.49 when applying 10-fold cross validation methodology using a 
6 component model and p = 0.084 was determined using prediction accuracy during training 
as the permutation test, using 2000 permutations (b) PLS-DA plot of control felines (n = 
21) vs untreated NPC felines (n = 22) showing PC1, PC2 and PC3 representing 12.6, 13.2 
and 14.6% of the dataset variance respectively. Q2 = 0.62 using a 6 component model 
applying 10-fold cross validation methodology and p = 0.0125 was determined using 
prediction accuracy during training as the permutation test, using 2000 permutations. 
PLS-DA has shown that the urine profiles are insignificant comparing control felines 
compared to NPC (Figure 4.5, (a)). Due to the disease being a neurological disorder and 
progressing further over time, the older felines with NPC disorder, cluster closer to the 
younger controls. Therefore, a 1H NMR methodology when using an age-matched feline 
model, might not be the best approach for early onset disease diagnostics suggesting early 
biomarkers for NPC. However, if the younger control felines are removed from this model 
(b)
v 
(a)
v 
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(weeks 8-10) the data becomes significant and the model becomes accurate hence, this is a 
better model for observing which metabolites are causing the changes in the later 
manifestations of NPC (Figure 4.5, (b)). Felines typically become fertile around 16 weeks of 
age and therefore, the extra variability of fertile and unfertile felines and the hormonal 
changes associated with this difference is removed. There are two clear sub clusters in the 
dataset which were investigated. It was found that these sub clusters were not due to age or 
sex (Figure 4.5, (b)). Bucket regions that are causing a significant difference in the PLS-DA 
plot were assigned and it is also defined as upregulated or downregulated in disease profiles 
respectively (Table 4.1).  
Significan
t Bucket 
(δ/ppm) 
Upregulated / 
Downregulated 
in NPC Disease 
Assignment 
1.33-1.35 ↓ α-Hydroxyisobutyrate-CH₃ (d)/Felinine-CH₃ (d)/Lactate-
CH₃ (d) 
3.25-3.27 ↑ Taurine-CH2-NH3
+ (t)/Betaine-CH₃ (s) /TMAO-CH3 (s) 
3.41-3.47 ↑ Taurine-CH2-SO3- (t) 
3.03-3.07 ↓ Creatinine-CH3 (s)/Creatine-CH3 (s) 
1.31-1.32 ↓ α-Hydroxyisobutyrate-CH₃ (d)/Felinine-CH₃ (d)/Lactate-
CH₃ (d) 
3.64-3.70 ↑ PAG-CH2 (s) 
1.32-1.33 ↓ α-Hydroxyisobutyrate-CH₃/Felinine-CH₃/Lactate-CH₃ (d) 
1.85-1.87 ↓ Lysine-CH2 (m) /Felinine Derivative-CH2 (m) 
3.33-3.36 ↓ Felinine-CH2 (m) 
2.90-2.94 ↓ Dimethylglycine-CH3 (s) 
1.82-1.85 ↓ Felinine derivative-CH2  (m) 
3.32-3.33 ↓ Felinine-CH2 (m) 
1.35-1.37 ↓ Felinine-CH3 (d) 
1.24-1.27 ↓ L-Fucose-CH3 (d) 
2.75-2.77 ↓ Citrate-CH2 (d)/DMA-N(CH3)2 (s) 
Table 4.1. Top 15 significant metabolites assigned that are upregulated or downregulated 
in NPC felines from the PLS-DA strategy applied (Figure 4.5, (b)). Abbreviations: PAG, 
phenyl-acetyl-glycine. Multiplicities are indicated in brackets: multiplet, triplet, doublet and 
singlet are denoted by (m), (t), (d) and (s) respectively. 
Metabolites that appear as significant include taurine, TMAO, betaine, felinine which has 
been previously linked to being significant in Figure 4.3. Hippurate was not highlighted as 
one of the top 15 significant metabolites unlike the previous test in Figure 4.3. Other 
metabolites that were shown to be significant include buckets that are attributable to 
creatinine/creatine, fucose, citrate and dimethylglycine. This is a representation of the 
importance of multivariate testing and univariate testing to distinguish different metabolites 
as significant, as some metabolites can be masked due to the quantity of bucket regions. 
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ANOVA (Figure 4.6) and fishers LSD/Tukeys test was repeated with the 16-20+ week 
datasets and both tests provided the same significant bucket regions. Some metabolites 
appeared significant that previously had not during MV analysis, this included bucket 
regions attributable to pyruvate and DMA/glutamine. Felinine and taurine bucket regions 
appeared as significant but hippurate was not a significant metabolite in this testing.  
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Figure 4.6. ANOVA analysis of control versus NPC felines grouped by gender, showing 
data from 16 – 24 weeks only. Above are 7 of the metabolites which showed statistical 
significance. Mean±SEM plots show those for pyruvate, taurine/betaine/TMAO, 
DMA/glutamine and felinine. 
Felinine 
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Further statistical analysis was performed in order to distinguish between the separation 
observed between the two cohorts. The sub-clustering of the controls and untreated NPC 
felines were explored and hence felines were grouped into female and male groups in order 
to investigate this further (Figure 4.7). However, from PCA and PLS-DA approaches it can 
be observed that this is indeed not the cause of the separation; therefore, it appears that this 
division arises between the datasets arises from another source. However, these models may 
be overfitted in view of the small number of samples in each group and the permutation 
testing value was not significant, and PLS-DA usually requires larger sample sizes per group. 
Figure 4.7. (a) PCA scores plot of control females, control males, untreated females and 
untreated males in red, green, blue and light blue respectively. PC1 and PC2 represent 25.4 
and 15.5% of the total dataset variance respectively. 95% confidence ellipses are mapped, 
and there are no evident outliers in this dataset. (b) PLS-DA plot of control females, control 
males, untreated females and untreated males in red, green, blue and light blue respectively. 
PC1, PC2 and PC3 represent 18.9, 17.6 and 15.5% of the total dataset variance respectively. 
 
4.7 Metabolic Differences between NPC felines and felines treated with 
HPβCD 
 
Three treatment regimens were trialled. In the first group, NPC disease felines were treated 
with Cyclodextrin/Kleptose IT (120 mg) early, i.e. initiated at 3 weeks of age (n = 36), whilst 
the second received the same treatment regimen but initiated at 16 weeks of age (n = 36). 
The third group of felines was treated with a combination SQ (1,000 mg/kg) and IT (120 
mg) early (n = 23).  
Student’s t-tests of all the bucket regions showed no significant differences between 
metabolite levels on comparison of Cyclodextrin/Kleptose IT 120 mg early group versus the 
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untreated NPC feline one. PCA showed no separation between these groups. PLS-DA model 
of NPC felines treated with Cyclodextrin/Kleptose IT 120 mg early-initiated at 3 weeks of 
age versus untreated NPC felines was accurate with the highest Q2 = 0.53 on a model 
containing 8 components, but showed no significance (p > 0.05) determined from 
permutation testing, which invalidated the model. Machine learning methods were initiated, 
but were also unable to distinguish between these two groups.   
Student’s t-tests showed no significant metabolites on comparison of Cyclodextrin/Kleptose 
IT 120 mg late group versus the untreated NPC feline one. PCA showed no separation 
between these groups. A PLS-DA model of NPC felines treated with Cyclodextrin/Kleptose 
IT 120 mg late versus untreated NPC ones showed no clustering, with the highest Q2 value of 
only 0.24 achieved on a 6 component model; similarly, no significance was found on 
permutation testing (p > 0.05). Machine learning methods were again unable to distinguish 
between these two groups.   
However, the third group was treated with a combination SQ (1,000 mg/kg) and IT 120 mg 
early showed separation between from untreated NPC felines using PCA, and also 
significance and accuracy in PLS-DA assessments (Figure 4.8). Three outliers were noted in 
the PCA approach. 
 
 
 
 
 
 
 
 
Figure 4.8. PLS-DA scores plot of untreated NPC felines (n = 22) vs. cyclodextrin-treated 
felines (a combination of SQ (1,000 mg/kg) and IT 120 mg early was administered) (n = 23), 
showing that PC1, PC2 and PC3 representing 17.1, 7.9 and 6.8% of the total dataset variation 
respectively. Q2 = 0.53 when applying 10-fold cross validation methodology on a 4 
component model, and p = 0.028 determined using prediction accuracy during training as 
the permutation testing regimen, which used 2,000 permutations. 
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Significant 
Bucket 
(δ/ppm) 
Upregulated / 
Downregulated in 
treated NPC 
felines 
Assignment 
1.33-1.37 ↑ α-Hydroxyisobutyrate-CH₃ (d)/Felinine-CH₃ (d) 
1.30-1.33 ↑ α-Hydroxyisobutyrate-CH₃ (d)/Felinine-CH₃ 
(d)/Lactate -CH₃ (d) 
3.03-3.07 ↑ Creatine-CH2 (s)/Creatinine-CH2 (s) 
1.82-1.88 ↑ Felinine Derivative-CH2 (m) 
3.41-3.46 ↓ Taurine-CH2-SO3- (t) 
0.86-0.87 ↑ Unassigned-CH3 (broad) 
3.25-3.27 ↓ Taurine-CH2-NH3
+ (t) /Trimethylamine-N-oxide-
CH3 (s)  
3.31-3.35 ↑ Unassigned (broad) 
7.67-7.71 ↓ Hippurate-CH (t) 
4.13-4.18 ↓ Lactate-CH (q) 
2.40-2.41 ↓ Glutamine-CH2 (m) 
4.05-4.10 ↑ Creatinine-CH2 (s) 
3.64-3.70 ↓ PAG-CH2 (m) 
3.27-3.31 ↓ Taurine-CH2-NH3
+(t) /Trimethylamine-N-oxide-
CH3 (s) /Betaine-CH3 (s) 
8.47-8.49 ↓ Tentative Protein Aromatic Amino Acids-CH 
(broad)  
Table 4.2. Top 15 significant bucket regions with metabolites assigned that were 
upregulated (↑) or downregulated (↓) in treated NPC felines using the VIP scoring system. 
Abbreviations: PAG, phenyl-acetyl-glycine. Multiplicities are indicated in brackets:  
multiplet, triplet, doublet and singlet and denoted by (m), (t), (d) and (s) respectively. 
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Figure 4.9. (a) Student’s t-tests using equivalent group variances with an adjusted p value 
cut off value of 0.005. Bucket regions are labelled with corresponding assignments and 
include hippurate, felinine, lactate, phenylacetylglycine, creatine/creatinine and a felinine 
derivative. (b) Volcano Plot showing significance (y-axis) versus fold-change (x-axis) in which 
the fold threshold is 2, and the equivalent group variance p value threshold is 0.1. Bucket 
regions in red are significant, and those in blue are insignificant. Bucket regions values were 
Unassigned-CH₃ 0.86 – 0.87 ppm 
Tentative Protein Aromatic  Amino 
Acids-CH (broad) Unassigned -CH₃ 0.86-0.87 ppm 
Page 130 of 216 
 
 
then displayed as box and whisker plots, in which red and green show the 1,000 mg/kg SQ 
and 120 mg IT HPβCD and untreated NPC groups, respectively.  
 
 
Figure 4.10. Mean±SD TSP-normalised integral values of felinine and hippurate bucket 
regions with corresponding feline age and treatment type. For the control group, males and 
females have been divided in order to evaluate between-gender differences. Data was not 
collected for treated 1,000 mg/kg SQ and 120 mg IT HPβCD felines at 10 weeks of age.  
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4.8 Discussion 
 
Felines have been previously shown to be ideal models for observing pathological changes 
in NPC disease for selected studies, such as those involving cholesterol-restricted diets [213] 
and treatment outcomes [204]. However, the feline urine is yet to be investigated in depth, 
inclusive of how feline metabolism changes with age and gender. Moreover, how these 
changes are affected by a disease, such as NPC, and how treatment impacts on urinary 
metabolism has yet to be explored in detail. This study, for the first time, has observed such 
urinary metabolic changes over time, along with those arising from the application of 
treatment regimens. This work could underpin new areas of metabolomics investigations 
into feline urine and support experimental design considerations. Some urinary profiles 
showed metabolites which were unassigned in this study, and were excluded (Appendix 7).  
Felinine and Felinine Derivatives 
Present research suggests that felinine is a testosterone-dependent urinary metabolite, and 
that this feline-specific β-amino acid may be involved in territorial marking [214], [215]. 
Injections of testosterone increased felinine levels, and that of its derivatives, in feline urinary 
profiles in male and female cats [215]. Interestingly, felinine is involved in two pathways and 
can be synthesised in the liver or kidney [216]. Both pathways involve the precursor 
dimethylallyl-PP (isopentyl-PP), which is involved in the biosynthesis of cholesterol and 
steroids [216]. Felinine in the 1D NMR spectra was determined using a 2D TOCSY analysis 
strategy (Appendix 10). Results from the 1H NMR urinary profiles acquired here 
demonstrated that felinine concentrations are higher in controls and treated 1,000 mg/kg SQ 
and 120 mg IT HPβCD felines than those of the untreated NPC group. Additionally, results 
observed in plasma show cholesterol is elevated in untreated NPC felines, and depleted in 
1,000 mg/kg SQ and 120 mg IT HPβCD-treated and control felines (Appendix 12). NPC 
felinine is depleted, and this observation suggests a possible promotion of the steroid and 
cholesterol synthesis pathways. This can be readily confirmed from the average spectral 
profiles (Figures 4.1 and 4.2), mean±SEM levels (Figure 4.10), and by univariate (Figures 4.3, 
4.6 and 4.9) and multivariate statistical analysis strategies (Figures 4.3-4.5, 4.7 and 4.8).   
In NPC murine models, overall testosterone secretions are decreased, and low serum 
testosterone levels were observed in NPC disease when compared to those of healthy 
controls [217]. Low testosterone alone cannot serve as a marker for NPC disease, since it is 
found in other phenotypes such as stress, anxiety, ageing and infertility. Nevertheless, this 
supports findings the findings made here, i.e. felinine has been shown to decrease in urinary 
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profiles in untreated NPC versus control felines. Felinine increases again upon treatment with 
1,000 mg SQ and 120 mg IT HPβCD, and this possibly suggests a positive therapeutic 
outcome. However, these changes were not observed in the 120 mg-dosed felines treated 
both pre and post-symptomatically. The same pattern is observed with the felinine derivative. 
This felinine derivative has been assigned previously [218] and signals can be observed at δ 
= 1.20 and 1.80 ppm.  
Age has also been shown to impact on the rate of felinine production in felines, and this was 
observed from mean±SEM level plots (Figure 4.10), and also in the 1H NMR spectra 
acquired (Appendix 9). The SEM error bars are relatively small, with very little overlap 
between the groups. Gender-related changes have also been observed for urinary felinine; 
specifically, males have higher levels than females (Figure 4.10). Indeed, felinine has been 
shown to be elevated in entire male cats versus entire female and castrated cats, both herein 
and elsewhere [214], [215]. Age-related modifications in felines have also been previously 
documented in the literature [219]. However, for the first time it has been observed that NPC 
felines have significantly lower levels of this metabolite, despite gender differences. The age-
related differences in felinine are only observed in the NPC disease group post-
symptomatically, i.e. past 16 weeks (Figure 4.10). Upon treatment of this condition with 
1,000 mg SQ and 120 mg IT HPβCD, levels appear to return to those similar to the control 
group. 
Taurine, Betaine and TMAO 
In a previous human urinary study, TMAO and taurine were observed to increase in male 
participants, and decrease in females [220]. Furthermore, these metabolites were observed to 
increase in older participants compared to younger subjects in this human study [220]. 
Additionally, urinary taurine in rats was also found to increase with age [221]. Urinary taurine 
and TMAO have also been correlated with dietary changes, specifically the Atkins diet, which 
consists of high fat, high protein and low carbohydrates, and which is observed more 
frequently in the Swedish population than it is in the British [222]. TMAO has been observed 
to be highly variable in human subjects [222]. Nevertheless, there are notable correlations of 
upregulated TMAO with increased endothelial dysfunction, adhesion of monocytes through 
activation of PKC NF-kB VACM-1 pathways, pro-inflammatory cytokines via MAPK and 
NFkB, tumour necrosis factor, interleukin IL-1β, increased cardiovascular disease and 
reduced endothelial self-reparation [223]. TMAO has also been observed to reduce the 
expression of intestinal cholesterol transporter Niemann-Pick C1-like1 (which is 
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downregulated by high cholesterol diets), and urinary TMAO has also been demonstrated to 
be elevated in neurological disorders [223].  
All felines were on the same diet and were of the same breed, therefore such changes 
observed here are not attributable to population or diet. Interestingly, taurine was noted to 
be markedly increased in the NPC felines over that of the controls, and was observed in the 
top 25 metabolites in the heatmap (Figures 4.8 and 4.9). This is of much importance, since 
this study is not age- and gender-matched, which is a vital consideration in the experimental 
design of metabolomics investigations. The felines were treated survive longer, and therefore 
it is to be expected that they have higher levels of TMAO and taurine. However, markedly 
higher levels of TMAO were observed in NPC felines; however, the TMAO resonance 
bucket region is unfortunately shared with signals arising from betaine and taurine. Elevated 
urinary TMAO in NPC disease, and reduced levels in controls and treated felines suggests 
that this variation could arise from altered cholesterol and sterol metabolism in NPC felines. 
This has also be documented elsewhere that TMAO has such an effect on cholesterol and 
sterol metabolism [224]–[226]. Disturbances in methylamine metabolism have also been 
discussed in previous works [13], and elevations in methylamines have been observed in 
NPC disease urine [13]. The findings would support this previous hypothesis, and also 
suggest a disturbance in gut microflora in NPC disease [13].  
Urinary taurine has been suggested previously as a non-invasive biomarker of liver damage 
[227], and in NPC, liver damage is a symptom, in the form of splenohepatomegaly. A positive 
correlation between urinary taurine and serum AST has been previously observed [227], and 
this is consistent with the findings made here. Taurine was observed to be elevated in NPC 
felines versus controls in both univariate and multivariate testing strategies (Figure 4.7 and 
Table 4.1). Also, taurine was observed to deplete in SQ 1,000 mg/IT 120 mg-treated felines 
versus untreated NPC ones (Table 4.2).  
Dimethylglycine 
Dimethylglycine has appeared as a significant biomarker metabolite in NPC felines when 
compared to the control group using multivariate statistical analysis (Table 4.1). However, 
using multivariate analysis, a reduction in dimethylglycine was not observed on treatment 
(Table 4.2). This could possibly be attributable to the slightly different age ranges in felines, 
since urinary dimethylglycine has been observed to elevate with age (Appendix 9). The 
control felines have survived for a slightly longer period than the NPC disease felines, and 
this possibly indicates the significance of this metabolite. However, an elevation in 
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dimethylglycine rather than a depletion would be expected in view of disease-mediated 
disturbances in gut microbiota, since dimethylglycine is a product of choline degradation and 
has been shown to be modulated in diseases related to cardiovascular disease, obesity and 
diabetes [228].  
Creatinine/Creatine 
Creatinine is a breakdown product of creatine. Creatinine has been demonstrated to be 
elevated in human males over those of females [220]. Furthermore, creatinine was observed 
to be elevated in older human participants over that younger human subjects [220], and a 
similar trend was also observed in rats [221]. However, the inverse is correct for creatine in 
human participants [220].  The combined creatinine/creatine >N-CH3 resonance (δ = 3.03-
3.07 ppm) is depleted in 8-week control group when expressed relative to control 24-week 
one (Appendix 9). Interestingly, this signal does arise in the top 15 significant metabolites in 
NPC disease felines, suggesting an abnormal aging process, since it is depleted significantly 
in the controls (Table 4.1). Upon treatment with HPβCD, however, this creatinine/creatine 
signal intensity elevates (Table 4.2), and this was also shown to be significant in a univariate 
t-test (Figure 4.10). However, this could also be ascribable to the skewed male:female ratio 
of the NPC cohort (Table 4.0).  
These results are particularly interesting, since in the plasma a lower creatine level of felines 
with SQ 1,000 mg/IT 120 mg treated and control groups was observed, together with an 
elevation in NPC and the other two pre- and post-symptomatic 120 mg treatments 
(Appendix 12). These results are the converse of those observed here for the 1H NMR 
urinary profiles. Previous investigations have observed no changes in plasma creatinine in a 
mouse model monitoring NPC disease and the impact of HPβCD treatment on it [229], but 
this is not what was observed here in feline models. It could be hypothesised that creatine is 
lowered in the SQ 1,000 mg/IT 120 mg HPβCD-treated felines versus the untreated NPC 
ones in view of age-related differences between these groups. This is a most likely 
explanation, since urinary creatine has be previously been observed to be elevated in a human 
model [13].  
Hippurate 
In a previous study, urinary hippurate was noted to be downregulated in female urine with 
respect to that of males [220]. Furthermore, younger participants have lower hippurate than 
older participants in humans [220] and rats [221]. Hippurate does not appear as a significant 
metabolite on comparison of ageing control felines in the heatmaps with the top 25 most 
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significant metabolites shown (Appendix 9); however, NPC felines exhibited an elevation in 
hippurate upon aging rather than a decline (Appendix 9). Figure 4.10 demonstrates that 
hippurate is highly variable amongst all felines at a range of ages, including those with NPC 
disease. It is not until 24 weeks of age that hippurate was significantly decreased in NPC 
felines over those of all other groups (Figure 4.10). Urinary hippurate has been observed to 
be decreased in Crohn’s disease, and has also been linked to alterations in gut microbiota 
[230]; this supports the findings made in this study.  
PAG 
PAG has been previously suggested as a putative biomarker of phospholipidosis [231], [232], 
another lysosomal storage disorder. In these particular studies, PAG was elevated in urinary 
profiles. From the results acquired here, PAG has been observed to be elevated in NPC 
disease over those of controls, and those treated with 1,000 mg SQ/120 mg IT HPβCD. 
PAG was also observed to deplete over time (8 versus 20 weeks) in control felines, whereas 
the converse was the case for NPC disease felines (Appendix 9). This metabolite is evidently 
age-related, but the pattern differed from those of the disease and control groups. This would 
suggest that PAG may serve as a valuable marker for the detection and treatment outcomes 
of NPC disease in felines. Similarly to the study performed on phospholipidosis [231], [232], 
citrate, a TCA intermediate, was also found to be depleted in NPC urine compared to control 
urine. In this previous investigation, it was proposed that mitochondrial citrate production 
for energy was found to be imbalanced [232]. PAG is part of phenylalanine metabolism, and 
disruption of this pathway has also been previously linked to mitochondrial disruption.  
PAG has been shown to be depleted in pigs undergoing treatment from liver injury [233]. 
Although there is liver injury in NPC disease in the form of hepatosplenomegaly, these 
results do not correlate with the findings made in this investigation, since PAG is elevated in 
NPC disease and not downregulated. Hence, it is more likely that the decrease observed in 
PAG is attributable to mitochondrial toxicity in NPC felines, and such a disturbance may 
arise from this rather than liver injury.  
Citrate 
As noted above, citrate was observed to decrease in NPC and control felines on comparison 
of the 8-to 20-week datasets (Appendix 9). These age-related changes might help understand 
why NPC urinary citrate levels are downregulated. The citrate 1H NMR bucket region (δ = 
2.75-2.77 ppm) is, however, partially shared with another metabolite (DMA).  
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In a human model, citrate was decreased in males relative to females [220]. Furthermore, 
citrate was also observed to be elevated in older human subjects over those of younger ones 
[220]. However, upon monitoring citrate in rats from 4 – 20 weeks, citrate was seen to slowly 
decrease from 4 – 10 weeks and then stabilise at a 20 week duration [221]. Data collected in 
this study to be consistent with these reports.  
Lactate 
The bucket region attributable to lactate’s -CH3 function signal (δ = 1.33 – 1. 37 ppm) was 
observed to decrease in the urinary profile’s comparison of untreated NPC versus controls. 
However, this bucket region is also shared with felinine’s-CH3 resonance. Lactate has another 
(-CH function) bucket region at 4.13 – 4.18 ppm, which was insignificant in this initial test. 
Lactate is elevated in female human urine over that of males [220]. Despite this, both buckets 
pertaining to lactate are depleted in NPC, despite the elevation of female felines monitored 
as part of this investigation. However, without further testing, it is difficult to distinguish 
whether lactate in urine is depleted in these samples in view of its overlap with another signal; 
this can be observed in the acquired 2D COSY spectroscopy (Appendix 4). The 2D spectral 
correlation of lactate resonances in the 1D NMR spectrum was confirmed using a 2D COSY 
approach (Appendix 10). This 2D profile shows several other correlations within this bucket 
region. Further work on the urinary profiles to complete the 2D spectral quantification of 
lactate could be performed in order to confirm the significance of this particular metabolite. 
Lactate has been previously observed to be upregulated in the presence of selected diseases, 
and as such this observation is unusual. Lactate is hypothesised to not be the cause of this 
bucket region to be significant, when comparing the difference between NPC and control 
groups, since it is generally elevated in disease states in other investigations [234], which is 
the converse of what was observed here. 
However, on comparison of untreated NPC disease felines with those treated with SQ 1,000 
mg/IT 120 mg HPβCD, the lactate bucket region 4.13 – 4.18 ppm is downregulated in the 
latter group. This is more consistent with what has previously observed in the literature, and 
elevated lactate levels may have some potential to be used as a biomarker in NPC disease.  
Outcomes in Serum, Liver and Brain Biochemistry 
Prior to investigating the urinary profiles in this study, it is important to consider the previous 
findings of investigations focused on serum, liver and brain biochemistry in studies using 
similar samples. Untreated NPC felines have previously showed an elevated hepatic alanine 
amino-transferase (ALT) and cholesterol, as well as decreased albumin in serum compared 
Page 137 of 216 
 
 
to those of control felines [207]. Body weight has also been noted to be lowered in untreated 
NPC felines versus controls [207]. Liver biochemistry showed elevated unesterified 
cholesterol, sphingomyelin, bis(monoacylglycero)phosphate (BMP), glucosylceramide, 
lactosylceramide, globotriaosylceramide, free sphingosine and GM3 ganglioside in NPC 
felines over those of controls [207]. Biochemical brain changes have been previously 
observed in NPC felines against a control groups [207]. GM2 elevated substantially at 4 
weeks of age from 9.5% of the total ganglioside content to 14% at 11 weeks [207]. However, 
elevations in GM3 were noted later in felines, and at a 4 week age point were substantially 
lower at 5.3% [207].  
Interestingly, NPC felines treated pre-symptomatically were neurologically normal until the 
age of 76 weeks, at which point they were exhibiting mild ataxia [207]. As a result, the 
observations made here may provide early markers of this disease in felines. In the brains of 
these felines, unesterified cholesterol and GM2 gangliosides markedly reduced in 
concentration [207]. However, there was no improvement in serum albumin, and ALT and 
cholesterol concentrations were only slightly decreased when compared to untreated NPC 
cats [207]. Moreover, lipid biochemistry and liver histology were similar to the untreated 
felines [207]. This corroborates with the findings found in the feline urinary profiles in this 
study, in which no significant differences in the downstream products in feline metabolism 
were observed when comparing the profiles of early treated NPC felines to the untreated 
NPC ones.  
However, felines treated with 1,000 mg SQ/120 mg IT were shown to be normal at 24 weeks, 
and only mild ataxia at 76 weeks of age [207]. This is consistent with the findings observed 
here in the urinary profiles. Unlike the felines administered with 120 mg beginning at 3 weeks, 
the levels of ALT and albumin in blood serum were consistent with normal felines [207]. 
Furthermore, serum cholesterol had significantly reduced when compared to untreated 
felines [207]. The liver showed significant improvements, such as decreased cholesterol, 
sphingomyelin, GM3 ganglioside, neutral glycolipids, and free sphingosine concentrations 
[207]. As significant differences are being observed in the plasma of these animals, this 
ultimately will also exert an impact on the feline urinary profiles. This further corroborates 
why significant differences are being observed in the feline urinary profiles that have been 
treated with combined 1,000 mg SQ /120 mg IT treatment, rather than 120 mg IT alone 
pre- or post-symptomatically.  
Drug Detection in 1H NMR 
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Despite some of the felines taking antibiotics, the parent drug and corresponding metabolites 
were not administered in doses which are detectable by 1H NMR analysis (Appendix 8). 
Furthermore, HPβCD was not NMR-observable in the urine (Appendix 8), and this 
observation is consistent with other studies that demonstrate HPβCD is rapidly cleared [202], 
[235]. 
Implications of Experimental Design 
Implications of this study which provide some limitations of the results acquired are that the 
NPC cohort is predominantly female, and also the overall small sample size in this 
investigation. More samples would be required in order to validate the findings that the 1,000 
mg SQ / 120 mg IT treatment is the most effective one for NPC felines, and also perhaps a 
human NPC disease population. This study is limited by these two factors, and in order to 
validate these findings, a more balanced cohort of female to male ratio, and more samples 
could be used in order to substantiate the findings made here. The significant differences 
observed could be amplified in view of these age and sex factors.  
Alternative proposed biomarkers for NPC disease 
Bile acids (BAs), which have been previously recognised as significant biomarkers [13], were 
not identified in the urinary profiles (δ = 0.50-0.75 ppm). This is most likely attributable to 
the NMR sensitivity used; indeed, 400 MHz profiles were acquired in this case whereas in 
the study of Ruiz-Rodado et al. (2014), a 600 MHz NMR facility was employed [13]. These 
markers were found to be significant in view of their nature as downstream products of 
cholesterol. Hence, 600 MHz profiles of feline urine, in particular observing the felines with 
NPC to observe BAs. However, no characteristic BA resonances in the 1H NMR profiles of 
NPC feline urine were obtained when employing an operating frequency of 600 MHz. 
(Appendix 11). Therefore, further metabolomics analysis using the 600 MHz facility were 
not performed and it maybe that BAs are not observed due to the early stage of the disease, 
as humans with NPC live much longer respectively. Another way to observe BAs using NMR 
is to complete an extraction using tetra-deutero methanol [218]. This could be observed as a 
further work for potential early biomarker detection in felines; however, these bile acid  
biomarkers have been established in human trials [13].  
3-Aminoisobutyrate was not found to be a significant metabolite, which was suggested as a 
biomarker for human NPC patients using multivariate analysis [13]. However, it is 
challenging to compare the human studies with the studies of the felines, since the 13 
untreated patients with NPC1 and 47 heterozygote carriers used in the trial were aged 2.7-30 
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and 25-62 years respectively, and therefore presumably the course of the disease will have 
been more manifested in these patients. Furthermore, comparison of these studies is also 
challenging in view of differences in metabolic pathways in the respective species.  
 
4.9 Conclusions 
 
1H NMR metabolomics analysis of feline urine has been performed for the first time on 
treated and untreated NPC1 disease and corresponding control animals. Significant 
differences in profiles in older felines were observed when the disease has further progressed. 
However, in the felines that are younger, these differences were not statistically significant. 
This would suggest that 1H NMR analysis of feline urine for early biomarker detection is 
unsuitable in felines. Nevertheless, treatment outcomes can be assessed in feline urine, with 
significant differences observed in NPC comparatively to treated 120 mg HPβCD IT and 
1,000 mg/kg SQ felines. Metabolites that were observed to be significant indicate 
disturbances in the gut microbiota and sterol/cholesterol metabolism pathways which is in-
line with the NPC disease pathology.  
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Chapter 5: 1H NMR Metabolomic Profiling of GM1 
Gangliosidosis (Type II) Patients: Potential Diagnostic 
Applications from Urinary and Blood Plasma Screens 
 
5.0 Abstract 
 
Background: GM1 Type II is a rare, autosomal, neurodegenerative disorder that arises from 
a mutation in the GLB1 gene. GM1 Type II has a range of symptoms, including but not 
limited to neurological defects, hepatosplenomegaly and skeletal abnormalities. Although 
some metabolomic investigations have been previously performed, a full global screening of 
metabolites in urine, plasma and cerebrospinal fluid (CSF) from these patients, and its 
biomarker potential, is yet to be explored. 
Methodology: GM1 Type II plasma, urine and CSF samples were collected at the National 
Institute of Health, and corresponding healthy control plasma and urine were collected from 
De Montfort University. 1H nuclear magnetic resonance (NMR) profiles were acquired using 
a 700 MHz NMR facility employing noesypresat and cpmg pulse sequences for these biofluids. 
The 1H NMR profiles were assigned and then processed into excel data matrices. Univariate 
(UV) and multivariate (MV) statistical analysis strategies were employed on datasets acquired. 
The identification of GM1 gangliosides using liquid chromatography-mass spectrometry 
(LC-MS) was also evaluated in the biofluids collected.  
Results and Discussions: GM2 gangliosides was not detectable using the LC-MS strategy 
employed on all GM1 Type II biofluids. Significant statistical differences in plasma and 
urinary profiles using 1H NMR profiles both in MV and UV strategies. Statistically significant 
metabolites include urinary upregulated citrate, N-acetyls, creatinine, creatine and lactate 
amongst other metabolites. Additionally, in plasma downregulated low-density lipoprotein 
(LDL) cholesterol and upregulated creatinine and lactate amongst other metabolic 
disturbances was observed. However, interpretation of these results is treated with caution, 
due to the different ages and fasting status in the two respective cohorts. The impact of 
xenobiotics, such as drugs and supplements, that the GM1 Type II cohort were exposed to 
as part of this investigation is also considered. This study reveals the complexity of analysing 
lysosomal storage disorders using a human model using a global untargeted approach.  
Conclusions: In this pilot study, it is challenging to validate GM1 Type II biomarkers, with 
so few samples available and due to the critical status of the patients to ensure equivalent 
conditions. Indeed, in combination with these variables and no treatment to validate findings 
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this presents a challenge in metabolomic investigations. Future validation studies could be 
performed, or the use of an animal model to create perfect conditions, in order to confirm 
findings. The potential for TAGs and LDL amongst other metabolites as unspecific markers 
in GM1 Type II plasma and n-acetyl groups, lactate, creatinine amongst other metabolites to 
be unspecific markers in GM1 Type II urine. This is consistent with other lysosomal storage 
disorders and the literature. 
Keywords: Nuclear Magnetic Resonance; Metabolomics; Lysosomal Storage Diseases; 
Gangliosidosis GM1 Type II; Blood Plasma; Urine; Biomarkers  
 
5.1 Introduction 
 
GM1 Type II (#OMIM 230600) is the juvenile form of GM1 disease, with onset typically 
occurring between in the first few months to years of life, and overall life expectancy is early 
adulthood [236]. Typical symptoms of this disorder include ataxia, seizures, dementia, 
difficulty with speech, skeletal abnormalities and hepatosplenomegaly [236]. The disease 
arises from a mutation in the GLB1 gene. At present, there is no established cure or treatment 
for GM1 Type II disease, although medication is frequently prescribed symptomatically, i.e. 
anticonvulsants to control associated seizures. 
As highlighted in the literature review (Chapter 1), to date few metabolomics investigations 
have been performed. In principle, such investigations have the potential to provide 
candidate biomarkers for this debilitating condition, together with a further understanding 
of the abnormal biochemistry mediated by GM1 Type II disease. Indeed, it has previously 
been demonstrated that N-acetylated biantennary octasaccharide, N-acetylated triantennary 
decasaccharide/tetraantennary dodecasaccharides are present in GM1 Type I (OMIM 
230500) urinary profiles using thin- layer chromatography (TLC) coupled with 1H NMR 
analysis [237]. GM1 Type I represents the most severe type form of gangliosidosis, with 
patient life expectancies within the childhood ranges, so it might be expected that this form 
has the highest possible level metabolic disturbances. GM1 Type III is the adult form of the 
condition. However, this investigation was targeted on these N-acetyl compounds alone, and 
not the global metabolome, in which a combination of markers could be attributable to GM1 
Type I. Metabolomics investigations have also observed the quantification of gangliosides, 
potentially key biomarkers in GM1 and GM2 gangliosidoses, in vitro but not in vivo [48]. 
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In this investigation, conventional 1H NMR- and LC-MS-based metabolomics approaches 
were employed in order to identify new, potentially valuable biomarkers for GM1 Type II 
gangliosidosis, particularly those which correlate with their severity and progression. In view 
of the age differences in the biofluid samples collected (blood plasma, CSF and urine) the 
abilities of these techniques to prognostically stratify such patients was also explored. 
Furthermore, these strategies were supplemented by the application of newly-developed 
metabolic pathway and quantitative metabolite set enrichment analyses; these software-based 
approaches serve to provide much valuable information regarding biomolecular 
connectivities, and hence the biological/metabolic pathways involved in the pathogenesis of 
GM1 diseases. This approach also permitted the recognition of metabolic ‘signatures’ that 
may enhance our understanding of the pathogenic mechanisms of GM1 at the molecular, 
biochemical and cellular levels. Therefore, the overall approach employed combined both 
targeted and untargeted metabolomics strategies. 
5.2 Specific Aims 
 
• Discovery of age-related changes arising from perturbed metabolic pathways which 
reflect pathogenic mechanisms associated with GM1 Type II gangliosidosis. 
• To seek and identify new biomarkers of GM1 Type II disease activities and 
progression in blood plasma, CSF and/or urine. 
• Employment of these multidimensional metabolic datasets in order to enhance our 
understanding of GM1 type II disease processes at the molecular, biochemical and 
cellular levels 
5.3 Approval for Research 
 
The investigation was carried out abiding by the rules of the Declaration of Helsinki 1975 
(revised in 2013). All subjects gave their informed consent for inclusion before they 
participated in the study. De Montfort University, Leicester provided ethical approval for the 
protocol of collection of plasma from control participants (reference no. 1936). The GM1 
Type II patients were consented under protocol 02-HG-0107 “Neurodegeneration in 
Glycosphingolipid Storage Disorders” under the National Human Genome Research 
Institute IRB. 
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5.3 Sample Collection of Human Biofluids 
 
10 matched blood plasma, urine and CSF specimens collected from groups of GM1 Type II 
patients were collected by Prof. Tifft’s team based at the National Institute of Health (NIH), 
Bethesda, Maryland, 20892, USA, and were transported on dry ice to Leicester School of 
Pharmacy, De Montfort University (DMU), Leicester, UK, and then immediately frozen at-
80°C on arrival at the laboratory. All samples were collected from different individuals, with 
the exception of one sample, which was derived from a male at two different time points 
(i.e., when this patient was aged 18 and 20 years). 
Blood plasma samples were not discoloured, and therefore it was presumed that no blood 
contamination had occurred; therefore, all samples were included in the 1H NMR and LC-
MS analysis regimens. A range of samples were collected from different age ranges and 
individuals in order to gain a longitudinal insight into the molecular mechanisms featured in 
the disease process. Blood plasma was collected into heparinized tubes in order to avoid 
NMR analytical complications arising from the use of collection tubes containing an EDTA 
anticoagulant discussed in Chapter 3. 
Class GM1 Type II Controls Total 
Mean Age 11.4 22.4 20.5 
Range (Years) (3-20) (18-54) (3-54) 
Males 4 10 14 
Females 6 27 33 
Total 10 37 47 
Table 5.0. Details and breakdown of GM1 Type II blood plasma and corresponding healthy 
control samples, i.e. age and gender for both groupings.  
Class GM1 Type II Controls Total 
Mean Age 11.4 40.4 37 
Range (Years) (3-20) (18-68) (3-68) 
Males 4 25 29 
Females 6 51 57 
Total 10 76 86 
Table 5.1. Details and breakdown of GM1 Type II urine and corresponding healthy control 
samples, i.e. age and gender for both groupings. 
CSF was only collected from the 10 GM1 Type II patients and not control participants. GM1 
Type II patients were on a combination of drugs, some of which have 1H NMR signals which 
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overlap with metabolite resonances in the 1H NMR profiles acquired. Since all participants 
were on a range of medications, as many drug metabolite signals as possible were determined 
prior to performing multivariate statistical analysis, in order to address their potential impact 
on the overall metabolomes.  
  
5.4 Preparation of Human Biofluids for 1H NMR Analysis 
 
Biofluid samples were thawed at room temperature and then immediately prepared for 1H 
NMR analysis. Preparation for this set of samples involved centrifuging 500 µl volumes of 
sample (urine or plasma) and removing 350 µl supernatants for analysis. Degradation of CSF 
and plasma has been observed when left at ambient temperature for periods of more than 
2.5 hours [238], so these samples were prepared and analysed immediately. A 50 µl aliquot 
of phosphate buffer (Acros Organics) at pH 7.00 was added to the supernatant, including 
0.05% (w/v) sodium azide (50 µl) (Sigma-Aldrich), and then 10% (v/v) D2O (45 µl) (Sigma 
Aldrich), also containing 0.05% (w/v) 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt 
(TSP) (Sigma Aldrich) was then added to the solution. For the plasma samples, the internal 
quantitative standard TSP was not added since its resonance can broaden substantially from 
binding to plasma proteins such as albumin. These mixtures were then thoroughly rotamixed 
and added to newly-purchased NMR tubes (Norell) ready for analysis. 
 
5.5 1H NMR Analysis  
 
Samples were analysed at the University of Oxford using the Bruker AVII 700 MHz NMR 
spectrometer equipped with a 1H TCI cryoprobe (Department of Chemistry) at an operating 
frequency of 699.989 MHz and a probe temperature of 298 K. Spectral acquisition involved 
the collection of 65,536 data points using 32 scans across a spectral width of 15.99 ppm. For 
the urine, plasma and CSF samples, NOSEY Presaturation (noesygppr1d) was used as 
previously described (Chapter 2), targeting the intense water signal located at δ = 4.70 ppm. 
For the plasma and CSF samples, the CPMG pulse sequence was employed in order to 
suppress the broad protein signal envelope which obscures the visibility, and hence 
quantification, of many low-molecular-mass metabolite resonances. Samples were loaded 
onto an automated sample belt using a sample changer. 
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5.6 NMR Data Preprocessing 
 
1H NMR data were preprocessed in the same manner as described in Chapters 3 and 4 for 
both plasma and urine samples. The removal of bucket regions attributable to drug 1H NMR 
signals, and those of their metabolites, is described below in section. 
 
5.7 Liquid Chromatography-Mass Spectrometry  
 
Using an Agilent 6120 quadrupole LC-MS system, a method was developed to identify GM2 
ganglioside (1383.4 m/z) in negative ion mode using signal ion monitoring (SIM) parameters. 
High-performance liquid chromatographic (HPLC) analysis was performed on an Agilent 
1260 infinity system, using a Supelcosil LC-18-DB, 3 µm, 3.3 cm x 4.6 mm column. 20 µl of 
the authentic GM2 standard was injected at a flow-rate of 1.00 ml/min. employing the 
following gradient elution profile: 0.00-2.50 min. 100% (C), 2.51 min. 10% (A) and 90% (B), 
5 min. 100% (B) [where A is water/methanol 98:2% (v/v)]; B: 100% (v/v) methanol; and C 
92:8% (v/v) water/methanol]. A signal observed at a retention time of 0.54 min. represented 
GM2 ganglioside (1383.4 m/z).  
5.8 1H NMR Profiles of Plasma and Urine from GM1 Type II Patients 
 
Figure 5.0. (a) Partial Profiles of CPMG 1H NMR spectra of GM1 Type II CSF in the 0.10 ppm-2.70 ppm range. Assignments: [1] Silicone grease-CH3; [2] 
2-Hydroxy-3-methylbutyrate-CH3; [3] Levetiracetam-CH3; [4] 2-Hydroxybutyrate-CH3; [5] Isoleucine-CH3; [6] Leucine-CH3; [7] Valerate-CH3; [8] α-
ketoisovalerate-CH3; [9] Methylsuccinate-CH3; [10] Propylene glycol-CH3; [11] 3-D-Hydroxybutyrate-CH3; [12] 2,2-Dimethylsuccinate-CH3; [13] Lactate-CH3; 
[14] 13C satellite; [15] Alanine-CH3; [16] Acetate-CH3; [17] N-Acetyl-function-CH3 of acute-phase glycoprotein molecularly-mobile carbohydrate side-chain N-
acetylsugars; [18] Glutamine-β- and γ-CH2 functions (2.12 and 2.45 ppm respectively); [19] Acetone-CH3; [20] Pyruvate-CH3; [21] Citrate-CH2A/CH2B. 
Chemical Shift 
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Figure 5.0. (b) Partial CPMG 1H NMR spectra of GM1 Type II CSF in the 2.70 ppm – 5.20 ppm range. Assignments: [22] Creatine-CH3; [23] Creatinine-
CH3; [24] Dimethyl Sulfone-CH3; [25] D-Glucose bulk chain-C2-C6-CH; [26] myo-Inositol-H/C2/C6,C4/C3,C1/C5; [27] Methanol-CH3; [28] 2-
Hydroxybutyrate-CH; [29] Lactate-CH; [30] tentative Ascorbate-CH; [31] β-Glucose-C1-CH; [32] α-Glucose-C1-CH. 
Chemical Shift 
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Figure 5.0. (c) Partial CPMG 1H NMR spectrum of GM1 Type II CSF (sample code GSL011) in the 5.65 – 8.55 ppm range. Assignments: [33] Urea-CO-
NH2; [34] L-Tyrosine-C3/C5-CH (trace levels detectable); [35] unassigned; [36] L-Phenylalanine-C4/C5,C3/C6,C2-H (trace levels detectable); [37] Formate-
CH. 
 
 
 
Chemical Shift (δ/ppm) 
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Figure 5.1. (a) Partial CPMG 1H NMR spectrum of typical blood plasma sample collected from GM1 Type II patients (0.80 -4.70 ppm range). Assignments: 
[1] Very-low-density-lipoprotein (vLDL) /low-density-lipoprotein (LDL)-triacylglycerol (TAG)-CH3s; [2] Isoleucine-CH3; [3] Leucine-CH3; [4] Valine-CH3; 
[5] 3-D-Hydroxybutyrate-CH3; [6] vLDL/LDL-bulk chain-(CH2)n; [7] Lactate-CH3; [8] Alanine-CH3; [9] TAG–CH2-CH2CO; [10] Lysineγ-CH2/Arginine-CH2; 
[11] Arginine-γ-CH2; [12] Acetate-CH3; [13] Lipoprotein-TAG-CH2-CH=CH-; [14] N-Acetyl-function-CH3; [15] Glutamine-β-CH2;[16] Acetone-CH3; [17] 
Acetoacetate-CH3; [18] Glutamate–γ-CH2; [19] Glutamate–γ-CH2; [20] Citrate-CH2A/-CH2B; [21] TAG-CH=CH-CH2-CH=CH; [22] Creatine/Creatinine-CH3; 
[23] unassigned; [24] Choline headgroup of high density lipoprotein (HDL) phospholipids (-N+(CH3)3); [25] Glucose-CH; [26] Glycine-CH2; [27] Glucose-
Bulk chain-C2-C6-H; [28] Tyrosine-CH/Phenylalanine-CH/L-Histidine-α-CH; [29] Creatine-CH2; [30] Lactate-CH; [31] L-Threonine-CH/3-D-
Hydroxybutyrate-CH3; [32] β-Glucose-C1-CH. 
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Figure 5.1. (b) Partial 1H NMR spectra of blood plasma samples collected from GM1 Type II patients. Typical spectra are shown  (5.00-9.50 ppm and 14.10-
14.50 ppm regions) Assignments: [33] α-Glucose-C1-CH; [34] TAG-CH=CH-; [35] Urea-CO-NH2; [36] L-Tyrosine aromatic-C3/C5-CH; [37] L-Histidine-
C2-CH; [38] L-Phenylalanine aromatic-C4/C5,C3/C6,C2-H; [39] Protein aromatic amino acid-CH (tentative assignment); [40] Protein aromatic amino acid-
CH (tentative assignment); [41] Formate-CH; [42] Trigonelline-Cδ/Cζ-CH; [43] Trigonelline-Cβ-CH; [44] unassigned.  
  
 
 
 
Chemical Shift (ppm) 
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Figure 5.2. (a) Partial NOESY single-pulse 1H NMR spectrum of GM1 Type II patient 
urine (0.85-4.70 ppm range). Typical spectra are shown. Assignments: [1] Bile acid-CH3s; [2] 
Tentative lamotrigine metabolite and miglustat parent drug resonances-CH3; [3] Isoleucine-
CH3; [4] Leucine-CH3; [5] Valine-CH3s; [6] Methyl Succinate-CH3; [7] 2-Oxoisovalerate-CH3; 
[8] Aminoisobutyrate-CH3; [9] 3-D-Hydroxybutyrate-CH3; [10] L-Fucose-CH3; [11] 3-
Hydroxyisovalerate-CH3; [12] Lactate-CH3/Threonine-CH3; [13] 2-Hydroxybutyrate-CH3; 
[14] Lysine-Cγ-CH2; [15] Alanine-CH3; [16] Unassigned; [17] Lysine-Cβ-CH2; [18] Thymine-
ε-CH3; [19] Aminoadipate-CH2; [20] Lysine-γ-CH2; [21] Acetate-CH3; [22] 2-
Hydroxyglutarate-CH2; [23-25] N-Acetyl-CH3 functions; [26] Glutamate-β-CH2; [27] 
Acetoacetate-CH3; [28] Glutamine-γ-CH2; [29] Acetoin-α-CH3; [30] Acetoacetate-CH3; [31] 
2-Hydroxyglutarate-δ-CH2; [32] Pyruvate-CH3; [33] Glutamate-γ-CH2; [34] Succinate-CH2’s; 
[35] Glutamine-δ-CH2; [36] Citrate-CH2A/CH2B; [37] tentative Lamotrigine Resonance-CH; 
[38] Dimethylamine-CH3; [39] Trimethylamine-CH3; [40] Dimethylglycine-CH3; [41] L-
Lysine-ε-CH2; [42] L-Tyrosine-β-CH; [43] Creatinine-CH3/Creatine-CH3; [44] Malonate-
CH2; [45] L-Histidine-β-CH2; [46] D-Glucose-CH [47] TMAO-CH3; [48] Taurine-CH2-
NH3
+; [49] Trimethylamine-CH3; [50] Glucuronate-γ-CH; [51] Methanol-CH3; [52] D-
Glucose-CH; [53] Cystine-γ/δ-CH2 [54] cis-Aconitate-CH3; [55] Taurine-CH2-SO3
-; [56] 3-
Hydroxyphenylacetate-CH2; [57] Phenylacetate-CH2; [58] unassigned; [59] Glycine-CH2; [60] 
Phenylacetylglycine-γ-CH2;/Threonine-β-CH; [61] Mannitol-CH2; [62] 
Phenylacetylglutamine-β-CH2; [63] Unassigned; [64] Lysine-ε-CH; [65] Ethanolamine-CH2; 
[66] Mannitol-CH2OH; [67] Mannitol-CH2; [68] Creatine-CH2; [69] Glycolate-CH2; [70] 
Hippurate-CH2; [71] Creatinine-CH2; [72] Pyroglutamate-β-CH; [73] Lactate-CH; [74] 
Threonine-β-CH; [75] Tartrate-CHOH; [76] Trigonelline-CH3; [77]  β-Glucose-C1H. 
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Figure 5.2. (b) Partial NOESY single-pulse 1H NMR spectrum of GM1 Type II patient 
urine (4.70-9.30 ppm range). Typical spectra are shown. Assignments: [78] Residual water-
OH; [79] Unassigned; [80] α-Glucose-CH; [81-82] Unassigned; [83] Sucrose-α-CH; [84] 
Unassigned; [85] Urea-CO-NH2; [86] 2-Furoylglycine-β-CH; [87] Tyrosine-γ/ε-CH; [88] 
Unassigned [89] Phenol-β/δ/ζ-CH; [90] Phenol-γ/ε-CH; [91] Tyrosine-ζ/η-CH; [92] 
Indoxyl-sulphate-η/θ/β-CH; [93] Indoxyl-sulphate-ζ/ι-CH; [94] Indoxyl sulphate-β-CH and 
Phenylalanine-β/ζ-CH; [95] Phenylalanine-γ/δ/ε-CH; [96] Indoxyl-sulphate-β-CH; [97] 
Indoxylsulphate-ζ-CH and Benzoate-γ/ε-CH; [98] Hippurate-γ/ε-CH; [99] Hippurate-δ-CH; 
[100] 1-Methylhistidine-δ-CH; [101] Hippurate-β/ζ-CH; [102] Histidine-β-CH; [103] 
Histidine-CH; [104] 3-Methylhistidine-β-CH; [105-107] Tentative (tolperisone metabolite) 
drug metabolite-CH; [108] Hypoxanthine-β/η-CH; [109] 1-Methylnicotinamide-ε-CH; [110] 
Tentative (tolperisone metabolite) drug metabolite-CH; [111] Quinolinate-CH; [112] 
Formate-CH; [113] Tentative (tolperisone metabolite) drug metabolite-CH; [114]  
Trigonelline-δ/ζ-CH; [115] 1-Methylnicotinamide-ε-CH; [116] 1-Methylnicotinamide-ε-CH; 
[117] Tentative (tolperisone metabolite) drug metabolite-CH; [118] Trigonelline-β-CH; [119] 
N-Methylnicotinamide-β-CH; [120] Nicotinamide riboside- β -CH. 
 
700 MHz single-pulse 1H NMR spectra of these biofluids contained many prominent, sharp 
signals assignable to wide range of low molecular-mass biomolecules. Indeed, more than 80, 
50 and 30 metabolites were detectable in the spectra acquired on urine, blood plasma and 
CSF respectively, and these included a range of biomolecules such as short-chain organic 
acid anions (e.g., acetate, formate, fumarate, lactate, pyruvate, succinate, glycolate and 3-D-
hydroxybutrate); amino acids, including leucine, isoleucine and valine (collectively known as 
branched-chain amino acids, abbreviated BCAAs), glycine, alanine, glutamate, glutamine, 
lysine, proline, taurine, histidine, phenylalanine and tyrosine, etc., together with N-
acetylamino acids; carbohydrates, most especially GM1 disease-relevant N-acetylsugars; and 
also nicotinate and nicotinamide pathway metabolites, amongst others (Figures 5.0-5.2). As 
expected, the 1H NMR profiles of blood plasma contained relatively broad resonances arising 
from a series of lipoprotein-associated triacylglycerol’s (TAG’s), with 1H NMR-
distinguishable very low-, low- and high-density-lipoproteins, the acetamido (-NHCOCH3) 
functions of N-acetylneuraminate and N-acetylglucosamine residues present in the 
molecularly-mobile carbohydrate side-chains of selected ‘acute-phase’ glycoproteins, in 
addition to those arising from aromatic amino acid protein residues. 
In addition to the above resonances, those attributable to drugs and their corresponding 
metabolites were also assigned in the urine and CSF of these individuals. On closer inspection 
of the spectra acquired, such drug metabolites were assignable (Figure 5.3). These signals 
were removed prior to multivariate analysis (MVA). Full elucidation of the molecular 
structures of drug metabolites was not possible without the application of 2D NMR 
techniques. 
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Figure 5.3 shows a range of urinary xenobiotic metabolite resonances observed, for example 
those clearly attributable to valproate and its glucuronide metabolite; the full list of signals 
for these agents is already established in the literature [37]. Since only one participant is 
receiving each drug respectively, some metabolite signals attributable to drugs were retained 
in the statistical analysis model and it was firstly considered if these participant samples 
represented outliers in the preliminary, unsupervised forms of analysis first, i.e. PCA. 
However, the majority of the urinary bucket regions shown in Figure 5.3 were removed from 
the different forms of statistical analysis conducted, and these included the δ = 0.85 – 0.95, 
5.54 – 5.56 ppm, 1.03 – 1.05 ppm, 1.37-1.39 ppm, 1.50 – 1.65 ppm, and 3.55 – 3.56 ppm 
regions, in addition to the xenobiotic signals highlighted in Figure 5.2, i.e. those at δ = 9.1, 
8.7, 8.3, 7.9 and 8.05 – 8.15 ppm were all removed therefrom. 
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(c) 
 
 
 
 
 
Figure 5.3. (a) Examples of resonances in the 1H NMR profiles of human urine collected 
from GM1 type II patients of valproate metabolite 1-O-valproyl-β-glucuronide, including 
methyl protons [1] (t); [2] and anomeric proton (d); [3] References showing previous 
assignments of these resonances [37], [239]. (b) Example of resonances in the 1H NMR 
profiles of human urine from GM1 Type II patients attributable to miglustat, including 
methyl protons [1]; β-CH2 [2]; γ-CH2 [3] and miglustat piperidine ring-γ/α-CH [4]. (c) [1]-[4] 
are resonances that arise from from drug administrations. Patient was receiving lamotrigine 
but these resonances do not correspond to this drug or its metabolites.   
2 
3 
4 
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5.9 Statistical Analysis of Plasma Dataset  
 
Multivariate Statistical Analysis 
Figure 5.4. (a) Left: PCA scores plot showing controls (red) and GM1 Type II (green) study 
participants, together with 95% confidence ellipsoids. PC1 and PC2 represent 62.7 and 
10.2% of the total dataset variance respectively. (a) Right: PLS-DA scores plot showing 
controls (red) and GM1 Type II (green), along with 95% confidence ellipsoids. PC1 and PC2 
represent 60.3 and 12.9% of the total dataset variance respectively. Removal of all glucose 
bucket regions, which were clearly elevated in GM1 Type II participants in view of non-
fasting of participants, was performed prior to performing this analysis. (b) VIP scores plot 
attributable to the PLS-DA analysis showing significantly elevated bucket regions, and 
corresponding metabolite assignments. Red and green represent metabolites elevated or 
depleted in GM1 Type II and controls respectively. The higher the VIP score, the more 
important the bucket region is considered in this PLS-DA model (all VIP values ≥ 1 were 
(a) 
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considered significant). Abbreviations: LDL, Low density lipoprotein; TAG, triacylglycerol; 
vLDL, very low-density lipoprotein.  
 
Using multivariate statistical testing, a clear distinction was found between the healthy 
controls and GM1 Type II plasma profiles. There was an outlier in the control group in the 
PCA plot that was removed prior to the final PCA and PLS-DA analysis for the reasons 
provided in Chapter 4. 
Figure 5.5. (a) PCA scores plot of plasma profiles from controls grouped by age 25 years 
or under, 30 years or under and 60 years or under, shown in red, green and blue, respectively. 
PC1 and PC2 are shown representing 69.2 and 12.7% of the dataset variance respectively. 
95% confidence ellipses are shown. PLS-DA analysis was also performed on this dataset 
(data not shown), and the highest Q2 value obtained was only 0.22 on a 3 component model 
using LOOCV and upon permutation testing using separation by distance p = 0.43 was 
determined with 2,000 permutations (b) PCA plot of plasma profiles from controls grouped 
by male (M) and female (F) represented in green and red respectively. PC1 and PC2 are 
shown representing 67.8 and 12.9% of the dataset variance respectively. 95% confidence 
(a) (b) 
(c) (d) 
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ellipses are shown. PLS-DA analysis was also performed on this dataset (data not shown), 
and the highest Q2 value obtained was only -0.35 on a 6 component model using LOOCV 
and upon permutation testing using separation by distance, a p value of 0.388 was determined 
with 2,000 permutations. (c) PCA scores plot of plasma profiles from GM1 Type II patients 
grouped by age 10 years or under and 20 years or under shown in red and green, respectively. 
PC1 and PC2 are shown representing 38.3 and 28.9% of the dataset variance respectively. 
95% confidence ellipses are shown. PLS-DA analysis was also performed on this dataset 
(data not shown) and the highest Q2 value obtained was only 0.24 on a 5 component model 
using LOOCV, and upon permutation testing using separation by distance p = 1 was 
determined using 2,000 permutations. (d) PCA scores plot of plasma profiles from GM1 
Type II patients grouped by male (M) or female (F) or under shown in green and red, 
respectively. PC1 and PC2 are shown representing 38.3 and 28.9% of the dataset variance 
respectively. 95% confidence ellipses are shown. PLS-DA analysis was also performed on 
this dataset (data not shown) and the highest Q2 value obtained was only 0.02 on a 1 
component model using LOOCV and upon permutation testing using separation by distance 
p = 0.582 was determined using 2,000 permutations. 
 
Univariate Statistical Analysis  
Student’s t-test analysis of the plasma from GM1 Type II and controls using FDR correction 
of 0.05 showed 25 metabolites as significant (p < 0.005), including 0.80 – 0.91 ppm (↓ very-
low-density-lipoprotein (vLDL)/low-density-lipoprotein (LDL)-triacylglycerol (TAG)-CH3); 
0.94 – 0.97 ppm (↑ leucine-CH3); 0.97 – 0.99 ppm (↑ valine-CH3); 1.02 – 1.05 ppm (↑ valine-
CH3); 1.34 – 1.38 ppm (↓ vLDL/LDL-bulk chain-(CH2-)n); 1.38 – 1.40 ppm (↓ unassigned); 
1.40 – 1.42 ppm (↓ unassigned); 1.46 – 1.50 ppm (↓ alanine-CH3); 1.54 – 1.61 ppm (↓ TAG–
CH2-CH2CO); 1.95 – 2.02 ppm (↓ TAG-CH2-CH=CH /N-Acetyl-CH3 ); 2.05 – 2.10 ppm 
(↓ N-Acetyl-CH3 ); 2.40 – 2.49 ppm (↑ glutamine-CH2); 2.69 – 2.72 ppm (↑ TAG-CH=CH-
CH2-CH=CH;, 2.94 – 2.97 ppm (↓ trimethylamine-CH3); 3.03 – 3.04 ppm (↑ creatinine-
/creatine-N-CH3); 3.26 – 3.28 ppm (↑ trimethylamine-N-oxide-CH3), 3.59 – 3.62 ppm; (↑ 
unassigned), 3.72 – 3.75 ppm (↑ unassigned); 3.65 – 3.66 ppm (↓ unassigned); 3.66 – 3.68 
ppm (↑ unassigned); 3.92 – 3.94 ppm (↑ tyrosine-α-CH/creatine-CH2); 3.96 – 4.00 ppm (↑ 
histidine-α-CH /phenylalanine-α-CH/creatine-CH2), 4.08 – 4.09 ppm (↑ creatinine-CH2/3-
hydroxybutyrate-CH) and 5.24 – 5.35 ppm (↑ TAG-CH=CH-).  
Volcano plots and fold-change analyses identified the same 6 bucket regions as significant 
including 4.08 – 4.09 ppm (↑ creatinine-CH2/3-hydroxybutyrate-CH); 4.04 – 4.08 ppm (↑ 
creatine/glycerol backbone of lipids -CH2OCOR); 8.04 – 8.11 ppm (↑ trigonelline-CH); 3.94 
– 3.96 ppm (↑ histidine-CH); 3.26 – 3.28 ppm (↑ unassigned); and 3.92 – 3.94 ppm (↑ 
creatine-CH2) in GM1 Type II plasma samples. 
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5.10 Statistical Analysis of Urinary Dataset  
 
Multivariate Statistical Analysis 
 
Figure 5.6. (a) 2D PCA scores plot from the 1H NMR urinary profiles of controls (red) and 
GM1 Type II (green) participants. PC1 and PC2 are shown to represent 56.6 and 13.3% of 
the total dataset variance respectively. 95% confidence ellipses are shown. Outliers are circled 
in blue. (b) Corresponding 3D PLS-DA plot with control (red) and GM1 Type II (green) 
participants denoted. PC1, PC2 and PC3 are shown to represent 48.7, 18.7 and 6.1% of the 
total dataset variance respectively. Accuracy = 0.965; Q2 = 0.56; and R2 = 0.73 using LOOCV 
on a model with 4 components. Permutation testing obtained: p < 0.0005, using 2,000 
permutations. 
Bucket 
Region 
(δ/ppm) 
Upregulated or 
downregulated in GM1 
Type II 
Assignment 
2.52-2.59 ↑ Citrate-CH2A/B 
3.56-3.58 ↑ Glycine-CH2 
2.66-2.73 ↑ Citrate-CH2A/B/DMA-CH3 
2.05-2.08 ↑ N-acetyl-CH3 
2.34-2.35 ↑ Pyruvate-CH3 
3.23-3.24 ↑ TMAO-CH3 
1.33-1.34 ↑ Lactate-CH3 
2.25-2.28 ↑ Acetoacetate-CH3 
1.47-1.50 ↑ Alanine-CH3 
2.02-2.05 ↑ N-Acetyl-CH3 
1.27-1.28 ↑ Acetoacetate-CH3  
1.92-1.93 ↑ Lysine-CH2/Acetate-CH3 
4.14-.4.18 ↑ Lactate-CH 
4.29-4.31 ↑ Threonine-γ-CH 
                            
  
  
  
   
 
   
 
   
 
 
   
    
    
     
    
 
    
   
    
 
     
    
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
       
           
(a) (b) 
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1.93-1.96 ↑ Lysine-CH2 
Table 5.2. Top significant bucket regions and corresponding metabolites that are 
upregulated or downregulated in GM1 Type II urinary profiles. These results are derived 
from PLS-DA plot in Figure 5.4. VIP scores were all ≥ 1, and therefore considered 
significant.  
 
MV testing revealed some differences in PCA analysis; however, complete separation 
between the two groups was not possible. GM1 Type II urinary profiles loaded more 
positively on PC1 and PC2 than control patients. Loadings on the PCA were investigated, 
and both the 3.03 – 3.08 and 4.06 – 4.12 ppm bucket regions loaded negatively on PC1 and 
positively on PC2. These bucket regions are attributable to creatinine/creatine-N-CH3 and 
creatinine-CH2 respectively. Outliers were identified and circled in blue, and hence these 
samples were removed from further statistical analysis. PLS-DA was able to successfully 
distinguish between GM1 Type II and control participants urinary profiles (Figure 5.4). The 
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VIP scores plot revealed many significant metabolites (Table 5.1). The model was accurate 
and performed well under permutation testing (Figure 5.5).  
Figure 5.7. (a) PCA scores plot of urinary profiles from controls and GM1 Type II grouped 
by age 10 years or under, 20 years or under, 30 years or under and 70 years or under, 
represented in red, green, blue and turquoise, respectively. PC1 and PC2 are shown 
representing 29.8% and 19.1% of the dataset variance respectively. 95% confidence ellipses 
are shown. (b) PCA plot of urinary profiles from controls and GM1 Type II grouped by 
male and female, represented in green and red, respectively. PC1 and PC2 are shown 
representing 29.8% and 19.1% of the dataset variance respectively. 95% confidence ellipses 
are shown. (c) PCA scores plot of GM1 Type II samples only grouped by age 10 years or 
under and 20 years or under in red and green respectively. PC1 and PC2 represent 41.7 and 
23.4% of the dataset variance respectively. 95% confidence ellipses are shown. PLS-DA plot 
of GM1 Type II samples only grouped by age 10 years or under and 20 years and under in 
red and green respectively was subjected to overfitting (Figure not shown here). PC1 and 
PC2 represented 41.1 and 17.1% of the dataset variance respectively and the highest Q2 value 
obtained was 0.63 using a 1 component model using leave one out cross validation. 
(a) (b) 
(c) (d) 
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Permutation testing using 2000 permutations determined a p value of p = 0.2445 showing 
overfitting as a result of small sample numbers. (d) PCA scores plot of control samples only 
grouped by age 20 years or under, 30 years or under and 70 years or younger in red, green 
and blue respectively. PC1 and PC2 represent 33.8 and 13.4% of the dataset variance 
respectively. 95% confidence ellipses are shown.    
 
Univariate Statistical Analysis 
Not only were there significant differences found in MV testing, but also in UV testing. 
Student’s t-tests with an FDR cut off value of p < 0.05 found the 1.07 – 1.09 ppm, 4.06 – 
4.12 ppm and 9.11 – 9.14 ppm frequency buckets to be significant. These metabolites are 
attributable to upregulated methyl succinate-CH3 and downregulated creatinine-CH2 and 
trigonelline-C2-CH resonances respectively in GM1 Type II patients. Further significance 
was found in assigned bucket regions with an FDR cut off value of p < 0.005, including 1.27 
– 1.28 ppm (acetoacetate-CH3); 1.33 – 1.34 ppm (lactate-CH3); 1.36 – 1.37 ppm (2-
hydroxybutyrate-CH3); 1.47 – 1.50 ppm (alanine-CH3); 1.93 – 1.96 ppm (lysine-β-CH2); 2.02 
– 2.05 ppm (N-acetyl-CH3); 2.25 – 2.28 ppm (2-Hydroxyglutarate-δ-CH2); 2.34 – 2.35 ppm 
(pyruvate-CH3); 2.52 – 2.59 ppm (citrate-CH2); 2.66 – 2.73 ppm (citrate-CH2/DMA-CH3); 
3.03 – 3.08 ppm (creatinine/creatine-CH2); 3.56 ppm – 3.58 ppm (glycine-CH2); and 4.14 – 
4.18 ppm (lactate-CH).  These bucket regions were all upregulated in GM1 Type II urine, 
with the exception of 3.03 – 3.08 ppm one which was downregulated. Heatmaps were unable 
to fully distinguish between GM1 Type II and control urinary profiles, and the GM1 Type 
II participants were clustered into two groups amongst the control participants. No trend or 
explanation was determined for these two groups on comparison of further possible 
explanatory variables, including age, gender and drug treatments. 
Enrichment Analysis 
Location-based enrichment analysis was performed on the urinary dataset. The lysosome was 
considered the most significant location in enrichment analysis (p < 0.00005) in view of the 
elevation of glycine and N-acetyls function resonances in GM1 Type II participants over 
those of control urinary profiles. Other significant locations revealed by enrichment analysis, 
in order of the most significance to first, were the peroxisome, bladder, placenta, 
mitochondria, spleen, pancreas and intestine with the significance of all these locations being 
p < 0.00005. Both the peroxisome and mitochondria are in close proximity to the lysosome, 
and hence this is expected since other cellular organelles are significant, since a deficient 
lysosome will impact the rest of the cell. The spleen is impacted in GM1 Type I gangliosidosis 
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in the form of splenomegaly, but this is not a common symptom of GM1 Type II 
gangliosidosis. It is, however, surprising that the bladder, intestines and placenta are 
significant locations in this analysis. 
Diseased-based enrichment analysis was also performed on the urinary dataset. This analysis 
revealed carbamoyl phosphate synthetase deficiency, iminoglycinuria, sarcosinemia, 
citrullinemia type I, glucoglycinuria, hydroxyprolinemia (type I-II), juvenile myoclonic 
epilepsy, methylmalonic aciduria (mma and cbla Type) and newborns, premature infants, 
transient immaturity of transport enzymes as the most significant diseases correlated to the 
urinary profiles in GM1 Type II versus controls (p<0.0000005). All of these disease statuses 
are significant in this form of enrichment analysis in view elevations in glycine, and notably 
all these diseases have similar symptoms to those of GM1 Type II. Typical symptoms of 
carbamoyl phosphate synthetase deficiency, citrullinemia type I and methylmalonic aciduria 
are seizures which are common in GM1 Type II patients. Other symptoms that align with 
GM1 Type II disease include mental retardation which is also present in iminoglycinuria, 
glucoglycinuria and hydroxyprolinemia. Sarcosinemia has many symptoms that align with 
GM1 Type II patients, including intellectual disability, neurological problems, skeletal 
abnormalities and enlarged liver. 
5.11 Discussion 
 
Potential Disease Biomarkers in Plasma, Urine and CSF 
Statistically significant differences in between the plasma and urine profiles was observed in 
GM1 Type II patients and those of control participants. These significant differences are 
highlighted in both UV and MV analysis conducted on the dataset acquired, and these are 
observed in Figure 5.4 and Figure 5.6; for plasma and urine; respectively. Unfortunately, 
matched control samples for the CSF were not obtained, in view of ethical reasons and also 
because of the difficulties associated with the collection of this type of sample. Hence it was 
not possible to perform statistical comparisons with the 1H NMR dataset acquired on CSF 
samples. Therefore, potential biomarkers in all other available biofluids were investigated.  
Plasma MV metabolomics analysis of these 1H NMR datasets by PCA, RF and PLS-DA 
approaches revealed a clear distinction between the two disease classification groups (i.e. 
GM1 type II gangliosidosis vs. healthy controls, Figure 5.4). With PLS-DA, permutation 
testing demonstrated a high level of discrimination between these two classifications (p = 
0.0015). VIP values also confirmed a high level of significant differences between many of 
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the 1H NMR bucket variables; for example, downregulated lipoprotein-associated TAGs in 
the GM1 type II gangliosidosis patients, observations which indicate overall perturbances in 
lipid metabolism in GM1 Type II (Figure 5.4). This observation is of particular interest, since 
the GM1 Type II participants were not fasted whilst the control ones were, and therefore an 
elevation in lipids would be expected in the GM1 Type II participants, and not a depletion. 
The top five most significant metabolites in the VIP bucket regions included 0.80-0.91 
(vLDL-/LDL-TAG-CH3), 1.95 – 2.02 (N-Acetyl-CH3/TAG-CH2-CH=CH- signal), 3.72 – 
3.75 (unassigned), 8.04 – 8.11 (aromatic amino acid) and 1.44 – 1.46 ppm (unassigned (d)) 
resonances (Figure 5.4). The most significant bucket found from this MV analysis was 
attributable to vLDL-/LDL-TAGs. Shared bucket regions attributable to TAGs have been 
observed to be either upregulated and downregulated, and thus it is difficult to distinguish 
whether the disturbance in TAGs is elevated or depleted. TAGs have been shown to be 
elevated in cardiovascular diseases [240], but this is not relevant to GM1 Type II disease 
since this condition is not the cause of mortality in these patients. More interestingly, 
depleted LDL and elevated TAGs have been observed in the plasma of patients with other 
lysosomal storage disorders, including Niemann Pick Disease Type C1 (NPC1) [26]. Overall, 
these disturbances are likely to be a result of changes in lipid trafficking, which is common 
in such disorders.  
 
Plasma creatinine is upregulated in GM1 Type II patients in view of muscle 
weakness/hypotonia observed in them, or alternatively, dietary sources [148]. Elevated blood 
histidine has been correlated with ataxia, psychosis and tremors [148], the former of which 
is consistent with GM1 Type II pathology. Disturbances of the valine, isoleucine and leucine 
pathway in serum has also been noted in another lysosomal storage disorder, NPC1 [26]. 
Disturbances in branched-chain amino acids (BCAAs) in plasma could be a reflection of liver 
condition as this has been observed elsewhere in patients with chronic active hepatitis [142]. 
Both the liver and spleen have been observed as enlarged in GM1 Type II patients, and this 
could correlate with the previous hypothesis presented by researchers working on NPC1 
disease [26].  
Gangliosides in CSF, urine and plasma were not identified or quantified using 1H NMR 
analysis, and this is ascribable to the limited sensitivity of this method. LC-MS analysis was 
also performed in order to complete targeted analysis to identify GM1 ganglioside in the 
biofluids (data not shown). However, gangliosides were not observed in vivo using the 
developed LC-MS methodology. More sensitive approaches, such as the use of LC-MS/MS, 
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could be applied in order to monitor and distinguish such saccharides [48]. Nevertheless, a 
significant increase in the N-acetyl function bucket region (2.05 – 2.08 ppm) was observed 
in spectra of GM1 Type II patient urine samples. This elevation in N-acetyl groups in urine 
could arise from other ganglioside oligosaccharides, or possibly other N-acetyl storage 
compounds such as N-acetylamino acids. The findings supports the work previously 
performed, and demonstrates that there is potential for 1H NMR analysis to distinguish 
between control and GM1 Type II patients using NMR-based cryoprobe technology [241]. 
This could lead to new biomarkers for GM1 Type II disease, with a combination of other 
markers. This may not be a biomarker specifically for GM1 Type II, since N-acetyl function 
upregulations have been correlated previously with many other lysosomal storage disorders, 
and therefore serves as a general indicator of lysosome metabolism imbalance [241]. The 
future employment of N-acetyl storage compounds as potential biomarkers in urine would 
also require further validation.  
Upregulated urinary and plasma lactate have been associated with many different diseases, 
for example, type I diabetes [242], ethanol intoxication [243], liver failure [244] and colorectal 
cancer [245], and is considered an oncometabolite, an immunosuppressant, an acidogen, and 
a metabotoxin [148]. Indeed, elevated urinary lactate in GM1 Type II patients, which in 
combination with other markers, could be considered as another unspecific marker for GM1 
Type II disease. Elevated urinary pyruvate and citrate may, however, indicate disturbances 
of the TCA cycle. As previously explored, urinary glycine levels were also shown to be 
extremely significant in enrichment analysis, and its upregulation may be associated with 
seizures. Overall, there a combination of potential non-specific biomarkers that could be 
used for GM1 Type II gangliosidosis diagnosis, and for the potential assessment of disease 
severity. 
Xenobiotics/Drugs 
Few metabolomics studies have been performed which assess the effect of the drugs on the 
metabolome as previously explored in Chapter 3. Potentially, drugs could be influencing 
biofluid metabolite levels; however, extensive studies addressing the effect of particular drugs 
on the human urine and plasma metabolome have yet to be performed. One of the 
participants were receiving no therapy, but the remainder were on a combination of 
medications. As required, none of the control participants were taking any medications or 
supplements.  
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Miglustat (n = 1) and valproate (n = 1) have both been previous explored in the urinary 
profiles in patients with NPC1 disease [201], and the valproate glucuronide metabolite and 
miglustat were also observed in urine collected from such GM1 Type II patients (Figure 5.3). 
Typically, these spectral regions must be removed from the spectrum prior to a 
metabolomics investigation. This hinders the experiment, since many metabolites can no 
longer be considered as part of the investigation. But with so few GM1 Type II samples, 
each with different drugs, it is a complex procedure to remove all metabolites associated with 
drugs, and their fasting and age status, using the described 1H NMR strategy.   
Clonidine (n = 3) is often received after opioid addiction or to help with withdrawal. Few 
metabolomics studies have been performed on urine and plasma prior and post taking this 
drug; however, rat brains have been analysed by NMR described elsewhere [246]. On this 
treatment glutamine, glutamate, creatine and taurine were demonstrated to return to normal 
in the brain with treatment of clonidine [246]. Therefore, it could be hypothesised that 
clonidine has capability to change metabolites in the blood plasma and even urinary 
metabolites, although metabolomics studies are yet to be performed to support this 
hypothesis. On multivariate testing, these samples (n = 3) did not appear to cluster together 
away from the other samples, an observation which may suggest no metabolic changes in the 
urine or plasma are observed, but this is only with very few numbers of samples, and a full 
pharmacodynamics investigation would therefore be required in order to justify this. 
Clonidine is usually eliminated unchanged by urinary excretion, and therefore it is surprising 
no signals attributable to this drug are observed. However, this most likely arises from a 
lengthy period between the sample being collected and dose administration, or the 
concentration was too low to be observed by 1H NMR analysis. 
Lamictal glycerine suppositories (n = 1) and Lamictal (n = 1) are the brand names for 
lamotrigine, and are taken by GM1 Type II patients on medication for seizures. Interestingly, 
10% of patients taking that lamotrigine have skin rashes as a side-effect. The epidermis was 
one of the locations of interest in the GM1 Type II group. However, similarly to the patients 
on clonidine, these patients did not appear to cluster together on multivariate analysis using 
PLS-DA/PCA or appear as outliers in the analysis. Resonances related to drugs were 
identified. However, they did not correspond to lamotrigine or corresponding metabolites 
identified in the literature in urine samples, and therefore a full elucidation of the structural 
nature of the drugs/corresponding metabolites was not completed (Figure 5.3). To date, this 
is the first time that this lamotrigine /metabolite(s) has be observed in urinary profiles by 1H 
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NMR, and 2D NMR spectroscopic analysis would be required in order to confirm their 
structural nature. 
Tolperisone (n = 1) is a muscle relaxant taken by a patient in the GM1 Type II cohort.  To 
date, no metabolomics investigations have been performed on tolperisone in urine and 
plasma so the impact of the participant taking this drug on this trial is not fully known. The 
patient has not appeared as an outlier in the study from the multivariate analysis. No any 
drug signals were assigned as a result of receiving this medication in the GM1 Type II patient. 
Tolperisone has been demonstrated to be excreted in urine, but only less than 0.1% of the 
dose was detected [247]. 
Levetiracetam (n = 1) is used to treat epilepsy. For the first time, signals attributable to 
levetiracetam and/or a related metabolite in CSF have been assigned (Figure 5.0(a)). 2D 
NMR analysis would be required in order to confirm the metabolite signals. The predicted 
NMR structure of levetiracetam is available on the HMDB as a solution in CDCl3 only. From 
this, it was possible to locate signals that were attributable to the same patterns in the urinary 
profile acquired. This drug was not observed in blood plasma, only in the CSF and urine. 
Albuterol (n = 1) is used to treat asthma and was taken by a patient in the GM1 Type II 
cohort. In a previous metabolomics study, observing the changes in plasma in autistic 
children, the participant receiving this drug did not appear as an outlier, which shows promise 
for this metabolomics study in that it may not impact metabolites in plasma[248], although 
urine and CSF remain unexplored. Notwithstanding, the above study used a more sensitive 
MS methodology [248] and not an NMR-based investigation as performed here.  
Cyclopentolate (n = 1) is a muscarinic antagonist, and was used to treat a patient in the GM1 
Type II cohort.  To date, no metabolomics investigations have been performed on 
cyclopentolate in urine and plasma so the impact of the participant taking this drug on this 
trial is not fully known. The patient did not appear as an outlier in the study in the multivariate 
analysis performed. No drug or drug-related 1H NMR signals in spectra acquired on this 
GM1 Type II patient. Since this drug is prescribed as an eye drop, it is perceived that it is 
unlikely to have much impact on the urinary or plasma profiles.  
A GM1 Type II patient was prescribed diazepam (n = 1). The patient was 3 years old meaning 
a child dosage was formulated and received which is maximum 10 mg. A metabolomic study 
has been performed on diazepam however; it concerned the brain and not urine or plasma 
like in these studies [249]. No resonances associated with diazepam were observed and this 
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might be due to the small dosage, mass spectrometry has been the main technique of focus 
for detection in biofluids in view of sensitivity issues [250].  
It has been previously highlighted that drugs can be detected in 1H NMR spectra and impact 
the overall statistical analysis results acquired, and therefore, it is important to take into 
account where drugs are resonating and either remove them entirely from the spectra, 
remove the sample or handle the significance of the results with caution. These buckets were 
removed prior to the performance of multivariate analysis as described in previous chapters. 
Drug Metabolite Chemical Shift 
(δ/ppm) 
Urinary Metabolite(s) 
that appear in region 
Significant 
buckets in 
GM1 Type 
II 
1-O-valproyl-β-
glucuronide  
0.88 
1.31 
1.53 
1.61 
2.59 
3.86 
3.52 
3.59 
 
Lactate-CH3 
 
L-Lysine-CH2 
Citrate-CH2 
Mannitol-CH2 
Phenylacetylglutamine-
CH3 
No 
No 
No 
No 
Yes 
No 
 
No 
Miglustat 1.02 
1.45 
1.74 
2.99 
3.05 
3.20 
3.39 
3.45 
3.60 
3.70 
3.91                      
4.12 
Valine-CH3 
Lysine-CH2 
 
 
Taurine-CH2 
Methanol-CH3 
 
Glycine-CH2 
Lysine-CH2 
Creatinine-CH 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Levetiracetam 1.67-1.72 
2.50-2.56 
4.44-4.48 
Lysine 
Citrate-CH2A/B 
Trigonelline 
No 
No 
No 
Lamotrigine/metabolite 0.86 
1.56 
1.73 
2.59 
 
 
 
 
No 
No 
No 
No 
Table 5.3. Metabolite signals impacted by drug metabolism of the various medications which 
were removed prior to the multivariate and univariate analysis conducted.  
Diet and Dietary Supplements 
Omega-3 PUFA (n = 1) and vitamin D3 (n = 1) that have been taken by GM1 Type II 
patients have already been previously explored in Chapter 3 in addition to dietary 
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supplements. However, vitamin B6 (n = 1) was not investigated as part of this discussion. It 
has been found that vitamin B6 increases the ratios of glutamine/glutamate  and 2-
oxoglutarate/glutamate in plasma alongside upregulations in acetate, pyruvate and TMAO 
[251]. As only one participant was taking vitamin B6 as a supplement it is unlikely that this 
would impact the statistical analysis of the whole cohort and this participant did not appear 
as an outlier as a result of taking this vitamin. No resonances in the 1H NMR spectra from 
administration of this vitamin were observed, largely because the dose applied was too small 
for it to be 1H NMR-detectable. 
Fasting and Non-fasting status 
Many of the metabolites can be introduced as a result of dietary differences between the 
fasted and unfasted cohort. This has been explored extensively in Chapter 3, but the 
metabolites that are significant in this particular investigation, and which may be as ascribable 
to a dietary difference, include citrate and amino acids, for example. The issues of analysis of 
fasted and unfasted samples have been previously addressed in Chapter 3, and similar 
considerations arise within this study with regard to specific metabolites such as citrate and 
amino acids, which can be ingested with corresponding increases in blood plasma and urine 
accordingly. Histidine, trigonelline and valine concentrations were also elevated in GM1 
Type II patients, but this is likely to arise from dietary sources, and the different fasting status 
of the participants involved in this investigation [148]. Additionally, disturbances in TAGs in 
GM1 Type II when expressed relative to control plasma samples were observed, which could 
be attributable to diet; this has been demonstrated elsewhere [252], [253].  
Sample Volume and Sample Storage 
The volume of sample was limited in this study, therefore less volume was used for analysis 
than that in the investigations described in previous chapters; a higher quantity of urine and 
plasma may reveal more sensitive results and potentially more metabolites in which are only 
present at lower concentrations; however, the results acquired are consistent with  molecules 
previously identified in 1H NMR studies of CSF [63]. Some methodologies have employed 
freeze-drying techniques using CSF to increase metabolite concentrations; however, this is 
usually useful for larger volumes of CSF. Sensitivity issues were avoided by using the highly 
sensitive 700 MHz NMR at Oxford University, and to date gangliosides have not been 
identified in biofluids via 1H NMR or LC-MS in vivo, which may have served as useful 
biomarkers. 
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Sample storage length could also impact on metabolite concentrations in the samples 
investigated, and this has been demonstrated elsewhere [102]. Samples analysed over a 2-year 
period demonstrated that metabolite determinations in the blood serum of fasting individuals 
are more reproducible, than those of unfasted individual sera [102]. This factor could also 
partially influence the results acquired here, since the GM1 type II samples were collected in 
the 2011-2017 period, and hence were stored for longer than the control samples, which 
were all collected in 2017. This presents some challenges in sample collection over a 
longitudinal period, which is essential in assessing disease severity over a period of time in 
rare disorders. 
Age and Sample Numbers 
Another limitation of this study is the limited number of samples available in this study. This 
is ascribable to the rarity of the disease studied. Furthermore, age- matched controls were 
not collected in view of the ethical approval for them only being valid for participants aged 
over 18 years. The importance of age-matching is, however, quite vital in metabolomics 
studies, since metabolic patterns modify with age. For example, it has been demonstrated 
that in the 1H NMR profiles of urine analysed in children of the ages of 12 and below that, 
creatine, creatinine, glycine, betaine/TMAO, citrate, succinate and acetone were all 
correlated with age [254]. Creatinine was the only metabolite that elevated with age, whereas 
that of all others decreased [254]. Creatinine and creatine are metabolites that are impacted 
by age, and are no doubt significant in this study in view of the different age ranges in the 
cohorts studied, and this has been demonstrated as a contributing metabolite in the PCA 
scores in this study. However, glycine, TMAO and citrate increased in the GM1 Type II 
patients’ urine, which are the younger cohort.  
Correlation networks have also been applied to the urinary profiles of older participant 
cohorts aged 40.9±10.3 years analysed by Liquid Chromatography-High Resolution Mass 
Spectrometry (LC-HRMS), and it was found that a number of metabolites were statistically 
associated with age [112]. Not only are these changes present in younger participants and 
urine, but on comparison of plasma profiles in elderly groups with centurions using 1H NMR, 
the latter group were found to have significantly higher citrate, phenylalanine, creatinine, 
glutamine, phoshatidylcholine and N-acetylglycoproteins [255]. This correlation with age and 
the 1H NMR profiles acquired in this study is important, since the cohorts investigated were 
not aged-matched, and some participants in the GM1 Type II cohort as young as 3 may have 
impacted on the statistical loadings in the profiles and hence impacted upon the sample 
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scores in PCA plots. This is one of the challenges in metabolomics; indeed, imperfect age 
matching renders it difficult to interpret results acquired in such inadequate study designs. In 
view of the rarity of GM1 Type II participants and the critical condition of these patients, 
clearly it is difficult to control all such variabilities.  
The most significant blood plasma 1H NMR frequency bucket found from this MV analysis 
was attributable to vLDL/LDL-TAGs; however, this may arise from age differences between 
GM1 Type II and the control participants, i.e. the GM1 Type II patients are younger with 
mean± SEM ages of 11±2.3 years versus 22±0.7 years for the non-age-matched controls in 
plasma profiles respectively (Table 5.0). Multivariate analysis differences observed between 
ages is more profound in the urine samples used in this investigation (Table 5.1). This 
highlights the importance of ensuring that such metabolomics studies recruit participants 
who are age-matched as much as possible. However, plasma creatinine levels are expected 
to elevate with increasing age [256], but the reversed effect was observed in our study 
participants, with the GM1 Type II patients representing the younger cohort. 
Figures 5.5 and 5.7 show that the GM1 Type II patients and control plasma and urine 
samples are able to be distinguished using PCA by age. The strongest correlations are 
revealed in the younger age group, i.e. < 10 years of age in both plasma and urine samples. 
As participants increase in age, the clustering becomes more variable within the age group in 
both biofluids. This again emphasises the requirement for an age-matched cohort in 
metabolomics investigations. Figures 5.5 and 5.7 also demonstrate the impact of gender on 
matching on the investigation. Clustering in the urinary profiles is completely overlaid and it 
is difficult to observe major urinary changes related to gender using the buckets selected. 
Moreover, in the plasma profiles, it was observed that no clear distinction between genders 
were found. However, this separation could, in principle, also arise from the fasting and 
unfasting status of these groupings. 
Unbalanced sample sizes can also lead to some unreliability regarding the predictive accuracy 
of the model explored [257]. This can be counteracted by using a sub-set of control samples 
[257]. More urine samples are present in the control group, and not many in the diseased 
group, this may cause some insignificant variables to appear significant. 
On reperforming this same analysis with controls (n = 11, mean±SEM age of 21.5±0.74, 2 
males and 9 females) and GM1 Type II patients (n = 10, ages and genders provided in Table 
4.0), the statistical modelling process was improved, as expected. RF was able to distinguish 
between the samples with no errors or misclassifications. PCA showed no outliers, and all 
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samples were within the 95% confidence ellipses for each cluster. PLS-DA revealed the same 
metabolites as significant in the corresponding VIP plot, and performed well with an 
accuracy of 1.0, (R2 = 0.92 and Q2 = 0.757). Bucket regions with VIP scores ≥1 comprised 
3.56 – 3.58 ppm (glycine-CH2), 3.03 – 3.08 ppm (creatinine/creatine-N-CH2), 2.05 – 2.08 
ppm (N-acetyl functions-CH3), 2.52 – 2.59 ppm (citrate-CH2), 2.34 – 2.35 ppm (pyruvate-
CH3), 1.33 – 1.34 ppm (lactate-CH3), 4.06 – 4.12 ppm (creatinine-CH2), 1.92 – 1.93 ppm 
(acetate-CH3/lysine-β-CH2), 2.25 – 2.28 ppm (2-hydroxyglutarate-δ-CH2), 2.02 – 2.05 ppm 
(N-Acetyl functions-CH3), 1.47 – 1.50 ppm (alanine-CH3), 1.93 – 1.96 ppm (lysine-β-CH2) 
and 1.36 – 1.37 ppm (2-hydroxybutyrate-CH3). SVM was able to distinguish fully between 
the two groups with 0% error with 41 variables, and 11.1% with only 25 variables.  
Univariate statistical analysis revealed slightly different results as three bucket regions had a 
fold-change of > 2.0, and these were 2.78 – 2.79 ppm (dimethylamine-N(CH3)2, 3.56 – 3.58 
ppm (glycine-CH2), and 1.92 – 1.93 ppm (acetate-CH3/lysine-CH2). Student’s t-test revealed 
upregulations in 1.27 – 1.28 ppm (acetoacetate-CH3), 1.36 – 1.37 ppm (2-hydroxybutyrate-
CH3), 1.47 – 1.50 ppm (alanine-CH3), 1.92 – 1.93 ppm (acetate-CH3/lysine-β-CH2), 2.02 – 
2.05 ppm (N-Acetyl functions-CH3), 2.05 – 2.08 ppm (N-Acetyl functions-CH3), 2.25 – 2.28 
ppm (2-Hydroxyglutarate-δ-CH2), 2.34 – 2.35 ppm (pyruvate-CH3), 2.52 – 2.59 ppm (citrate-
CH2), 2.66 – 2.73 ppm (citrate-CH2/DMA-CH3), and 4.14 – 4.18 ppm (lactate-CH), along 
with downregulations in 4.06 – 4.12 ppm (creatinine-CH2) in GM1 Type II of which have an 
FDR-corrected p value of < 0.05. Student’s t-tests revealed upregulations of 1.33 – 1.34 ppm 
(lactate-CH3) and 3.56 – 3.58 ppm (glycine-CH2), and downregulations in 3.03 – 3.08 ppm 
(creatinine/creatine-N-CH2) in GM1 Type II patients were also significant (p < 0.005). 
 
5.12 Conclusions 
 
1H NMR analysis provides an insight into some new potential biomarkers in plasma and 
urine samples in patients with GM1 Type II disease, particularly disease relevant N-Acetyl 
groups, which appear as a chemopathological markers in urine, in addition to other 
metabolites such as lactate, citrate and pyruvate. Disturbances in plasma LDL and its 
associated TAGs appear to represent a common marker amongst lysosomal storage 
disorders. The many complications of this study were explored, including participant fasting 
status, drug therapies, and the genders and ages of the participants in both cohorts, and the 
potential impacts of these on the experimental design and implications on the results 
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acquired were fully investigated. The LC-MS approach applied was unable to identify 
gangliosides in plasma or CSF samples, although more sensitive MS strategies could be 
employed in a future investigation inclusive of LC-MS/MS. 
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Overall Thesis Conclusions 
 
An extensive review of the literature in Chapter 1 revealed key new areas of developments 
in metabolomics analyses for Gaucher’s Disease, GM1 Gangliosidosis and Niemann Pick 
Disease Type C. These included (1) systematic sample collection and handling; (2) further 
validation of at least some of the potential biomarkers suggested via the rigorous 
monitoring of their biofluid levels along with simultaneous co-ordinated assessments of 
clinical responses to treatment(s); (3) detailed correlations of biomarker concentrations 
with disease severity, and also the strict consideration of demographic variables such as age, 
gender and diet, etc.; and (4) a further detailed review in order to ensure that biomarker(s) 
identified are solely specific to particular LLSDs. This thesis aimed to contribute to 
developments in (3) and (4) within this field.  
Chapter 2 highlighted current, appropriate methods to approach metabolomics 
investigations. 
Chapter 3 demonstrates advancements in Gaucher’s Disease metabolomics by 1H NMR 
analysis of plasma and urine samples using a 1H NMR strategy. Statistical techniques such 
as PLS-DA showed significant metabolic differences between GD and control cohorts of 
participants, and these included disturbances in plasma lipid profiles, e.g. the TAG profiles 
of vLDL, LDL and HDL. No statistical differences were observed on comparison of the 
urinary profiles of Gaucher’s Disease with control participants (drugs and drug metabolite 
resonances were removed from spectral profiles prior to analysis). Unfortunately, Gaucher 
Disease patients were receiving a range of treatments, and this may complicate such 
metabolomics studies.  
Chapter 4 investigates the 1H NMR profiles of urine collected from NP-C1 diseased 
felines, along with the influence of hydroxypropyl-β-cyclodextrin (HPβCD) therapy on 
these. Statistically significant differences were found on comparison of untreated NPC 
felines and treated 1,000 mg SQ/IT 120 mg NPC felines. Moreover, statistically significant 
differences between controls and NPC feline urine profiles were only observed in older 
felines (age range 16-24 weeks). Notwithstanding, imperfect sex-matched cohorts involved 
may be contributing to the statistical differences observed, and this was further explored as 
part of this investigation. Potential metabolic disturbances in NPC felines included 
upregulations in felinine, for example.  
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Chapter 5 shows for the first time the 1H NMR analysis of GM1 Type II Gangliosidosis 
CSF, plasma and urine samples, and a metabolomics investigation was performed. 
Upregulated citrate, N-acetyl function-containing biomolecules, creatinine, creatine and 
lactate, amongst other metabolites, were observed in GM1 Type II urine over those of 
controls. Downregulated LDL-TAGs and upregulated creatinine and lactate, were 
examples of alternative metabolic disturbances observed. 
In conclusion, further research investigations are required in order to validate the findings 
observed here, which involve the careful design of such studies featuring (1) systematic 
sample collection and handling; and (2) further validation of at least some of the potential 
biomarkers indicated via the rigorous monitoring of their biofluid levels, together with 
simultaneous co-ordinated assessments of clinical responses to treatment(s). However, 
such studies remain challenging in view of the critical illness of patients with LSDs, and 
relatively small sample sizes in the human investigations described here. 
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Appendices 
 
Appendix 1 – CPMG versus NOESY PRESAT GD1 Samples 
 
 
Figure 1. Top: Typical NOESY PRESAT spectrum (red) with clear distortions to the 
baseline as a result of the protein in the plasma sample. Bottom: CPMG pulse sequence of 
the same samples (blue) with a clear straight baseline.  
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Appendix 2 – Outlier identified by PCA in GD1 Plasma 
Figure 2. Sample 70P (blue) against a typical spectrum from the control group (red). 
Clear outlier in the control group with high lipid resonances observable at δ = 0.88 ppm, δ 
= 1.33 ppm, δ = 1.55 ppm, δ = 2.01 ppm, δ = 2.22 ppm and δ = 5.25 ppm. This outlier was 
removed from further statistical analysis.  
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Appendix 3 – Univariate Data Analysis in GD1 Plasma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3a. Box plots of significant buckets in MVA analysis in PCA plots. Buckets include 
4.26-4.34, Glyceryl of lipids (broad), 4.22-4.26, Threonine-CH /glyceryl of lipids (m) 1.91-
2.01, CH2CH2CH= (broad), 4.41-4.46 Unassigned broad singlet (s) and 4.08-4.13 Lactate-
CH (q)/ 3-hydroxybuyrate-CH (m). 
Control | Type I GD 
Control | Type I GD 
Control | Type I GD Control | Type I GD 
Control | Type I GD 
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Figure 3b. Univariate ROC Curve analysis for significant metabolites showing false 
positive rate on the x-axis vs true positive rate on the y-axis. These metabolites are 
comparing controls vs GD. 
 
 
 
 
 
 
 
 
Cholesterol and LDL/vLDL Lipid (broad) Lipids unsaturated fatty acids 
CH2CH2CH= (broad) Glyceryl of lipids (broad) 
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Appendix 4 – Signals Attributable to Drug Metabolites in GD1 Urine 
Figure 4. Top: Presence of key acetaminophen and corresponding resonances in human 
urine from GD patient labelled [A] acetaminophen [B] glucuronide derivative [C] sulphate 
derivative [D] L-cysteinyl derivative [E] N-acetyl-L cysteinyl derivative Bottom: 
Assignments in salicyluric acid assigned in human urine in patients with GD [F] salicyluric 
acid -CH2 [G] salicyluric acid -CH [H] salicyluric acid -CH. 
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Appendix 5 – Further Multivariate Data Analysis in GD1 Urine 
Figure 5a. Left: PCA plot of GD urine on comparison of two treatment types in urinary 
profiles, with imiglucerase (red) and velaglucerase alfa (green). PC1 vs PC2 shown 
representing 31.1% and 19.4% of the dataset variation respectively. Right: The PLS-DA 
plot shows PC1 vs PC2 which represent 19.9% and 18.5% of the dataset variation 
respectively. Q2, R2 and Accuracy are all less than >0.5, 2000 permutations, p>0.05. The 
plot shows 95% confidence ellipses.  
Figure 5b. Left: PCA plot of GD urinary loadings with participants above 50 (red) and 
below 50 (green). PC1 and PC2 show 28.3% and 17.9% of the dataset variance 
respectively.  Right: PLS-DA plot of GD urinary loadings with participants above 50 (red) 
and below 50 (green). PC1 and PC2 show 16.1% and 15.8% dataset variance respectively. 
Q2, R2 and accuracy are all less than >0.5, 2000 permutations, p>0.05.  95% confidence 
ellipses are shown for both statistical diagrams. 
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Appendix 6 – Significant Metabolite in Univariate testing in GD1 Urine 
 
 
 
 
 
 
 
 
Figure 6. fold change analysis of the signal at δ = 9.10-9.15 ppm attributable to 
trigonelline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Trigonelline-CH 
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Appendix 7 – Excluded Bucket Regions for Multivariate Analysis in Feline 
Urine 
 
Anomalous signals  
Figure 7.0. Resonances from two untreated NPC felines at 8 weeks of age. Resonances 
appear in the red spectrum which are not present in the blue spectrum at δ = 3.69 ppm (m), 
3.77 ppm (m), 4.05 ppm (t), 4.14 and 4.11 ppm (d).  
The above spectra show the presence of some anomalous signals in the feline urine samples. 
These signals are observed in urine from untreated control felines, HPβCD treated felines, 
treated felines, untreated NPC felines and antibiotic treated felines.  
 
Figure 7.1. Resonances from HPβCD only. Purchased from Sigma Aldrich. 
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Figure 7.2. HPβCD spiked into control feline urine. Complex formed at δ = 1.4 ppm. No 
complexation was observed in feline urine from controls and treated felines in the study. 
Shifting resonances are observable as a result of the addition of HPβCD presence due to 
complexation of HPβCD with the metabolites. No shifting is observed in this investigation 
using 252 feline urine samples of which 3 different treatment strategies are employed. The 
higher the concentration of HPβCD the more signals appear to shift to the right of the 
spectrum. 
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Appendix 8 – Drug Metabolism in Felines 
 
Drug treated feline spectra  
AZI is barely metabolised with no active metabolites and is predominantly excreted in bile 
and faeces [258]. AZI has been recovered by 6% - 12% in urine previously [258]. 
Therefore, unsurprisingly this drug is not observed in the 1H NMR feline urinary profiles.  
In contrast, CLAV and AMOX are metabolised unchanged in urine. CLX administration is 
dependent on weight of the feline and has a half-life of 1-2 hours [259]. In felines, the 
maximum concentration of amoxicillin and clavulanate found in plasma is 6.6µg/ml and 
3.7µg/ml respectively [259]. Additionally, elimination of CLX is fast for amoxicillin and 
clavulanate, with 12% and 17% eliminated in the urine respectively [259]. Therefore 
unsurprisingly, CLX was not found in the feline urine samples. 1H NMR profiles have been 
previously observed of clavulanate in aqueous solutions [260] and resonances for this 
molecule include δ = 4.78, 5.67, 3,46, 2.95, 4.89, 4.18 and 4.12 ppm [260]. Amoxicillin can 
be observed in human urinary profiles and distinct resonances can be observed at δ = 1.43, 
1.44, 4.46, 5.16, 5.51, 5.56, 6.98, 7.37 and 9.11 ppm [261]. Amoxicilloic acid and amoxicillin 
diketopiperazine‐2′,5′‐dione, metabolites of AMOX, have been observed in pigs plasma 
and the former, amoxicilloic acid, observe in pig urine [262]. In rats and dogs it was found 
that CLAV produced a metabolite 1-amino-4-hydroxybutan-2-one in addition to being 
excreted unchanged [263] however, in humans another metabolite was found namely, 2,5-
dihydro-4-(2-hydroxyethyl)-5-oxo-1H-pyrrole-3-carboxylic acid [264].  However, these 
metabolites were not found in the feline urine samples. AMOX and CLAV have been 
shown to be unstable in different aqueous solutions at a range of pH’s however at a neutral 
pH they are typically stable [265]. Higher acidity or alkalinity showed a significant 
decomposition rate in both CLAV and AMOX [265]. As the feline urine was typically a 
neutral pH this should not affected the decomposition of the drugs in the urinary profiles.  
MET is predominantly metabolised unchanged. However, suggested metabolites have been 
proposed through multiple routes unlike the other drugs in this study for example, methyl-
5-nitrodiazole-1-acetic acid in humans [266]. In humans and murine models, a range of 
metabolites have been shown to be excreted in urine including 2-carboxylic, N-(2-
hydroxyethyl)-oxamic acid, acetamide, 2-hydroxymethyl, 1-acetic acid 2-methyl and 
glucuronide derivatives [267]. Despite this, the primary drug resonances itself which can be 
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found on human metabolome database [148] are not found within the 1H NMR feline 
urinary profiles. MET has distinct 1H NMR signals at δ = 8.028 and 2.463 ppm [148] which 
are not seen in the profiles from the felines herein.  
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Appendix 9 – Average Spectral Differences in Feline Urinary Profiles 
showing Age and Sex Groupings  
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Figure 9.0. 1H NMR profiles of control felines. Average stack plots of each age group at 8, 
10, 16, 20 and 24 weeks in blue, orange, yellow, purple and green respectively. Formate is 
italicised here as there is a clear shift in the formate signal attributable to the molecule 
which typically arises at δ = 8.45 ppm. The other italicised molecules have not been shown 
to be present in whole feline urine in NMR elsewhere however, there is evidence that they 
are present in urine [209]. U1 and U2 represent unknown metabolites. Abbreviations: 1-
MH, 1-methylhisitidine; 1-MN, 1-methylnicotinamide; 3-HB, 3-hydroxybutyrate; DMA, 
dimethylamine; DMG, dimethylglycine; I-3-I, indole-3-lactate; IS, Indoxyl sulphate; LAC, 
L-acetyl carnitine; NAC, N-acetyl groups; PAG, phenyl-acetyl-glycine; p-creatine, 
phosphocreatine; TMA, trimethyl amine; TMAO, trimethylamine-n-oxide  
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Figure 9.1. 1H NMR profiles of NPC felines. Average stack plots of each age group at 8, 
10, 16, 20 and 24 weeks in blue, orange, yellow, purple and green respectively. Formate is 
italicised here as there is a clear shift in the formate signal attributable to the molecule 
which typically arises at δ = 8.45 ppm. The other italicised molecules have not been shown 
to be present in whole feline urine in NMR elsewhere however, there is evidence that they 
are present in urine [209]. U1 and U2 represent unknown metabolites. Abbreviations: 1-
MH, 1-methylhisitidine; 1-MN, 1-methylnicotinamide; 3-HB, 3-hydroxybutyrate; DMA, 
dimethylamine; DMG, dimethylglycine; I-3-I, indole-3-lactate; IS, Indoxyl sulphate; LAC, 
L-acetyl carnitine; NAC, N-acetyl groups; PAG, phenyl-acetyl-glycine; p-creatine, 
phosphocreatine; TMA, trimethyl amine; TMAO, trimethylamine-n-oxide  
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Figure 9.2. Heatmap of 7 control felines urinary profiles at 8 weeks and at 24 weeks 
inclusive of the top 25 metabolites 
Table 9.0: Significant Metabolites Assigned in control felines profiles at 8 weeks and at 24 
weeks  
Significant 
bucket (ppm) 
Assignment Week 8 Week 24 
3.64-3.70 Phenylacetylglycine-CH2 ↑ ↓ 
3.74-3.76 1-Methylhisitidine-CH3 ↑ ↓ 
3.76-3.81 Felinine-β-CH2 ↑ ↓ 
3.70-3.72 Phenylacetylglycine-CH2 ↑ ↓ 
3.93-3.96 Creatine-CH2 /p-creatine-CH2 /Glycolate-CH2 ↑ ↓ 
2.02-2.03 N-acetyl-CH3 ↑ ↓ 
2.00-2.02 N-acetyl-CH3 ↑ ↓ 
2.03-2.08 N-acetyl-CH3 ↑ ↓ 
1.85-1.87 Felinine Derivative-CH2 ↓ ↑ 
1.87-1.88 Felinine Derivative-CH2 ↓ ↑ 
1.45-1.49 Alanine-CH3 ↓ ↑ 
1.49-1.51 Lysine-CH3 ↓ ↑ 
1.51-1.53 Lysine-CH3 ↓ ↑ 
1.82-1.85 Felinine Derivative-CH2 ↓ ↑ 
2.90-2.94 Dimethylglycine-CH3 ↓ ↑ 
1.31-1.32 Felinine-CH3/L-Lactate-CH3 ↓ ↑ 
2.75-2.77 Citrate-CH2/DMA-CH3 ↓ ↑ 
0.86-0.90 Unassigned-CH3 ↓ ↑ 
0.90-0.92 Unassigned-CH3 ↓ ↓ 
1.53-1.58 Lysine-CH3 ↓ ↑ 
1.35-1.37 Felinine-CH3/2-Hydroxyisobutyrate-CH3 ↓ ↑ 
3.09-3.13 Felinine-CH2 ↓ ↑ 
3.03-3.07 Creatine/Creatinine-CH2 ↓ ↑ 
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Figure 9.3. Heatmap of 5 NPC Felines urinary profiles at 8 weeks and at 20+ weeks 
inclusive of the top 25 metabolites 
Significant 
bucket (ppm) 
Assignment Week 8 Week 20+ 
8.38-8.41 Tentative aromatic amino acid-CH ↑ ↓ 
0.96-0.99 Isovarylglycine-CH3/Lipids-CH3 ↑ ↓ 
1.98-2.00 N-acetyl-CH3 ↑ ↓ 
2.02-2.03 N-acetyl-CH3 ↑ ↓ 
3.09-3.13 Felinine -CH2 ↓ ↑ 
1.33-1.35 Felinine-CH3/2-Hydroxyisobutyrate-CH3 ↓ ↑ 
1.31-1.32 Felinine-CH3/L-Lactate-CH3 ↓ ↑ 
3.41-3.47 Taurine-CH2-SO3- ↓ ↑ 
7.28-7.32 p-toluyl derivative-CH ↓ ↑ 
3.13-3.18 L-acetyl carnitine-CH2/Felinine-CH2 ↓ ↑ 
7.35-7.39 Indole-3-lactate-CH ↓ ↑ 
7.98-8.07 Tentative broad amino acid protein-CH  ↓ ↑ 
7.67-7.71 Hippurate-γ/δ/ε-CH ↓ ↑ 
6.02-6.11 Lipid resonance-CH ↓ ↑ 
2.75-2.77 Citrate-CH2/DMA-CH3 ↓ ↑ 
7.41-7.43 phenylacetylglycine-CH ↓ ↑ 
8.52-8.62 Broad amino acid protein-CH ↓ ↑ 
7.56-7.58 Hippurate-γ/ε-CH ↓ ↑ 
7.84-7.86 Hippurate-β/ζ-CH ↓ ↑ 
6.69-6.72 Unassigned ↓ ↑ 
7.45-7.50 phenylacetylglycine-CH ↓ ↑ 
2.96-2.98 Unassigned  ↓ ↑ 
2.90-2.94 Dimethylglycine-CH3 ↓ ↑ 
2.60-2.64 Citrate-CH2 ↓ ↑ 
Table 9.1. Significant Metabolites Assigned in control felines profiles at 8 weeks and at 24 
weeks  
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Figure 9.4. Left: PCA plot of control cat ages whereby blue, green, pink, orange and navy 
represent week 8, 10, 16, 20 and 24 weeks respectively. Right: PCA plot of control cat 
numbers whereby blue, green, pink, orange, navy, grey and yellow represent cat numbers 
8449, 8500, 8502, 8517, 8518, 8538 and 8590 respectively. 
 
Figure 9.5. PCA plot of gender in control felines whereby female and male felines are 
represented in blue and green respectively. 
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Appendix 10 – Metabolite Confirmation using 2D NMR for Feline Urine 
Samples 
 
Felinine ((R)-2-amino-3-(4-hydroxy-2-methylbutan-2-ylthio) propanoic acid) has previously 
been elucidated in feline urine [209] and has been found and confirmed here using 2D-
TOCSY. This molecule enables an easy distinction between human and feline urine. 
Figure 10.0. Confirmation of felinine using 400 MHz NMR 2D TOCSY; 6-CH2 (δ = 1.86 
ppm) triplet and 7-CH2 (δ = 3.77 ppm) triplet. 
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Figure 10.1. Confirmation of lactate using 600 MHz NMR 2D COSY; -CH3 (δ = 1.33 
ppm) doublet and -CH2 (δ = 4.14 ppm) quartet. Other correlations can be observed here at 
the δ = 4.14 ppm resonance. 
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Appendix 11 – Partial 600 MHz 1D Feline Urinary Profile using WET solvent 
suppression sequence  
Figure 11.0. Partial 600 MHz of urinary profile from a typical feline urine sample with NPC. 
600 MHz NMR spectra were acquired in order to distinguish any bile acid (BA) signals in 
the feline urine as a result of upregulated cholesterol. From profiles acquired herein, no BA 
signals were observed.  
 
 
 
 
 
 
 
 
 
Appendix 12 – Control and Treated Felines Plasma analysis 
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ANOVA was performed on plasma biomarkers in the same felines within 16-50-week 
period. Although the dataset is substantially smaller, due to missing the earlier and later time 
points, a clear distinction can be observed when using an adjust p value of p>0.0005 using 
Fishers/LSD non parametric testing.  
Figure 12.0. ANOVA of plasma with adjusted p value (FDR) cut off p>0.0005 using 
Fishers/LSDs non-parametric. Alanine transferase (ALT), Aspartate transaminase (AST), 
Cholesterol, Blood Urea Nitrogen (BUN)/Creatine Ratio, Alkaline Phosphatase (Alk. 
Phosp) and Total Bilirubin were measured in plasma from the same felines however, only 
aged matched plasma was available from felines >16 weeks. 
Although it is unknown in the plasma samples whether changes are able to observed pre-
symptomatically because of the samples collected were < 16 weeks, evident changes are 
observable post-symptomatically (>16 weeks). 
